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Zusammenfassung 
Malaria ist nach wie vor eine Krankheit von immenser gesundheitspolitischer Tragweite, 
vor allem in den Tropen und Sub-Tropen und verursacht jedes Jahr 300 Millionen Grippe-
ähnliche Erkrankungen und tötet dabei eine Million Menschen. Die sich schnell 
ausbreitenden Medikamenten-Resistenzen, klimatische Veränderungen, aber auch nicht 
mehr intakte Gesundheitsversorgungen und bewaffnete Konflikte tragen zu einem steten 
Anstieg von Malaria bei. Dabei wird ein Impfstoff gegen diese Infektionskrankheit noch 
für längere Zeit nicht verfügbar sein.  
Malaria wird von dem einzelligen Protozoen Plasmodium ausgelöst und durch die 
weibliche Anopheles Mücke übertragen. Von den 4 Plasmodien Arten, die Menschen 
infizieren können, ist Plasmodium falciparum bei weitem die virulenteste und auch für 
einen Grossteil der tödlichen Ausgänge verantwortlich. Diese ausgeprägte Virulenz von P. 
falciparum ist vor allem auch auf ein spezielles Phänomen zurückzuführen, das 
Zytoadhärenz heißt. Diese umfaßt die Sequestrierung und Bindung von infizierten 
Erythrozyten (IE) an die Endothelzellen des Mikrokapillarsystems. Zytoadhärenz ist für 
den Parasiten ein klarer Vorteil, da er die Eliminierung der IE in der Milz verhindert. Für 
den Wirt, den Menschen also, kann diese Adhäsion jedoch verheerende Konsequenzen 
haben, denn sie führt zu schwersten Behinderungen im Blutfluß, zu schlecht durchblutetem 
Gewebe und Hypoxia und trägt damit wesentlich zu schweren Krankheitsmanifestationen 
bei.  
Nebst der Sequestrierung, beinhaltet die Zytoadhärenz auch noch die Rosetten-Bildung. 
Dies ist die Bindung von IE an uninfizierte Erythrozyten. Diese Klumpen-Bildung führt 
ebenfalls zu vermindertem Blutfluß und wurde mit schwerer Malaria assoziiert.  
Hauptverantwortlich für diese Bindungsprozesse ist die auf der Oberfläche von IE 
exprimierte und vom Parasiten abstammende Proteinfamilie "Plasmodium falciparum 
erythrocyte surface protein 1" (PfEMP1). Durch die Exposition von PfEMP1 an der 
Erythrozyten Oberfläche setzt sich der Parasit aber auch dem Immunsystem aus und wird 
dadurch angreifbar. Der Parasit entgeht dieser Attacke durch Antigen Variation, d.h. durch 
die abwechselnde Exprimierung von verschiedenen Mitgliedern einer Proteinfamilie, in 
unserem Fall PfEMP1.  
PfEMP1 wird von ungefähr 60 var Genen pro haploides Genom kodiert. Diese diversen 
und auch großen Gene werden in verschiedene adhäsive, semi-konservierte Domänen 
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strukturiert. Fast alle var Gene können zudem in verschiedene Gruppen aufgeteilt werden, 
d.h. in var Gruppe A, B oder C, gemäß ihren sehr unterschiedlichen, aber innerhalb einer 
Gruppe, konservierten untranslatierten Regionen. 
Trotz der großen Einwirkungen von PfEMP1 auf die Malaria Pathogenese und auf das 
Parasiten Überleben, haben nur wenige Projekte var Gene und PfEMP1 in vivo untersucht. 
Das läßt sich vor allem auf die große, nicht abschätzbare Vielfalt der var Gene in vivo 
zurückführen, die eine Analyse äußerst erschweren. 
Wir haben 2 Studien über die var Gen Expression in natürlich infizierten Kindern in Papua 
Neuguinea durchgeführt.  
In einer longitudinalen Studie haben wir die Antigen Variation von var Genen in P. 
falciparum von älteren, semi-immunen Kindern analysiert. Mittels reverser Transkription, 
PCR, klonieren und sequenzieren wurde über 4 Monate in Zeitabständen von 2 Wochen 
die zeitliche Dynamik und Verteilung von var Transkripten ermittelt. Dabei haben wir ein 
äußerst dynamisches Bild der var Expression erhalten. Zum größten Teil wurden alle 2 
Wochen neue var Transkripte ermittelt, wobei einige in einem Zeitrahmen von 10 Wochen 
wiederholt auftraten. Die Zahl der detektierten var Transkripte korrelierte mit der Anzahl 
von P. falciparum Stämmen, die ein Kind gleichzeitig infizierten. Im Durchschnitt wurden 
1.7 verschiedene var Transkripte pro Kind und P. falciparum Stamm gefunden. Zudem 
wurde die rekombinogene Natur der var Genfamilie durch die Analyse von 286 
verschiedenen Sequenzen von ausgesuchten var Gen Domänen bestätigt.  
In einer zweiten Studie untersuchten wir die Frage, ob sich die strukturelle Gruppierung 
der var Gene auch in unterschiedlichen Funktionen widerspiegelt und sich in einer 
heterogenen Virulenz äußert. Die Exprimierung verschiedener var Gen Gruppen könnte 
demnach verschiedene pathologische Auswirkungen auf den Wirt haben. In einer Malaria 
Fall Kontroll Studie untersuchten wir daher die quantitative Verteilung der var Transkripte 
in den var Gen Gruppen A, B und C in Kindern mit schwerer Malaria, in Kindern mit 
milder Malaria und in asymptomatischen Kindern. Durch die Anwendung der real-time 
quantitativen PCR, fanden wir tatsächlich einen wesentlichen Unterschied in der 
Expression von var Genen zwischen Parasiten von kranken Kindern und Parasiten aus 
asymptomatischen Kindern. Dies äußerte sich in einer signifikanten Aufregulierung von 
Genen der var Gruppe B in Kindern mit klinischer Malaria verglichen zu 
asymptomatischen Kindern, in denen vor allem die var Gruppe C aktiv war. In Kindern mit 
klinischer Malaria fanden wir keine signifikanten Unterschiede der var Gen Expression 
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zwischen Kindern mit milder und schwerer Malaria. Nicht zuletzt stellten wir auch eine 
Aufregulierung der var Gene der Gruppe A in den Parasiten fest, die Rosetten bildeten.  
Zusammenfassend, sind diese Studien über die var Gen Expression die ersten in ihrer Art, 
die in natürlich infizierten Kindern aus einem Malaria endemischen Gebiet durchgeführt 
wurden. Sie ermöglichen uns einen guten Einblick in die Dynamik und in die 
Auswirkungen der var Gen Expression in vivo. Zusammen mit früheren Studien, sind sie 
auch ein weiterer Beweis für den substantiellen Einfluß von PfEMP1 auf die Malaria 
Pathogenese. 
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Summary 
Malaria is a tremendous global public health problem. While especially hitting the poorest 
countries in the world, malaria elicits each year 300 million febrile illnesses and up to 1 
million deaths. Widespread drug resistances, climatic changes, but also disintegrated health 
services and armed conflicts have contributed to a global increase of malaria while a 
vaccine will not be at hand for many more years to come.  
Malaria is caused by the protozoan parasite Plasmodium and transmitted by the female 
Anopheles mosquito. Of 4 Plasmodium species infecting humans, Plasmodium falciparum 
is by far the most harmful parasite responsible for nearly all mortality. The increased 
virulency of P. falciparum can be ascribed to special immune evasion strategies inherent of 
this species. This mainly refers to a process called cytoadherence, the sequestration and 
adhesion of infected erythrocytes (IE) to endothelial cells of the microcapillary system. To 
evade spleen dependent killing, cytoadherence is a benefit for the parasite, but detrimental 
to the host by leading to poorly diffused tissues and hypoxia in the upstream segments and 
thus, contributing substantially to severe manifestations.  
Related to sequestration is a process called rosetting, the binding of IE to uninfected 
erythrocytes. This leads to erythrocyte clusters impeding local blood flow and accordingly, 
rosette formation was also associated with severe disease. 
On the surface of IE, the parasite derived protein family Plasmodium falciparum 
erythrocyte membrane protein 1 (PfEMP1) is thought to be the key mediator for 
sequestration and rosetting.  
However, by exposing a parasite derived antigen on the surface of IE, the parasite gets 
vulnerable to immune attack. Therefore, P. falciparum evades the immune system by a 
process called antigenic variation, the switching of the expression between different 
members of PfEMP1.  
PfEMP1 is encoded by approximately 60 var genes per haploid genome. The highly 
diverse and large var genes are structured into several adhesive, semi-conserved domains. 
Most var genes can be subgrouped into var group A, B and C according to their diverse, 
but within one group highly conserved untranslated regions.  
Despite of the substantial contribution of PfEMP1 to malaria pathogenesis and parasite 
survival, few studies on var genes and PfEMP1 have been carried out in vivo. This is 
mainly due to their immense diversity interfering with most study designs.  
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We conducted 2 studies on var gene expression in naturally infected children from Papua 
New Guinea.  
 
In a longitudinal study over a 4-month period in older, semi-immune children, we studied 
antigenic variation of var genes, namely the dynamics and distribution of var transcripts 
over time. Diversity and patterns of full-length var transcripts were evaluated by magnetic 
bead-anchored reverse-transcription polymerase chain reaction (RT-PCR), cloning and 
sequencing. We identified a highly dynamic picture of var expression with mostly new var 
transcripts at a 2-weeks interval but with some var transcripts recurring for up to 10 weeks. 
The number of detected var transcripts correlated with the number of infecting P. 
falciparum strains. On average, 1.7 different var transcripts were detected per child and 
infecting strain. The analysis of 286 different sequences of selected var gene domains 
confirmed the recombinogenic nature of var genes. 
 
In a malaria case-control study on children from Papua New Guinea, we quantitatively 
compared the distribution of var transcripts among var groups A, B and C in children with 
severe malaria, with mild malaria and in asymptomatic children. The sub-division of var 
genes into these var groups raises questions about the biological or clinical significance of 
these structural differences. Upon expression, different var groups might have different 
pathological implications on the host leading to distinct virulences and different clinical 
outcomes. By using real-time quantitative PCR, we found a major expression difference 
between parasites causing clinical attack and parasites leading to asymptomatic infections. 
A significant up-regulation of var group B transcripts was evident in children with clinical 
malaria (mild and severe) while var group C genes were mainly switched on in 
asymptomatic children. No change in the distribution of var transcripts was detected 
between mild and severe disease. Finally, we found a significant up-regulation of var 
group A genes in parasites conferring the formation of rosettes.  
 
Together, these studies on var gene expression are the first of its kind, conducted in 
naturally infected children in an endemic area. They are a step towards the comprehension 
of the dynamics and impacts of var gene expression in vivo. Together with previous 
studies, our data emphasize the substantial implications of PfEMP1 in malaria morbidity. 
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Abbreviations 
 
ATS acidic terminal segment 
CIDR cysteine rich interdomain region 
CR1 complement receptor 1 
CSA chondroitin sulphate A 
DBL duffy binding like domain 
GPI glycosylphosphatidylinositol 
HDMECs human dermal microvascular endothelial cells  
HLECs  human lung endothelial cells  
ICAM-1 intercellular adhesion molecule 1 
IE infected erythrocytes 
iNOS inducible form of nitric oxide synthase 
KAHRP  knob associated histidine rich protein 
NTS N-terminal segment 
PAM pregnancy associated malaria 
PfEMP1 Plasmodium falciparum erythrocyte membrane protein 1 
PNG Papua New Guinea 
RT-PCR reverse transcription polymerase chain reaction 
TM transmembrane domain 
TNF tumour necrosis factor 
TrHBMEC transformed human bone marrow endothelial cell 
VSA variant surface antigen 
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1. Introduction 
Malaria is found in most tropical and sub-tropical regions of the world affecting 
approximately 40% of the world's population and leading to annually 300 million acute 
illnesses and up to 1 million deaths (Roll Back Malaria; www.rbm.who.int.; 2004). 90% of 
malaria deaths occur in South Sahara African children. In Africa, malaria also presents a 
major obstacle to social and economic development, claiming annually up to US$ 12 
billion economic costs. 1 Malaria is caused by the protozoan intracellular parasite 
Plasmodium and transmitted by the female mosquito of the genus Anopheles. Of the 4 
Plasmodium species infecting humans (P. falciparum, P. vivax, P. ovale, P. malariae), P. 
falciparum is responsible for a high proportion of the morbidity and nearly all the 
mortality. Plasmodium belongs to the large phylum Apicomplexa which also includes 
opportunistic pathogens such as Cryptosporidium or Toxoplasma and some veterinary 
pathogens important for husbandry and agriculture, for instance Babesia and Theileria 
infecting cattle.  
1.1. Malaria morbidity  
Most of malaria morbidity is the result of the unrestrained asexual parasite amplification. 
The vast majority of malaria cases presents as non-specific acute febrile illness 2 and only 
about 1% proceed to severe manifestations of this disease. Traditionally, severe malaria 
was subdivided into cerebral malaria and severe anemia (haemoglobin < 5g/dl). 3 The latter 
is the consequence of haemolysis and an inappropriate bone marrow response. 3 In cerebral 
malaria, parasites obstruct the cerebral microcirculation contributing to increased cerebral 
capillary permeability and cerebral oedema (see also section 1.2.). 4 Recent studies 
indicated that also metabolic acidosis leading to the clinical picture of respiratory distress, 
is an important feature of severe malaria being also the strongest predictor of death in 
severe malaria. 5 Hypovolemia, hyperlactatemia and impaired renal function have been 
shown to mainly contribute to metabolic acidosis. 5 More and more, severe malaria is 
thought to be a complex multisystem disorder with many similarities to sepsis syndromes. 2 
Immunopathogenic processes with excessive proinflammatory cytokine productions such 
as IFN-γ and tumour necrosis factor (TNF) play an important role. TNF is also known to 
induce the generation of the inducible form of nitric oxide synthase (iNOS). iNOS 
produces nitric oxide in vast amounts which was implicated in cerebral malaria by 
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interfering with neuro-transmission and leading to vasodilation of cerebral vessels. 6 The 
rupturing of erythrocytes to release new merozoites is suggested to trigger excessive 
proinflammatory cytokine cascades and oxygen free radicals. Furthermore, the 
glycosylphosphatidylinositol (GPI) of P. falciparum has been shown to act as malarial 
toxin contributing to the cytokine cascades. 7  
However, probably the most important virulence factor of P. falciparum has not been 
mentioned yet - this is a process called cytoadherence. 
1.2. Cytoadherence and pathophysiological consequences 
Cytoadherence is the adhesion of infected erythrocytes (IE) to other host cells during the 
trophozoite and schizont stage, which is the last half of the parasites' asexual blood stage 
replication cycle. Cytoadherence can be differentiated into sequestration - the adhesion of 
IE to endothelial cells in the post-capillary venules 8 - into rosetting - the adhesion of IE to 
other non-infected erythrocytes 9 - and into clumping - the platelet mediated binding of IE 
to other IE. 10 Cytoadherence is believed to confer a fitness benefit to the parasite such as 
by evasion of spleen dependent killing. For the host, these microvascular obstructions have 
clear pathogenic consequences leading to poorly perfused host tissues, anaerobic 
metabolism and hypoxia which further contributes to metabolic acidosis. An association 
has been found between binding of IE to intercellular adhesion molecule 1 (ICAM1) and 
cerebral malaria. 11,12 ICAM1 is prominently expressed on endothelial cells in the brain and 
involved in local inflammatory responses allowing the passage of leukocytes into the 
perivascular space. Binding of IE to ICAM1 was hypothesized to mimic the binding of 
leukocytes eliciting signalling cascades which result in the leakage of plasma proteins into 
the perivascular space contributing to cerebral oedema. 4,13 It has been shown that TNF 
enhances ICAM1 expression on endothelial cells and thus, high levels of TNF are thought 
to contribute further to parasite sequestration in the brain. It was also shown that binding of 
IE to human lung endothelial cells (HLECs) induces apoptosis in these cells. 14 Apoptosis 
of endothelial cells in the brain might lead to lesions and could further contribute to blood-
brain barrier dysfunctions.  
Another important receptor for IE binding is CD36, a scavenger class B receptor which is 
found on phagocytic cells and on endothelial cells in muscle tissues. Most isolates have 
been shown to bind to CD36, whereas binding of isolates to ICAM1 is only occasionally 
seen and is also of weaker strength. Controversial data exist on the contribution of IE 
binding to CD36 to malaria pathogenicity. Binding to CD36 was implicated with disease 
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by sequestration and by conferring platelet mediated clumping which correlates with 
severe disease. 10,15 Conversely, in a field study, CD36 binding isolates were found to be 
associated with non-severe disease, 12 it was proposed to be protective by sequestering IE 
in non-essential muscle tissues (reviewed by Serghides et al. 16) and by promoting non-
inflammatory phagocytosis of IE. 17,18 Also immune-modulatory functions were correlated 
to CD36 binding such as the down-regulation of dendritic cell activity by binding of IE to 
dendritic cells via CD36. 19  
A number of other receptors such as heparin, TSP, non-immune immunoglobulins, P-
selectin, PECAM (CD31) or αvβ3-integrin have all been shown to bind to IE in vitro, but 
its implications in vivo and role in malaria pathology are not yet clear (reviewed by 
Sherman et al.20). However, it is known that the binding of IE to chondroitin sulfate A 
(CSA) in the placenta plays an important pathological role in pregnancy associated malaria 
(PAM). 21  
Finally, a process called rosetting - the binding of IE to uninfected erythrocytes - has been 
shown to be associated with severe malaria in Africa. 22 Rosetting has been found to be 
serum dependent 23 and complement receptor 1 (CR1) was shown to be the main ligand on 
uninfected erythrocytes. 24 Rosetting is thought to be advantageous for the parasite by 
providing improved invasion of merozoites into uninfected erythrocytes or by shielding IE 
from host phagocytic cells or antibodies. 25  
1.3. PfEMP1 
The highly polymorphic Plasmodium falciparum erythrocyte membrane protein 1 
(PfEMP1) family contributes mainly to cytoadherence. These are large proteins (200-350 
kDa) deposited on the surface of infected erythrocytes (IE) from approximately 18 hours 
post invasion onwards. 26 PfEMP1 is located on the infected erythrocyte surface on knob-
like structures. The parasite derived proteins KAHRP (knob associated histidine rich 
protein) 27 and probably PfEMP3 play a role in knob formation and anchoring of PfEMP1 
to the erythrocytic cytoskeleton. 28 It has been shown that large amounts of PfEMP1 
molecules remain within the erythrocyte in vesicle like structures, the Maurer's clefts, 
suggesting possible post-translational control or slow and inefficient transport of this 
protein to the surface. 28,29 
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1.4. var genes  
In 3D7 P. falciparum culture strain, PfEMP1 is encoded by 59 highly diverse var genes, 
each of 8 to 14 kb of length. 30-33 They have a 2 exon-structure with exon 1 encoding the 
highly diverse extracellular part of PfEMP1 and a predicted trans-membrane domain (TM) 
and exon 2 encoding the conserved intracellular acidic terminal segment (ATS) anchoring 
the protein to the cytoskeleton. PfEMP1 molecules are structured into several semi-
conserved domains namely a N-terminal segment (NTS), duffy binding like (DBL) 
domains, cysteine-rich interdomain regions (CIDR) and in some instances a “constant 2” 
(C2) region (see Figure 1)(reviewed by Smith et al.34). DBL domains belong to a family of 
receptor binding motifs, which were previously described in merozoite proteins involved in 
erythrocyte invasion, such as P. vivax duffy binding proteins or P. falciparum EBA-175. 35 
DBL and CIDR domains are numbered in order of their location from the 5'end of 
PfEMP1. Furthermore, based on sequence similarities, mostly conserved cysteine residues, 
different subclasses of DBL domains (α to ε, x) and CIDR domains (α-γ) have been 
identified. The most N-terminal DBL1α and CIDR1α form the structurally conserved head 
structure which is found in almost all PfEMP1 molecules.  
Binding to specific receptors has been associated to various domains of PfEMP1, such as 
DBL1α to CR1 in rosetting 36, CIDR1α to CD36 37, DBL2β-C2 to ICAM1 38 and DBLγ 
and CIDR1α to CSA 39,40.  
Recently, a recombinant peptide which corresponds to the minimal CD36-binding domain 
of PfEMP1 was shown to bind to human dermal microvascular endothelial cells 
(HDMECs) which activated a signalling pathway in these cells, namely the Src-family 
kinases and downstream the mitogen-activated protein (MAP) kinase pathway. 41 It was 
suggested that this activated a dephosphorylation process of CD36 molecules on these 
endothelial cells which could result in an increase of IE adherence to CD36. 
However, not all PfEMP1 molecules with a certain adhesive domain also bind to the 
corresponding receptor and it has also been shown, that only 3 amino acid changes in a 
CIDR1α domain greatly reduced binding to CD36. 42 This indicates that binding abilities 
also rely on tertiary folding structures and are not obvious from primary sequence. 
Additionally, binding characteristics of a single domain of PfEMP1 might not correspond 
to the binding abilities of the whole protein. This discrepancy is seen in pregnancy-
associated malaria (PAM), where contradictory results exist on serological data, in vitro 
CSA binding studies on domains of PfEMP1 and in vivo binding characteristics of PAM 
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associated parasites. There is also evidence for non-specific or cross-reactive binding of 
antibodies to CSA-selected parasites. This questions previous reports of successful CSA 
binding inhibition assays or immunizations with CSA binding recombinant PfEMP1 
domains (reviewed by Rowe et al. 43). 
1.5. var gene subgroups  
Most var genes can be grouped regarding their different, but within each group, highly 
conserved 5’ upstream sequences (upsA, upsB and upsC) 30,44 (see Figure 1 [after Smith et 
al. 45,46]). In 3D7, the majority of var genes belong to var group B flanked by an upsB 
sequence and located subtelomerically on the chromosomes. This region is 
recombinogenic with various repetitive elements which was suggested to support ectopic 
recombination by clustering heterologous subtelomeric stretches (including var genes). 47 
It might be speculated that var genes generate their immense diversity in this region by 
various recombination events. var group A consists of 10 larger var genes with a distinct 
domain structure. var group A genes are also located subtelomerically, however, they are 
transcribed towards the opposite direction as var group B genes, which was proposed to 
reduce potential DNA exchange between var group A and B.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Characteristic domain structure of a var group A gene and a var group B or C gene. 
Domains which have been shown to be involved in binding are indicated. See text for explanations  
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Figure 1: var genes and domain structure
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Finally, 13 var genes called var group C are clustered centrally on chromosomes with a 
similar domain structure and length than var group B genes.  
Not much is known about the evolution of var genes which are to date only found in P. 
falciparum. It can only be speculated that an ancestral var gene had incorporated adhesive, 
cysteine rich domains such as the domain DBL. This domain seems to be of older origin 
since it is found in different Plasmodium species (see above). Insertion of this domain and 
its further duplication together with the assembly of other adhesive domains rendered the 
var gene to a sticky molecule. It is questionable if a stable chromosomal environment 
could have been the basis for the relatively fast evolution of a large gene family not present 
in other Plasmodium species. Therefore, it seems more likely that the original var gene was 
located subtelomerically embedded in a highly repetitive and recombinogenic region 
subject to a fast evolution force. eba-175 which is a potential source of the acquired DBL 
domain is also located on the subtelomers. Duplication event of this ancestral var gene 
likely generated the 3 subgroups. The highly conserved flanking sequences of var genes 
and phylogenetic analyses suggest that further duplications and recombinogenic events 
were mainly concentrated within var groups.  
 
Apart of var groups A, B and C, there are 2 particular var genes in 3D7 - var1 and var2. 
They belong to var group A according to their chromosomal location and transcriptional 
direction. 45 However, both have a distinct 5' upstream region (upsD and upsE). var1 is 
similarly structured than var group A genes, but has no ATS domain in 3D7. var2 shows 
an unusual domain structure with a DBL1x and no CIDR. Both var genes have been shown 
to be highly conserved among field isolates and have been associated with pregnancy 
associated malaria (PAM) and CSA binding 48,49(reviewed by Rowe et al.43). 
1.6. PfEMP1 and potential immune-modulatory functions 
PfEMP1 has also been discussed to mediate immune-modulatory processes. Blood stage 
parasites are thought to be mainly controlled by innate immune responses such as by 
phagocytosis of IE by splenic macrophages, and by adaptive responses such as antibodies 
which either inhibit cytoadherence, erythrocyte invasion or mediate antibody dependent 
cytotoxicity and cellular inhibition (reviewed by Artavanis et al. and by Urban et al. 50,51 ). 
To prime the adaptive immune response, antigen presenting cells such as dendritic cells 
play an important role in stimulating T cells. As mentioned above, there is evidence that 
binding of IE to dendritic cells down-regulates the activation of these cells and reduces 
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their ability to stimulate T cells. 19 This is thought to be mediated by binding of PfEMP1 to 
CD36 on dendritic cells. Phagocytosis of IE by macrophages was also shown to lead to 
their inactivation. Apart of the involvement of lipoperoxides generated by the haemozoin 
of the ingested parasite (reviewed by Urban et al. 51), it was found that macrophages which 
phagocyte IE involving binding to CD36 do not elicit the usual pro-inflammatory cascade. 
17,18
 At last, the CIDR1 domain of PfEMP1 was recently identified to be a poly-clonal B 
cell activator similar to protein A of Staphylococcus aureus and able to divert specific 
antibody responses. 52 
1.7. var genes - expression regulation and antigenic variation  
To evade the immune system, antigenic variation occurs in P. falciparum. This is the 
switching of expression between members of a surface antigen family. In the case of P. 
falciparum this is the switching of var genes. Antigenic variation is characteristic to 
parasites maintaining chronic infection and is also found in African trypanosomes, 
Neisseria, Borrelia or Giardia lamblia (reviewed by Kyes et al.53). There are still many 
questions regarding var gene regulation. It has been shown that every var gene represents a 
single transcriptional unit capable of in situ activation believed to involve epigenetic 
mechanisms. 54,55 Parasites are thought to express one PfEMP1 variant on the IE surface. 
By northern blots and reverse-transcription polymerase chain reaction (RT-PCR), a "leaky" 
transcription from the 5'end of most var genes in ring stage parasites was detected. 56,56,57 It 
was shown that the var gene encoding the expressed PfEMP1 is transcribed for about the 
first 24h of the erythrocytic cycle and might involve some form of epigenetic 
programming. 56,57 Voss et al. performed var promoter analyses by transient transfections 
which resulted in the identification of promoter motifs involved in var group specific 
repression and silencing (see Supplement III 58). In the same study, a slightly shifted period 
of transcription was found between var group B and var group C genes raising questions 
on potentially different functional features of these 2 groups. 
1.8. Molecular mechanisms of var switching 
S-phase dependent chromatin assembly has been suggested to be implicated in silencing of 
var genes involving the interactions between the var intron and a var upstream region. 55 
By transient transfection assays, Voss et al. 58 identified a var upstream motif which seems 
to be involved in silencing (see Supplement III). Calderwood et al. 59 showed that the var 
intron also possesses promoter activities speculating that the intron acts as an insulator 
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element building a boundary between transcriptionally active and silent chromatin regions. 
Moreover, boundary elements have been shown to be actively transcribed in Drosophila 
and in yeast. This could also explain the presence of sterile var transcripts consisting of the 
var intron and var exon 2. These were discovered together with var genes 31 but could not 
be explained to date.  
1.9. Antigenic variation and cytoadherence in Plasmodium 
Various other Plasmodium species are provided with multi-gene families potentially 
mediating antigenic variation such as the well studied SICAvar genes with 50-100 copies 
in the simian malaria P. knowlesi. 60 In SICAvar expression regulation, post-transcriptional 
gene silencing involving the 3'UTR was suggested to be involved. 60 Despite of highly 
conserved 3'UTR sequences within var groups, no such mechanisms were found for var 
genes. Another large multi-gene family of up to 1000 copies is called vir and was 
described in P. vivax. Homologs are found in various Plasmodium species such as in P. 
knowlesi, P. yoelii, P. chabaudi, P. bergheii or P. cynomolgi but not in P. falciparum 
(reviewed by Kyes et al. 53). Antibody responses against these proteins were shown to be 
elicited in vivo. But despite of their location on the erythrocyte surface and potential 
antigenic variant character, in contrast to PfEMP1 most of them do not mediate 
cytoadherence. However, heavy loads of late-stage P. knowlesi were shown in the placenta 
of pregnant macaque monkeys suggesting some sort of sequestration. Furthermore, P. 
knowlesi parasites in splenectomized monkeys did not express SICAvar anymore and were 
less virulent. 61 This classifies SICAvar as a potential virulence factor of P. knowlesi 
similar to PfEMP1 in P. falciparum. But no homology to var genes could have been shown 
apart of the existence of cysteine rich domains. These analogous multi-gene families seem 
to have evolved independently but display a similar function. Also P. chabaudi IE in mice 
were shown to sequester, but mainly in the liver. 10 multi-copy families were recently 
identified in this species, but the family responsible for sequestration was not identified yet 
and no var gene homologs were found. 62 It is a matter of discussion why these surface 
antigen families evolved and whether they first evolved the ability for cytoadherence 
followed by antigenic variation to escape the immune system (reviewed by Kyes et al. 53). 
However, since most Plasmodium strains apart of P. falciparum and few others do not 
sequester, it is likely that cytoadherence is a particular virulence factor characteristic of P. 
falciparum which evolved at a later time point. Also, the evolutionary driving force of 
cytoadherence is not yet totally clear. Evasion of spleen dependent killing is the most 
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accepted assumption. This is supported by reports on late stage P. falciparum parasites 
circulating in splenectomized humans. 63 In another study, P. falciparum parasites lost the 
ability to sequester in splenectomized Saimiri monkeys but displayed a different antigenic 
variant phenotype suggesting the involvement of another multi-gene family (reviewed by 
Kyes et al. 53). Other multi-gene families have been detected in P. falciparum such as the 
immunogenic rifins encoded by about 200 rif genes per haploid genome. 64 It is still 
unclear whether they are expressed at the surface of erythrocytes. Apart of spleen 
dependent killing, other factors have been proposed to drive the evolution of 
cytoadherence such as the provision of a favourable microaerophilic venous environment 
for parasite maturation, specific sequestration of gametocytes ensuring long-term 
transmission or the shielding of IE from host phagocytic cells or antibodies by binding to 
uninfected erythrocytes (rosetting).  
But why does the parasite send proteins onto the surface if not by rendering the surface of 
IE sticky? Apart of potential immune-modulatory functions, 19,52 Kyes et al. 53 also 
suggested a shielding function of PfEMP1 molecules covering the infected senescent 
erythrocyte and prevent recognition by autologous IgGs or complement. The human 
erythrocyte anion exchanger 1, called band 3, is the main target of anti-senescent 
erythrocyte antibodies in its modified form. It is believed that denatured haemoglobin 
forms hemichrome which cross-links to the cytoplasmic domain of band 3 eliciting 
aggregates of band 3. 65 The fact that these modified band 3 proteins cluster in the knobs 
together with PfEMP1 might not be coincidence. Finally, Saul et al. 66 even argued that 
parasites deliberately present parasite-derived antigens to the immune system to generate 
an immune response. By restricting parasite growth a premature death of host and thus 
aborted transmission is prevented. However, this hypothesis is inconsistent with data on P. 
falciparum and P. chabaudi mutants showing no detectable surface antigens while being 
less virulent. 53  
To sum up, antigenic variation is a common feature of Plasmodium species ensuring long-
term survival. Cytoadherence seems to have evolved in addition in few species 
representing a devastating virulence factor for the host. Nevertheless, advantages for the 
parasite seem to outweigh a potential premature death of the host. 
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1.10. PfEMP1 in vivo 
Apart of studies on binding abilities of field isolates or recombinant PfEMP1 peptides (see 
section 1.4.), not much is known about pathological impacts of different PfEMP1 or their 
role in eliciting a specific immune response. However, serological studies on PfEMP1 have 
shown that this family is a target of naturally occurring antibodies which also provides 
variant specific protection. 67,68 Important findings were obtained by Bull et al. 69 on the 
potentially different virulent nature of variant surface antigens (VSA), of which PfEMP1 is 
the best characterized. By comparing agglutination frequencies of parasites of Kenyan 
children, they found that children with a low antibody repertoire against VSA were 
infected with parasites expressing a restricted virulent subset of VSA which was 
commonly recognised by heterologous community plasma while parasites of hosts with a 
large anti-VSA antibody repertoire expressed rarer VSA which were rarely recognised by 
heterologous plasma. The question arises if these VSA subsets coincide with var groups, 
namely var group A, B or C. Recent studies indicated an involvement of var group A in 
severe malaria such as the finding of larger PfEMP1 on the surface of parasites conferring 
cerebral malaria 70 and the detection of a subgroup of DBL1α sequences of var transcripts 
isolated of parasites eliciting severe disease. 71 The involvement of var group A was 
further confirmed by the findings of Jensen et al. 72 who found an up-regulation of several 
var group A genes in 3D7 culture strains which were in vitro selected for severe malaria 
VSA phenotype by panning parasites on plasma pools of semi-immune children and by 
panning parasites on transformed human bone marrow endothelial cells (TrHBMEC) 
which express various receptors such as VCAM-1, P-selectin or ICAM-1, but not CD36.  
Apart of the open question about the virulent nature of different PfEMP1s, there is very 
little known about expression and dynamics of var gene switching in vivo. In vitro, high 
switching rates of 2% per generation were measured. 73  
The only data on var switching in vivo were received by volunteers artificially infected 
with 3D7. 74 Surprisingly, the same var gene was found early in infection in different 
volunteers suggesting some form of imprinting. The initial switching rate was estimated to 
be at 16% but decreased thereafter also suggesting different switching rates for different 
var genes and host conditions. 
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1.11. Aim of this study 
PfEMP1 encoded by var genes is an important virulence factor of P. falciparum 
successfully evading the immune system. However, few studies have been carried out to 
study the dynamics and expression of var genes in vivo. We carried out a longitudinal 
study during a 4-month period in malaria semi-immune children from Papua New Guinea. 
The longitudinal distribution and structure of var transcripts was analyzed by RT-PCR, 
cloning and sequencing. Furthermore, by amplification of the conserved 5' upstream 
sequences of var groups, we also analyzed var transcripts with respect to their affiliation to 
var group B or C.  
Moreover, in a malaria case-control study in children from Papua New Guinea we 
evaluated the potential difference in the virulence of var group specific PfEMP1. The 
distribution of var transcripts among var group A, B and C was analyzed by quantitative 
real-time PCR and compared in children with severe malaria, mild malaria and 
asymptomatic malaria.  
These studies are an important step towards understanding the effect and the dynamics of 
var gene expression in naturally infected individuals. 
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M A J O R A R T I C L E
Longitudinal Assessment of Plasmodium falciparum
var Gene Transcription in Naturally Infected
Asymptomatic Children in Papua New Guinea
Mirjam Kaestli,1 Alfred Cortes,3,a Moses Lagog,3 Michael Ott,2 and Hans-Peter Beck1
1Swiss Tropical Institute and 2F. Hoffmann-La Roche AG, Basel, Switzerland; 3Papua New Guinea Institute of Medical Research, Madang,
Papua New Guinea
Sequestration and antigenic variation are essential for Plasmodium falciparum survival in vivo contributing
to severe pathologic findings and, also, chronic infection. Both are conferred by P. falciparum erythrocyte
membrane proteins encoded by ∼60 var genes. To study the dynamics of var gene expression, we conducted
a 4-month longitudinal study of semi-immune children from Papua New Guinea. By use of magnetic bead–
anchored reverse-transcription polymerase chain reaction analysis performed over 5 var regions, as well as
cloning and sequencing, the longitudinal distribution of full-length var transcripts was analyzed. We identified
a dynamic picture of var gene expression with rapid switches but with identical var transcripts recurring for
up to 10 weeks. The number of var transcripts was correlated to the number of infections, with a mean of
1.7 var transcripts identified per sample and infecting strain. Analysis of 158 different Duffy binding–like 1a
sequences confirmed the recombinogenic nature of var genes. This is the first report of the dynamics of var
gene expression in chronically infected children.
Cytoadherence and sequestration of Plasmodium falci-
parum–infected red blood cells (RBCs) are considered
to be among the most important factors associated with
the pathogenicity and virulence of P. falciparum malaria.
Cytoadherence is mediated by the polymorphic P. fal-
ciparum erythrocyte membrane protein 1 (PfEMP1),
which is located on the surface of infected RBCs. PfEMP1
is encoded by 1 of ∼60 var genes, each of which is 8–
14 kb in length [1–3]. These large proteins of 200–350
kDa mediate binding to various cell surface receptors
(reviewed in [4]). Cytoadherence is thought to prevent
spleen-dependent killing, but it also has been shown
that binding of PfEMP1 to CD36 presented on den-
dritic cells down-regulates dendritic cell activity, sug-
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gesting an immune modulatory role for PfEMP1 [5].
PfEMP1 has also been implicated in rosetting [6], is a
target of naturally occurring immune responses, and
shows antigenic variation [7, 8]. The expression of dif-
ferent PfEMP1 variants is accompanied by changes in
the adhesive phenotype of infected RBCs [7].
PfEMP1 proteins are structured into several semi-
conserved domains—namely, an N-terminal segment
(NTS); various Duffy binding–like (DBL) domains; a
cysteine-rich interdomain region (CIDR); in some in-
stances, a “constant 2” (C2) region; a transmembrane
domain; and the conserved, C-terminal acidic terminal
segment (ATS), which represents the intracellular part
of PfEMP1 that anchors the protein to the cytoskeleton
(reviewed in [9]). Different subclasses of DBL domains
(a– and x) and CIDR domains (a–g) have been iden-
tified. The most N-terminal DBL1a and CIDR1a form
the conserved head structure of the protein. This head
structure is found in almost all PfEMP1 molecules.
Binding has been associated with various domains of
PfEMP1 [6, 10–15], such as DBL1a to CR1 (in rosette
formation), CIDR1a to CD36, or DBLb-C2 to in-
tracellular adhesion molecule 1 (ICAM1). Binding to
chondroitin sulphate A in samples from placental ma-
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laria has been shown to occur not only with DBL-g but, also,
with CIDRa [12–14].
Most var genes can be classified into 3 groups, on the ba-
sis of their different but, within each group, highly conserved
5′ upstream sequences [16, 17]. The majority of var genes are
located subtelomerically and possess a upsB-type upstream re-
gion. These var genes are located in a region that is highly
recombinogenic with various repetitive elements that support
ectopic recombination by clustering of heterologous subtelo-
meric stretches (including var genes) [18]. Another small set
of var genes is arranged in chromosome internal clusters; these
genes possess upsC-type upstream regions. A third group of
var genes consists of subtelomerically located var genes, which
are transcribed toward the telomeres (upsA-type regions [17]).
That var gene transcription of the upsB- and upsC-type regions
is regulated differently [19] raises questions about the different
functional features of these 2 var gene groups.
The detailed mechanism of var gene regulation is still un-
known, but it has been shown that every var gene represents a
single transcriptional unit that is capable of in situ activation
involving epigenetic mechanisms [20, 21]. The var genes are
transcribed for the first 24 h of the erythrocytic cycle [4]. Whereas
relaxed transcription of multiple truncated var genes was found
at the ring stage, only one full-length var transcript was found
at the early trophozoite stage [22]. A switching rate of 2.4%/
generation was calculated in vitro [23], but little is known about
var gene expression and switching in vivo. In a longitudinal study
involving nonimmune adults who were artificially infected with
the 3D7 laboratory-adapted strain, Peters et al. [24] showed that
the first transcribed var gene in the erythrocytic stage was iden-
tical in different adults. The initial switching rate was estimated
to be 16%, but it decreased thereafter, suggesting different switch-
ing rates for different var genes and host conditions.
In the present study, we describe var gene expression in nat-
urally infected semi-immune children from Papua New Guin-
ea during a 4-month period. The longitudinal distribution and
structure of the expressed var transcripts were analyzed by re-
verse-transcription polymerase chain reaction (RT-PCR), clon-
ing, and sequencing. We also analyzed var transcripts, with re-
spect to the chromosomal location using the conserved 5′ up-
stream regions for amplification. Using this approach, we de-
scribe the dynamic nature of var gene expression in several
asymptomatic children. Many var genes were transcribed si-
multaneously with switches at short intervals, but some iden-
tical transcripts recurred in the same child, even after 10 weeks.
MATERIALS AND METHODS
Study area and collection of blood samples. From April to
August 2001, the period of transition from the wet season to the
dry season, we performed a longitudinal study at the Maiwara
Primary School on the Madang North Coast in Papua New
Guinea. In this region, where malaria with perennial transmission
is endemic, infections with P. falciparum and P. vivax are com-
mon. P. malariae and P. ovale are also present in this area.
Written, informed consent was obtained from the children’s
parents or guardians. The study was approved and ethical clear-
ance was given by the Medical Research Advisory Committee
of Papua New Guinea. According to national treatment guide-
lines, children with parasites but without malaria symptoms
were not treated.
After informed consent was obtained from parents, we ob-
tained blood samples, by fingerprick (0.2–0.5 mL) or venopunc-
ture (2 mL), from 11 children who had asymptomatic P. falci-
parum infections. The children were 8–10 years of age. Samples
were obtained from 8 children every 2 weeks for 4 months and
from 3 children every 5 days for 1 month.
Assessment of P. falciparum infections. Giemsa-stained
blood slides were analyzed by microscopy. For blood samples
that were found to be positive, by microscopy, for P. falciparum,
the number of P. falciparum infections was determined by msp2
genotyping, as described elsewhere [25]. In brief, 30 mL of full
blood was spotted on filter papers (Isocode Stix; Schleicher &
Schuell) and was dried for 20 min at 80C. After washing, msp2
PCR was performed directly on the filter papers, and restriction
fragment–length polymorphism (RFLP) analysis of nested PCR
products was used to record the number of infecting strains.
Isolation of full-length var transcripts and RT-PCR. Total
RNA was extracted using TRIzol (Invitrogen), according to the
manufacturer’s instructions. Extraction with TRIzol was per-
formed twice, to decrease DNA contamination. After RNA was
treated with 3 U of RQ1RNase-free DNase (Promega), another
extraction with TRIzol was performed. To obtain only full-length
var transcripts, RNA was dissolved in binding buffer (0.5 mol/
L LiCl, 1 mmol/L EDTA, 10 mmol/L Tris, pH 7.5), and 1 pmol
of biotinylated oligonucleotide complementary to the ATS do-
main (Biotin-5′-GGTTC(A/T)A(A/G)TAC(C/T)ACTTC(A/T)
AT(C/T)CCTGGT(A/G)CATATATATCATTAATATCCAATT-
CTTCATA(C/T)TCACTTTC(T/G)GA(A/T/G)GA-3′) was added
and was incubated at a temperature gradient from 65C to 4C
over 30 min. One hundred fifty micrograms of Dynabeads M-
280 streptavidin, washed according to the manufacturer’s pro-
tocol and dissolved in 5.5 mol/L LiCl, was added to the RNA.
After undergoing rotation for 30 min at 37C, the beads were
washed 3 times with washing buffer (10 mmol/L Tris, 1 mmol/
L EDTA, 0.15 mol/L NaCl, pH 7.5) and 1 time with 10 mmol/
L Tris. RT was performed on the captured hybrids, primed by
400 ng oligo(dT)12–18, and was done by use of Sensiscript (Qiagen)
reverse transcriptase, according to the manufacturer’s protocol,
in a final volume of 20 mL. An aliquot without reverse tran-
scriptase was used as a negative control. After RT, cDNA was
treated with RNase A, and 1 mL was used for each of the various
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Table 1. Oligonucleotide primers used for amplification of var gene regions.
var Gene region
Length of
amplified
product Tanneal Name Primer sequence Reference
upsB-type 5′UTR-DBL1a 1 kb 53C var 4A3-5′ a
var 4A3-3′ b
5′-CTCAT(A/T)TATAATTTTACAAAATATATAAAAC-3′
5′-CC(A/T)AT(A/G)GC(A/G/T)GCAAAACT(G/C/T)CG(A/T)GC-3′
[16]
[16]
upsC-type 5′UTR-DBL1a 1 kb 54C var 5B1-5′
var 4A3-3′
5′-CACATATA(A/G)TACGACTAAGAAACA-3′
5′-CC(A/T)AT(A/G)GC(A/G/T)GCAAAACT(G/C/T)CG(A/T)GC-3′
[16]
[16]
DBL1a 400 bp 52C DBLa-5′
DBLa-3′
5′-GCACGAAGTTTTGCAGATAT(A/T)GG-3′
5′-AA(A/G)TCTTC(T/G)GCCCATTCCTCGAACCA-3′
400 bp 51C aAF
aBR
5′-GCACG(A/C)AGTTTTGC-3′
5′-GCCCATTC(G/C)TCGAACCA-3′
[22]
[22]
CIDR1a 400 bp 45C CIDR1-5′
CIDR1-3′a
CIDR1-3′b
5′-GGT(A/T/G)(A/C/T/G)(A/C)TGATATGTTA(A/C)A(A/C)GATTC-3′
5′-T(C/T/G)TAGTAATTTATC(A/T/C)ATTGT-3′
5′-T(C/T/G)TAATAAGAATTCGATTGC-3′
[14]
DBLb 500 bp 50C DBLb-5′
DBLb-3′
5′-CGACGT(C/G)AACA(C/T)ATGTGTACATC-3′
5′-CA(C/T)TC(T/G)GCCCA(C/T)TC(A/T)GTCATCC-3′
NOTE. CIDR, cysteine-rich interdomain region; DBL, Duffy binding–like sequence; Tanneal, annealing temperature; UTR, untranslated region.
a Forward primer.
b Reverse primer.
PCR amplifications (table 1) with Advantage cDNA polymerase
(Clontech), by use of the primers shown in table 1. The PCR
conditions were 35 cycles for 30 s at 95C, for 1 min at the
annealing temperature (table 1), and for 70 s at 64C. One mi-
croliter of negative control (without reverse transcriptase) was
amplified in parallel. If this negative control yielded a product,
then the positive sample was discarded and was excluded from
the analysis.
To exclude cross-contamination of RT-PCR products, se-
quence-specific primers were designed for those sequences that
occurred in 11 child. Sequence-specific PCR was performed on
the genomic DNA of the parasites of those children, to confirm
the presence of each particular sequence.
Cloning and sequencing of PCR products. PCR products
were cloned into pGEM-T vector (Promega) or pGEM-3Zf(+)
vector (Promega), according to the manufacturer’s instructions,
and they were transfected into Escherichia coli SURE cells (Stra-
tagene). An average of 20 positive clones was processed for
sequencing (Montage Plasmid Miniprep96 Kit [Millipore]; 96
capillary ABI Prism automated sequencing system [Applied
Biosystems]). Multiple alignment of identical sequences derived
from the same probe allowed the exclusion of PCR-derived
mutations. Two sequences were considered to be identical when
!3 single-nucleotide polymorphisms (SNPs) were detected.
Sequence analysis. DNA sequence analysis was per-
formed using DNASTAR (version 4; http://www.dnastar.com/),
BLAST (from the National Center for Biotechnology Information
Web page [http://www.ncbi.nlm.nih.gov/BLAST/]), plasmoDB,
CLUSTALW (http://searchlauncher.bcm.tmc.edu/multi-align/ or
http://www.ebi.ac.uk/clustalw/), and BioEdit (version 5; http://
jwbrown.mbio.ncsu.edu/BioEdit/bioedit.html). Phylogenetic anal-
yses were performed using PHYLIP (version 3.6; http://evolution
.genetics.washington.edu/phylip.html) or Molecular Evolutionary
Genetics Analysis (MEGA, version 1.02; The Pennsylvania State
University [http://evolgen.biol.metro-u.ac.jp/MEGA]), withneigh-
bor-joining or maximum parsimony methods and accompanied
by bootstrap analysis with 1000 replicates. Predictions of second-
ary structure were performed using PredictProtein (http://cubic
.bioc.columbia.edu/predictprotein/). Population comparison anal-
ysis was performed using ARLEQUIN (version 2; analysis of mo-
lecular variance; Genetics and Biometry Laboratory, University of
Geneva [http://anthropologie.unige.ch/arlequin/]). Nucleotide se-
quence data are available in GenBank (accession nos. AY462581–
AY462851).
RESULTS
var Gene transcription in individual children. We studied var
gene transcription longitudinally in asymptomatic children in
Papua New Guinea for 4 months. RT-PCR was performed on
full-length var transcripts over 3 adhesive domains (DBL1a,
CIDR1, and DBLb) and 2 upstream regions (subtelomeric upsB-
type 5′ untranslated region [UTR] to DBL1a and central upsC-
type 5′UTR to DBL1a) (figure 1A). RT-PCR was followed by
cloning and sequencing of the PCR products. The DBL1a do-
main yielded the most-informative PCR product, because it
contains conserved blocks that enable the design of universal
primers and thus ensures the amplification of the majority of
var transcripts with minimal bias [22]. However, we are aware
that, with this approach, potential bias in the identification of
sequences might occur.
We observed a highly dynamic and variable picture of var
transcription, which, in the next section, is described in detail
for 4 representative children (figures 1–4). The longitudinal dis-
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Figure 1. A, Schematic representation of sequenced var domains and upstream regions. B, Longitudinal distribution of Duffy binding–like 1a
(DBL1a) sequences in child L6. The first major column shows the msp2 genotyping data from the polymerase chain reaction–restriction fragment–
length polymorphism analysis. The second major column indicates time points (in weeks) when samples were found to be positive for Plasmodium
falciparum by microscopy. Different strains (A–F) are indicated in the minor columns. The third major column shows the longitudinal distribution of
var gene sequences. Bars, individual sequences of DBL1a. Recurring sequences are indicated as white bars. The size of the bar reflects the relative
frequency of a particular sequence (log10).
tribution of var sequences and msp2 genotypes, for all time points
and among all children, is shown in figure 5, which is available
in the online version of this article, at the Journal’s Web site
(http://www.journals.uchicago.edu/JID/journal/home.html).
In most children, a large number of different sequences were
identified from single blood samples, and, at subsequent time
points, mostly new sequences that had not been previously
detected were identified. For example, for child L6, the majority
of DBL1a sequences identified, which were isolated in 2-week
intervals, were different at every time point (figure 1B). During
14 weeks, 48 different DBL1a sequences were identified. Some
sequences were still present after 2 weeks or even recurred at
later time points. It is important to note that child L6 was
constantly infected with a large number of different P. falci-
parum strains, having 2–5 infections.
In contrast, some individuals, such as child L11, showed a less
diverse var gene transcription, with only 1–3 different var tran-
scripts identified per time point (figure 2). In child L11, all 5
domains were amplified from samples that were found to be
positive for P. falciparum, according to microscopy, at weeks 0,
10, and 12, when the child was infected with only 1 or 2 strains.
At week 10, 1 DBL1a, 1 CIDR1a, and 1 DBLb sequence were
found, suggesting that the origin of these sequences was in a
single expressed var gene. The observed DBLb sequence had
already been observed 10 weeks earlier (figure 2). To test whether
this reemerging sequence derived from 1 var gene or whether it
was an identical domain of an otherwise different var gene, we
amplified and sequenced genomic DNA with sequence-specific
primers that targeted the domains 5′UTR-DBL1a and DBL1a-
DBL2b. Identical sequences over this stretch were obtained, sug-
gesting the presence of the identical var gene (data not shown).
In child L8, both upstream types (upsB-type and upsC-type
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Figure 2. Longitudinal distribution of 5 different var gene regions in samples obtained from child L11. For details, see figure 1.
regions) were found at time points when samples were positive
for P. falciparum by microscopy (figure 3). Between 1 and 11
different sequences of the upsB-type 5′UTR-DBL1a region were
detected, whereas 11 upsC-type 5′UTR-DBL1a sequence was
never found.
In child L12, identical sequences reemerged several times
(figure 4). A upsC-type 5′UTR-DBL1a sequence recurred 3
times, at weeks 2, 4, and 12, and a CIDR1a sequence was found
at weeks 0 and 4. Amplification of cDNA from week 2, by use
of sequence-specific primers, also revealed the presence of this
CIDR domain, and this indicates continuous transcription of
this var gene for 4 weeks.
To test whether sequences from different domains of 1 sample
were derived from the same var gene and to test the quantitative
distribution of these sequences, the most abundant upsB-type
5′UTR and DBL1a sequences of child L6 (from the sample
obtained at week 4) and child S12 (from the sample obtained
at day 10) were linked with genomic DNA by PCR. Specific
forward primers were designed in the upsB-type 5′UTR domain,
and degenerated reverse primers were used for DBL1a. Sub-
sequent sequencing showed that, in both children, the previ-
ously identified most abundant DBL1a sequence was connected
with the most abundant upsB-type 5′UTR-DBL1a sequence,
indicating their origin in the same var gene.
Distribution of var sequences in different children. Be-
tween 1 and 15 different sequences per domain were found in
a single child. The average number of DBL1a sequences found
per child was 5.2, and between 1.5 and 3.7 sequences were
found for the other amplified domains (table 2).
Thirty-two identical sequences, which differed by no more
than 1–3 SNPs, were found in 11 child (table 2). Twenty-three
of those sequences were DBL1a domains. An additional 2
DBL1a sequences from child L3 and L8 differed by only 10
SNPs. DBLb transcripts could be amplified from only 33% of
samples in which we identified DBL1a transcripts.
Using the upstream sequence of transcribed var genes to de-
termine their chromosomal location, we found that more var
transcripts derived from subtelomerically located genes (upsB-
type var transcript) than from centrally located genes (upsC-type
var transcript). A mean of 1.3 upsB-type var gene transcripts was
detected per infecting strain, compared with a mean of 0.7 upsC-
type var gene transcripts (table 2).
Multiple infections and var gene transcription. Using msp2
genotyping, we found, in 86% of all cases, multiple infections
(2–5 infections), with an average of 2.8 infecting strains. When
the average of 5.2 DBL1a sequences per sample was adjusted
to the number of infections present, we found an average of
1.7 DBL1a sequences per infecting strain (table 2). Linear re-
gression analysis revealed a significant correlation between the
number of infecting strains and the number of DBL1a se-
quences identified ( ; ; confidence limits,2Pp .0002 r p 0.31
0.45). In some instances, the number of var gene sequences
observed was less than the number of infecting strains present.
This finding might be ascribed either to technical limits, such
as sensitivity or primer bias, which we cannot exclude while
amplifying such a diverse gene family, or to the lack of the
respective domain in a transcribed var gene (e.g., no DBLb
domain). At all time points when var sequences reemerged,
identical strains were detected, indicating the presence of the
same parasite. These identical strains were also detected in sam-
ples obtained between both time points (figures 1–4).
Analysis of var domain sequences. All multiple alignments
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Figure 3. Longitudinal distribution of var gene sequences of both upstream regions and Duffy binding–like 1a (DBL1a) in samples obtained from
child L8. For details, see figure 1.
of the different domains can be found in figure 6, which is
available in the online version of this article, at the Journal’s
Web site (http://www.journals.uchicago.edu/JID/journal/home
.html). Multiple alignment of 150 DBL1a sequences confirmed
the existence of “universally” conserved blocks (reviewed in
[9]). We found clear evidence for recombination—for example,
2 sequences in samples from child S12 and child L3, which
differed in the first 180 bp and which were identical after the
universally well-conserved homology block F. Furthermore, for
child L6, over the first 255 bp to homology block F, a DBL1a
sequence from a sample obtained at week 12 was identical to
another DBL1a sequence obtained at the same time point,
whereas, after this 255-bp stretch, the sequence was identical
to a DBL1a sequence isolated from a sample obtained from
the same child 2 weeks later.
Sequences similar to the previously described DBL-a1 sub-
type [26, 27] were found 40 times (25%). Also, the varCOMMON
type [28], which has been shown to be constitutively transcribed
in 60% of malaria-infected Gabonese children, was found 3
times (twice in samples from child L6 that were obtained 2
weeks apart and once in a sample obtained from child L8).
Alignment and phylogenetic analysis of the Papua New
Guinea–derived DBL1a sequences with 50 previously se-
quenced DBL1a sequences from African P. falciparum strains
did not show any separate clustering of PNG or African sam-
ples (data not shown). In contrast, stretches of 10–20 amino
acids in the polymorphic region of DBL1a occurring in only
1 PNG sample recurred in 1 of the African samples. No geo-
graphic patterns could be detected, which is consistent with
the results of other studies [29, 30].
Multiple alignments with 40 upsB-type 5′UTR-ATG sequences
and 9 upsC-type 5′UTR-ATG sequences confirmed the conserved
character of upsB- and upsC-type upstream sequences [16].
However, 150 bp upstream of ATG, some sequences showed
deletions of up to 100 bp. One upsB-type 5′UTR-DBL1a se-
quence occurred in 1 child and in 3D7 parasites as var group
B/C (PF08′0103), and it showed small differences from the char-
acteristic upsB-type upstream sequence. It had a different length
of poly(dA-dT) and homopolymeric (dA:dT) tracts and a de-
letion of 117 bp in an otherwise well-conserved stretch, located
250 bp upstream of the ATG.
In multiple alignments and in phylogenetic and protein-
structure analysis of 38 upsB-type and 15 upsC-type var genes
over the NTS region and the first 100 amino acids of DBL1a,
no difference was observed between subtelomeric and central
var genes. NTS and DBL1a sequences derived from either sub-
telomeric or central locations did not cluster separately in phy-
logenetic analyses or by computing population comparison
tests, and the difference in this stretch of sequence between
subtelomeric and central var genes was not significant (fixation
index, 0.015; ).Pp .088
Sequences identified in field isolates and from 3D7 in the
genome project. We identified 1 upsB-type 5′UTR-DBL1a se-
quence and 3 DBL1a sequences that were identical to var gene
domains in 3D7 parasites. One particular 3D7 var DBL1a se-
quence was detected 3 times (once in child L13 and twice in
child L6). According to PlasmoDB, this DBL1a sequence rep-
resents a var pseudogene (PFL1970w) with a premature stop
codon 4275 bp downstream of the ATG. However, when we
designed PFL1970w-specific primers to sequence over this stop
codon, PCR on genomic DNA of 3D7, followed by cloning and
sequencing of 10 clones, revealed an insertion relative to the 3D7
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Figure 4. Longitudinal distribution of both upstream regions, Duffy binding–like sequence 1a (DBL1a), and cysteine-rich interdomain region–a
(CIDRa) in samples obtained from child L12. The hatched and dotted bars in the “CIDR1a” panel denote 1 CIDR1a clone that was detected at weeks
0 and 4 (white bars) and that was also detected by sequence-specific primers on cDNA at week 2 (hatched bar) and on genomic DNA at week 12
(dotted bar). For details, see figure 1.
sequence producing a frameshift mutation (4233 bp downstream
of ATG), resulting in a continuous open-reading frame.
DISCUSSION
During the past years, much information on var gene tran-
scription has been gained; however, most of this informa-
tion has been based on the findings of in vitro studies, and
few studies have looked at var gene transcription in vivo [24,
26, 31]. To our knowledge, this is the first longitudinal study
of var gene transcription in naturally infected children. We
generated cDNA and cloned and sequenced 3 adhesive var
gene domains (DBL1a, CIDR1, and DBLb) and 2 var 5′UTR
stretches (upsB-type and upsC-type regions) from blood sam-
ples obtained, over 4 months, from asymptomatic children liv-
ing in an area where malaria is endemic. Using this approach,
we identified a large number of different sequences, and we
observed a dynamic picture of var gene transcription. However,
despite such a dynamic transcription pattern, some sequences
persisted or recurred for up to 10 weeks.
It has often been argued that RT-PCR could identify the
smallest amounts of RNA, and, in the case of var gene tran-
scription, it is indeed unclear whether cDNA represents only
functional full-length mRNAs, because incomplete and 3′-trun-
cated var transcripts have been observed [22]. By selecting var
transcripts that contained the 3′ATS domain before RT-PCR
was performed, we are confident that the number of incomplete
mRNAs was reduced to insignificant levels. This was confirmed
by the use of tags, other than the anti-ATS, that resulted in no
product at all (data not shown). Furthermore, when Peters et
al. [24] compared the number of var transcripts from 3D7
between the ring stage and the trophozoite stage, they observed
no difference in the number and proportion of transcripts, and
they even questioned the relaxed transcription in vivo. More-
over, by use of single-cell RT-PCR for trophozoite-stage cells,
up to 5 different transcripts were observed in 3D7 [32], which
questions the hypothesis of mutually exclusive var gene tran-
scription that was previously suggested by results of cultures
selected for receptor binding [20, 33].
We observed the largest diversity within the DBL1a se-
quences, with an average of 5.2 different sequences per blood
sample. This finding is similar to previous reports of 3–15 dif-
ferent var gene transcripts in natural infections or from laborato-
ry-adapted strains [22, 24, 31, 32, 34]. One explanation for the
large number of observed var transcripts at 1 time point might
be the presence of multiple concurrent P. falciparum infections.
It is noteworthy that the mean number of var gene transcripts
per sample very much resembles the mean number of concur-
rent infecting strains in this age group [35]. It has been speculat-
ed that multiple infections provide protection against hyperin-
fection by stimulating the immune system with a broad range
of diverse antigens, such as PfEMP1 [35, 36]. Concomitantly
expressed PfEMP1 variants could also explain the findings of
Bull et al. [37], who showed that children with asymptomatic
infections had a greater repertoire of variant-specific antibodies.
Most children had multiple infections, and multiple var tran-
scripts were detected in these children. This clearly added to
the complexity of the observed var gene expression dynamic.
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Table 2. Overview of analyzed sequences of different transcribed var gene regions.
General overview of the no. of sequences
var Gene regions
Subtelomeric
upsB-type
5′UTR-DBL1a
Central
upsC-type
5′UTR-DBL1a DBL1a DBLb CIDR1a
No. of sequences (no. of positive blood samples) 417 (20) 133 (17) 789 (39) 97 (13) 118 (8)
No. of different sequences 66 23 158 22 17
Average no. of different sequences per child and time point 3.7 1.5 5.2 2.0 3.0
Average no. of different sequences per infecting strain,
child, and time point 1.3 0.7 1.7 0.8 1.7
No. of transcribed different sequences in 3D7 culture strain 7 1 8 5 ND
No. of recurring sequences in the same child
After 10 days 2 … 2 … …
After 2 weeks 2 2 7 … …
After 4 weeks … … 2 … 1
After 5 weeks 1 … … … …
After 6 weeks … … 4 … …
After 8 weeks … 1 … … …
After 10 weeks … 1 2 1 …
No. of identical sequences in different children
In 2 children 3 … 16 4 …
In 3 children … 1 4 … …
In 3D7 culture strain 1 … 3a … …
NOTE. CIDR, cysteine-rich interdomain region; DBL, Duffy binding–like sequence; ND, not done; UTR, untranslated region.
a One of these 3 sequences was detected in 2 children.
However, in samples obtained from children who had single
infections, only 1 DBL1a sequence was found to be abundant
or present. There was a linear correlation between the number
of detected transcripts and the number of infecting strains pres-
ent. The relatively low number of var transcripts in children
who had a single infection suggests a tight regulation that al-
lowed the transcription of only 1 or a few var genes at 1 time
in the clonal parasite population. However, the observation of
rapidly changing var transcripts suggests high switching rates.
Peters et al. [24] reported different switching rates between
initial and subsequent switching events in laboratory-induced
infections. Our data suggest different switching rates for some
var genes that were transcribed for only a short period, whereas
others persist for weeks or recur. In the present study, we cannot
distinguish between different switching rates or selection forces
acting on previously expressed PfEMP1 molecules. We also can-
not completely rule out that recurring var gene sequences are
derived from a closely related parasite strain that expresses a
highly similar var gene. However, the detection of these recurring
var sequences at intermediate time points (figure 4) and the
presence of the same P. falciparum strain suggest that these var
sequences are derived from a constantly expressed var gene.
Although we have no quantitative data for the detected var
transcripts, we were able to semiquantify the presence of var
transcripts, to a certain degree, and to show that the most
abundant sequences of 2 var regions in the same probe orig-
inated in 1 var gene (see the “var Gene Transcription in In-
dividual Children” subsection in Results). We are currently ad-
dressing this question in ongoing case-control studies that use
real-time PCR to quantify var transcripts, with respect to the
various groups of upstream regions.
The previously described conserved character of dimorphic
var gene upstream regions [16] and the different regulation
mechanisms of these var gene groups [19] led us to speculate
that they might be functionally different. Therefore, we am-
plified both 5′UTR stretches and the adjacent NTS-DBL1a se-
quences, and we then compared expression dynamics and cod-
ing sequence. Of all analyzed 5′UTR sequences, 26% were of
the upsC type, which reflects the proportion of upsC-type var
genes in the 3D7 genome, which is 22%. We never detected
expression of 13 different centrally located var genes in a sam-
ple. We had speculated that centrally located var genes would
be more conserved because of a location that was less prone
to recombination. This is supported by the findings of Rubio
et al. [38], who showed that centrally located var genes were
more related to each other than to subtelomerically located var
genes. Consequently, we hypothesized that upsC-type var genes
would be recognized faster by the immune system. However,
in the present study, upsC-type sequences were found to persist
for 8–10 weeks, suggesting that these var genes can be also
Longitudinal assessment of var gene transcription in asymptomatic children                                       33
expressed over a long time. Furthermore, we were unable to
show any structural or phylogenetic differences within the short
sequence of the NTS-DBL1a domain of both var gene groups.
However, this stretch of sequence is known to be conserved,
represents only a limited stretch of the whole var gene, and
does not allow for further conclusions to be made.
In summary, we have shown that chronically infected chil-
dren express several var genes simultaneously, with a mean of
1.7 different var genes per infecting strain. The repertoire of
var genes circulating in a parasite population seems to be large
and recombinogenic. We have shown a rapid change in var
gene expression, but we also detected, for the first time, re-
curring var genes after 10 weeks.
Expression of many and rapidly changing var genes is ex-
pected in asymptomatic children, in whom parasite survival is
a balance between antigenic escape and binding capacity to
avoid splenic clearance. These children must be considered to
be semi-immune, and the var gene repertoire of the infecting
parasites might already be exhausted. Therefore, the parasite
might be forced to rapidly switch to new var variants. To un-
equivocally understand var gene expression in vivo, studies
involving naive individuals must be conducted. Furthermore,
comparing var gene expression in subjects who have severe
malaria with that in subjects who have mild malaria should
shed more light on the complex cascade of var gene expression
and an immunological escape mechanism.
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Abstract 
Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) is considered to be a 
major pathogenicity factor in malaria by mediating cytoadherence. PfEMP1 is encoded by 
approximately 60 var genes per haploid genome. Most var genes can be grouped into 3 
subgroups A, B and C according to their, within groups, conserved non-coding upstream 
region. This raises questions about the clinical significance of these structural differences. 
Using real-time quantitative PCR in a case-control study conducted in Papua New Guinea, 
we compared the distribution of var gene transcripts of var groups A, B and C among 
children with severe, mild and asymptomatic malaria. We found a significant up-regulation 
of var group B transcripts in children with clinical malaria (mild and severe), whereas var 
group C genes were mainly switched on in asymptomatic children. Furthermore, rosetting 
parasites showed a significant up-regulation of var group A transcripts. Our data suggest 
that a major difference in var gene expression exists between parasites causing clinical 
attack and parasites leading to asymptomatic infection. These findings reflect the 
pathological consequences of the differential expression of var genes which further 
emphasizes its substantial implication for malaria morbidity. 
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Introduction 
In malaria endemic areas of Papua New Guinea, Plasmodium falciparum accounts for 4-
13% of deaths in children. 1 There are various factors contributing to severe malaria 
pathology including cytoadherence. 2 This is the adhesion of late stage infected 
erythrocytes to various receptors such as CD36 or ICAM1 on the vascular endothelium, 
CSA in the placenta and CR1 on red cells 3 leading to microvascular obstructions in 
various organs. Cytoadherence is mainly mediated by the parasite derived polymorphic P. 
falciparum erythrocyte membrane protein 1 (PfEMP1) family. 4-6 These are large 
antigenically variant proteins (200-350 kDa) on the surface of late stage infected 
erythrocytes (IE). PfEMP1 are structured into different semi-conserved, adhesive domains 
namely duffy binding like (DBL) domains and cysteine rich interdomain regions (CIDR) 
(for a review, see Smith7).  
The sequencing of the laboratory-adapted P. falciparum line 3D7 enabled scientists to look 
at the entire var gene repertoire of a single strain. In these parasites, PfEMP1 is encoded by 
one of 59 var genes, each of 8 to 14 kb of length. 8 Most var genes can be subgrouped into 
3 types (var groups A, B, and C) mainly according to their conserved 5' upstream 
sequences. 8,9 In 3D7, the majority of var genes belongs to the subtelomerically located var 
group B whereas a smaller set of 13 var genes called var group C are arranged in 
chromosome internal clusters. 10 larger, subtelomerically located var genes with a distinct 
domain structure belong to var group A. 10  
Many attempts have been made to find different pathological implications in the binding of 
IE to distinct receptors. Various studies have shown that numerous PfEMP111 12 and most 
field isolates 13,14 bind to CD36 which was correlated with non-severe malaria. 13 While 
adhesion of IE to CSA was associated with pregnancy associated malaria, 15,16 binding to 
ICAM1 was correlated with cerebral malaria. 17 Rosetting, the binding of IE to uninfected 
erythrocytes, was shown to associate with severe disease in a variety of studies in Africa. 
18,19
 However, less work has been done to correlate the expression of distinct PfEMP1 
variants with disease severity. Bull et al.20, found by agglutination assays that parasites of 
hosts with a low antibody repertoire against variant surface antigens (VSA) express a 
virulent subset of VSAs which is prevalent in the community whereas individuals with a 
larger repertoire of anti-VSA responses are infected by parasites expressing rarer VSAs. 
The question arises if this restricted virulent VSA subset coincides with a subgroup of var 
genes, namely var groups A, B or C. First indications that this could indeed be the case 
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were the findings of larger PfEMP1 on the surface of IE of children with cerebral malaria 
21
 and a subgroup of var DBL1α sequences isolated of parasites of children with severe 
malaria. 22 This indicated the involvement of var group A genes which was further 
confirmed by the findings of Jensen et al. 23 who in vitro selected 3D7 for severe malaria 
antigenic properties and found an up-regulation of several var group A genes.  
To further study the association between the expression of var groups A, B and C and 
pathologocial outcome in vivo, we enrolled 65 children in a malaria case-control study in 
Madang, Papua New Guinea (PNG), in February to May 2003. The relative contribution of 
var gene transcripts among var groups A, B or C was evaluated by quantitative real-time 
PCR and compared between children with severe malaria, children with mild malaria, and 
asymptomatic children. To our knowledge, this is the first study to evaluate and compare 
the expression of var gene subgroups and clinical outcome in vivo.  
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Methods and Materials 
Population and study design 
From February to May 2003, during the wet season, we performed a severe malaria case-
control study of children admitted to the Modilon General Hospital of Madang, Papua New 
Guinea (PNG). During 1994-1995, malaria accounted for 15.3% of deaths in children in 
this hospital with a severe malaria case fatality rate of 3.6%. 24 The Madang area is 
holoendemic for malaria with perennial transmission, and infections with P. falciparum 
and P. vivax are common. P. malariae and P. ovale are also present in this area. This study 
was approved and ethical clearance was given by the Medical Research Advisory 
Committee of Papua New Guinea. Children at an age of 0.5-6y were defined as cases if 
they had clinical manifestations of severe malaria according to the World Health 
Organization (WHO) criteria for severe and complicated malaria (2000). 2 Together with 
the presence of asexual P. falciparum parasites, these included criteria such as cerebral 
malaria, severe anemia (haemoglobin < 5 g/dl), prostration, metabolic acidosis, i.e. 
respiratory distress and hyperlactataemia (lactate > 5 mmol/L), and hypoglycaemia 
(glucose < 2.2 mmol/L). At admission, full clinical histories were recorded, an examination 
was performed and biochemical tests were done. Exclusion criteria were the confirmed 
diagnosis of a co-infection with any other disease, malnutrition (mid upper arm 
circumference (MUAC) < 12 cm) or an antimalarial treatment in the last 2 weeks. After 
informed consent was obtained from the parents, venous blood (1 ml) was taken from 14 
children with severe malaria (age range 8-60 months, mean 35.8 months) admitted to the 
hospital. None of these cases were fatal. 26 children of similar age (+/- 20% of age) with 
mild malaria were enrolled at the hospital and at the Town clinic, Madang. Mild malaria 
was defined as the presence of asexual P. falciparum and an axillary temperature ≥ 37.5 ˚C 
or in the absence of the latter, symptoms or a history of headache, fever or myalgia. We 
also enrolled 25 asymptomatic children who were positive for P. falciparum by 
OptiMAL® test and subsequent microscopy and who age and location matched to the 
children with severe malaria.  
Assessment of P.falciparum infections 
Thick blood films were stained with Giemsa and the number of malaria parasites per 200 
white blood cells was counted. Parasite densities were converted to parasites per µl by 
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multiplication with 40 under the assumption of 8000 white blood cells by µl. In samples 
positive by microscopy for P. falciparum, the number of P. falciparum infections was 
determined by msp2 genotyping as described previously. 25 Briefly, 30µl of full blood was 
spotted on filter papers (Isocode Stix; Schleicher&Schuell) and dried for 20min at 80˚C. 
After washing, msp2-PCR was performed directly on the filter papers and nested PCR 
products were analysed by RFLP to record the number of infecting strains. 
Parasite culture and assessment of rosetting frequency 
If parasitemia was above 5000 parasites/µl, parasites of children with severe or mild 
malaria were cultured according to standard methods in 10% heterologous AB serum. 18 
When most parasites were at the late trophozoite / early schizont stage, rosettes were 
counted as follows. An aliquot of culture at 2% haematocrit was stained with ethidium 
bromide and by using a fluorescence microscope, rosettes were counted as a proportion of 
200 mature stage parasites. Rosettes were defined as the binding of an infected RBC to at 
least 2 uninfected RBCs. The rosette frequency is indicated as the percentage of mature-
parasite-infected cells found in rosettes. 
Isolation of full-length var transcripts and cDNA Synthesis 
Isolation of full-length var mRNA and reverse transcription was done as described 
elsewhere. 26 Briefly, total RNA was extracted using TRIzol (Invitrogen) according to the 
manufacturer’s instructions. RNA was treated with 3U of RQ1 DNase (Promega). To 
obtain only full length var transcripts, RNA was incubated with 1pmol of biotinylated 
oligonucleotide complementary to the ATS domain. 200µg Dynal beads M-280 
Streptavidin were added to the RNA. After washing, reverse transcription (RT) was 
performed on the captured hybrids, primed by 700ng hexamers (Invitrogen) and using 
Sensiscript (Qiagen) reverse transcriptase according to the manufacturer’s protocol in a 
final volume of 20µl. 
An aliquot without reverse transcriptase was used as negative control. After RT, cDNA 
was RNase A treated. 
Isolation of genomic DNA 
DNA extraction was done as described elsewhere. 27 Briefly, 30µl of full blood was spotted 
on filter papers (Isocode Stix; Schleicher&Schuell) and dried for 20min at 80˚C. After 
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washing according to the supplier’s instructions, PCR was performed directly on the filter 
papers. 
Quantitative Real-time PCR 
Prior to Real-time PCR, 1µl of DNA was amplified in a primary PCR to enrich material. 
Over var 5’UTR-DBL1α, DNA was amplified in 50µl volumes with Advantage cDNA 
polymerase (Clontech) using 400 nM var group specific 5’UTR forward primers and a 
degenerated DBL1α reverse primer (see Table 1). PCR conditions were 94˚C for 5min and 
16 cycles (for cDNA) or 14 cycles (for gDNA) of 95˚C for 30sec / 52˚C for 1min / 64˚C 
for 1min10sec. Real-time PCR was performed over var group A, B and C 5’UTR using a 
ABI PRISM 7000 Sequence Detection System (Applied Biosystems). Reactions were done 
with 5µl of primary PCR product in 25µl volumes with Advantage cDNA polymerase 
(Clontech) using 250 nM minor groove binder (MGB) probes labelled with FAM (Applied 
Biosystems) and 900 nM primers for the respective sequences (see Table 1). Real-time 
oligos were designed according to alignments of 5’UTR var gene sequences of the 3D7 
genome project (www.plasmodb.org; Joe Smith, Seattle Biomedical Research Institute, 
oral communication, May 6, 2004) and var gene sequences of Papua New Guinea 
(AY462581-AY462851). PCR conditions were 94˚C for 5min and 40 cycles of 95˚C for 
30sec / 54˚C for 1min / 65˚C for 1min10sec. Electrophoresis of real-time PCR products 
was performed to control for single bands and equal size. All cDNA samples were run in 
triplicates. If all Ct values of var group A, B and C were above 31, the sample was 
discarded. Negative cDNA controls (no reverse transcriptase) of all samples and No 
Template Controls (NTC) (per 96well plate) were amplified in parallel. If the NTC was 
positive, the plate was discarded. If the negative cDNA control was positive, the sample 
was discarded. As positive control and plate calibrator, 2.5ng of gDNA of P. falciparum 
3D7 were amplified in parallel per plate and var group. Quantification was done using ABI 
Prism 7000 SDS Software, version 1.1.  
Standard curve and relative quantification 
Standard curves were generated using a dilution series over 6 logs of 10-14 different 
dilutions, each dilution in triplicates. The PCR efficiency (E) was calculated using the 
formula, E = 10 (1/-slope) – 1. The mean efficiencies of 3 independent standard curves with 
high reproducibility were 100% for var group A, 86% for var group B and 95% for var 
group C. The detection limit of the system was below 50 copies (data not shown). Relative 
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quantification was done according to the ∆∆CT method (Application guide, Qiagen AG) 
with following modifications: Ct values were converted to approximate copy numbers by 
the formula C/E∆Ct , where "C" is the number of var gene copies in the corresponding var 
groups A, B or C of the plate calibrator (2.5ng of 3D7 gDNA). "E" is the real-time PCR 
efficiency of the corresponding var group (var group A, 2; group B, 1.86 and group C, 
1.95) and ∆CT is the difference of average CT values between the sample and the 
corresponding var group plate calibrator. The numbers of var copies in the plate calibrator 
("C") were estimated by comparing the real-time PCR oligo sequences (see Table 1) and 
5’UTR var gene alignments (see above). Due to the var specific mRNA isolation, no 
endogenous reference gene could be used. For the statistical analysis, we used proportions 
of var group transcripts. 
Verification of real-time PCR 
To test the accuracy of our approach, AT Jensen kindly provided us with RNA isolated of 
P. falciparum 3D7 parasites which were in vitro selected for severe malaria antigenic 
properties and the corresponding unselected controls. 23 Jensen et al. compared var gene 
transcription in these strains by performing var gene-specific quantitative real-time PCR. 
Our results of real-time PCR, which mainly consisted of an up-regulation of var group A 
and slight down-regulation of var group C genes (data not shown), agreed with the 
findings of Jensen et al.  
Statistical Analyses 
Statistical analysis was performed using Stata (Intercooled Stata, version 8.2; 
www.stata.com). Statistical analyses were done on transcript proportions of var groups, i.e. 
on the number of transcripts of one var group over the sum of transcript numbers of var 
groups A, B and C. Associations between var group proportions and clinical outcome were 
analysed using Mann-Whitney U test. Logistic regression analyses and likelihood ratio 
tests were performed to calculate the odds ratio (OR) for disease. The ORs were calculated 
and compared unadjusted or in multivariate logistic regression analyses, with adjustment 
for parasitemia. There was no significant difference between the age and sex distribution of 
cases and controls (age and clinical outcome, P = 0.6; sex and clinical outcome, P = 0.72). 
However, parasitemia showed a significant association with "clinical outcome" (P < 
0.001), but showed no association with ratios of var groups (Spearman rank P = 0.3). 
There was no significant difference between clinical outcome and collection site (P = 0.9) 
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or ethnicity of children (P = 0.27). All tests were 2-tailed and considered significant if P 
values were less than 0.05. 
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Results  
65 children were enrolled in a severe malaria case-control study in Papua New Guinea (see 
Table 2). By real-time PCR, the distribution of var gene transcripts among var groups A, B 
or C was compared in 14 children with severe malaria, 26 children with mild malaria and 
25 asymptomatic children. 
Analyses were done on proportions of transcripts of one var group over the sum of all 
amplified transcripts of var groups A, B and C.  
var group B transcripts are upregulated in clinical malaria 
A significant increase of the proportion of var group B transcripts was found in children 
with clinical malaria (mild and severe), compared to children with asymptomatic malaria 
(odds ratios in Table 3) (see Figure 1). This was confirmed by the observation that both 
fever and headache also correlated significantly with more var group B transcripts. There 
was a further increase of var group B proportions in severe malaria compared to mild 
malaria, however this was not significant probably due to the small number of children 
with severe malaria. No difference in var group B proportions was found between children 
with cerebral malaria and severe malaria cases without cerebral involvement nor between 
severe anemic children and not anemic children with severe malaria (data not shown).  
var group C transcripts are mainly transcribed in asymptomatic malaria 
var group C proportions were below 10% of all detected var transcripts in 33 of 40 (83%) 
children with clinical malaria compared to only 10 of 25 (40%) asymptomatic children. In 
only one child of all children with clinical malaria, more var group C than var group B 
transcripts were found. However, this child had a high white blood cell count and only 160 
parasites/µl indicating another infection and cause for the disease. Conversely, in 11 of 25 
asymptomatic children, more var group C than var group B transcripts were found. The 
increase of var group C proportions in asymptomatic children was highly significant 
compared to var group C proportions in children with mild disease while it was not 
significant compared to children with severe malaria despite of a low odds ratio. (see Table 
3, Figure 1). There was no significant change in var group C specific transcript numbers 
between children with mild or severe malaria.  
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Increased var group A transcription in parasites conferring rosetting 
Isolates with rosetting frequencies >10% were found in 33% (10/30) of parasites from 
children with mild or severe disease. The occurrence of the rosetting phenotype did not 
correlate with the severity of disease. However, significantly more var group A transcripts 
were detected in parasites with rosetting frequencies > 10% with a 3 fold increase of the 
median and 13 fold increase of the geometric mean of var group A proportions (Mann-
Witney U test, P = 0.012). 
var group A transcripts were less amplified than var group B or C transcripts. There was 
no significant difference of var group A proportions in children with severe malaria 
compared to children with mild malaria and there was only a slight decrease of var group 
A proportions in children with asymptomatic malaria compared to children with mild 
malaria. However, due to outliers of increased var group A proportions in asymptomatic 
controls, this decrease was only significant by performing a median test (P = 0.006, 
continuity corrected). 
Quantitative analysis of genomic DNA of var groups A, B and C  
To test for the equal presence of var subgroups among cases and controls and to exclude 
primer bias, quantitative PCR analyses of var groups A, B and C were also performed on 
genomic DNA of most samples. Numbers of amplified var group templates correlated well 
with parasite loads of the corresponding children (P = 0; Spearman's rho of var group A = 
0.72, group B = 0.84, group C = 0.77). The distribution of the 3 var subgroups was very 
similar among different clinical outcomes. On average, the amplified var genes were 
distributed among var groups with 10% var group A, 80% var group B and 10% var group 
C genes. However, in 1 of 59 samples, proportions of var group C genes were below 5% 
while in 5 of 59 samples, proportions of var group A genes were below 5% indicating the 
absence of var genes or var gene stretches to which the primers were targeted in these 
parasites.  
Multiple infections and var gene transcription 
Using msp2 genotyping, we found multiple infections (2 to 3 infections) in only 32% of all 
children, with an average of 1.4 infecting strains. There was no association between the 
number of infecting P. falciparum strains and clinical outcome.  
var transcription in a malaria case-control study in children in PNG 47 
Association between parasitemia and proportions of var groups A, B and C 
In asymptomatic children, we found a significant positive association between parasitemia 
and var group C proportions (Spearman's rho 0.51, P = 0.013), i.e. more parasites were 
detected in children with increased var group C proportions (>0.4). In contrast, in children 
with clinical disease, there was a negative, but not significant association between 
parasitemia and var group C proportions. Regarding var group A and B proportions, these 
correlations were exactly reversed but not significant. 
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Discussion 
The intriguing observation of distinct var gene subgroups and previous reports of disease 
associated var genes called for further studies on natural infected children. To identify 
potential differences in virulence associated with the expression of either var groups A, B 
or C we performed a case-control study on children with severe, mild and asymptomatic 
malaria. By quantitative real-time PCR, we found a significant increase of parasites 
transcribing var group B genes in clinical malaria whereas parasites of asymptomatic 
children transcribed more often var group C genes. Furthermore, we detected a significant 
up-regulation of var group A transcripts in parasites conferring rosetting.  
These differences in expression are probably due to different transcriptional regulations 
leading to distinct switching rates. This might be supported by the observation of different, 
but within one group highly conserved 5' and 3' untranslated regions. 10,28 A mathematical 
model on var switching suggested that var genes with fast switching rates might be 
predominantly expressed in acute disease which is followed by parasites expressing var 
genes with slower switching rates. 29,30 This was indeed observed in volunteers which were 
artificially infected with 3D7. 31 If we adapt this hypothesis to our findings, increased 
switch on rates would be ascribed to var group B genes. However, to date, group specific 
switching rates have not been demonstrated, and one report, on the contrary, showed that 
different switching rates of var genes were independent of their 5'UTR sequence. 32 
Different switching rates might not apply to all members of a group, but it was impossible 
in our study to analyse individual var genes. Therefore, the observed differences might 
also be due to few specific var genes which are switched on more often in cases or in 
controls. In 2 volunteers artificially infected with 3D7 Peters et al. 31 detected the same var 
gene, belonging to var group B, expressed at the start of infection.  
The prominent presence of var group B transcripts in clinical malaria cannot be explained 
by increased switching rates alone. Successful immune evasion leading to parasite growth 
and pathogenicity occurs at the same time. It has been shown that clinical malaria is the 
consequence of infecting parasites which express variant surface antigens (VSA) that are 
not recognized by the existing repertoire of antibodies. 33 In 3D7, var group B represents 
the largest group with 22 different var genes 10 providing a large diversity. As 
sequestration is another important function of PfEMP1 in clinical malaria, our data would 
suggest that group B var genes code for good binding PfEMP1s, in contrast to var group C 
genes. Initially this seems unlikely, because the overall length and domain structure of var 
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group B and C is very similar in 3D7. And phylogenetic analyses on var coding regions 
shows only limited separate clustering of var group B and C genes 10,28(own observation). 
But minimal differences in the amino acid sequence could result in different binding 
phenotypes. A substitution of 3 amino acids in the CIDR domain of a var gene was shown 
to largely reduce binding to CD36. 12 Binding studies with 3D7 var genes showed that in 
contrast to var group A, most var group B and C encoded peptides bind to CD36. 11  
The role of CD36 binding IE in pathogenicity is controversial. Binding to CD36 was 
suggested to contribute to disease by sequestration and by conferring platelet mediated 
clumping which correlates with severe disease. 34,35 Conversely, CD36 binding isolates 
were found to be associated with non-severe disease, 13 and it was suggested to be 
protective by sequestering IE in non-essential muscle tissues (reviewed in 36) or by 
promoting non-inflammatory phagocytosis of IE. 37  
We have found parasites with up-regulated expression of var group B genes in mild but 
also in severe malaria. The reason that we found no significant differences could be due to 
different subpopulations of var genes within var group B. It could also be due to technical 
limitations because var group B primers used for quantitative real-time PCR hybridised to 
upsB type 5'UTR sequences, which also included var genes of the intermediate var group 
"B/A" in 3D7. These are hybrid forms between var group A and B, and encode larger 
PfEMP1 similar to those encoded by var group A genes suggesting different binding 
abilities of these hybrids similar to var group A genes. 10 To sum up, whether PfEMP1 
molecules encoded by var group B and C genes show different binding features relevant 
for the outcome of this study remains speculative and our data allow no further 
conclusions.  
In asymptomatic children, we detected a significantly higher proportion of parasites 
transcribing var group C genes. It is a surprising finding that the comparatively small var 
group C with only 14 var genes in 3D7 should be able to sustain chronic infection. 
Asymptomatic malaria is characterized by low parasite loads reflected by a broad antibody 
repertoire against many VSAs of the infecting parasites. Recker et al. 38 recently suggested 
in a mathematical model that VSA epitopes eliciting short-lived and partially cross-
reactive immune responses could sustain sequential var gene expression needed for 
chronic infection. We found previously in a longitudinal study in asymptomatic children in 
PNG, 26 a highly dynamic picture of var transcription with mostly new var transcripts at 2 
weeks interval. Such dynamic and transient mixture of parasites in asymptomatic children 
might be generated by the continuous elimination of parasites presenting previously 
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expressed PfEMP1s. The development of an effective large antibody repertoire against 
PfEMP1 could be accelerated by cross-reactivity between different variants. According to 
our hypothesis these would comprise mainly group B var genes and various recombination 
and conversion processes in var group B genes might have had a homogenizing effect. 
This is supported by phylogenetic analyses in which several var group B genes cluster 
together (own observation). The up-regulation of var group C transcribing parasites in 
asymptomatic children could suggest an increased switch-off rate of this group, which 
would result in a rapid turnover with low parasite density and impeding successful 
antibody maturation by inducing anergy. The positive correlation of parasitemia and var 
group C transcripts in asymptomatic children would reflect the fitness of parasites 
transcribing var group C PfEMP1s in semi immune children. 
 
We also found an increase of var group A transcripts in parasites conferring rosetting. This 
is in concordance with observations with culture strains, in which the rosetting phenotype 
was mostly attributed to var group A genes (own observation). It has been shown that 
rosetting is correlated with severe disease in African children 18,19 but not in PNG. 39 These 
controversial results could be explained by the frequent presence of red blood cell traits in 
PNG such as α-thalassaemia 40 or CR1 deficiency which was found in up to 79% of the 
population of Madang, PNG. 41 It is tempting to speculate that the lack of a disease 
association with rosetting in PNG is due to the large proportion of CR1 deficient 
individuals. 41 Therefore, it is not surprising to find no up-regulations of var group A genes 
in severe malaria cases, 23 but only an association with rosetting.  
The lack of a significant difference of var group transcripts between mild and severe cases 
was somehow unexpected. Yet, malaria is a multi-system disorder (for a review, see 
Mackintosh 42) and not only caused by PfEMP1, but also by immune-mediated 
inflammatory processes (for a review, see Artavanis-Tsakonas 43). The disease progression 
can be seen as continuum and the time between onset of symptoms and final presentation 
at the hospital is important. Children with severe disease might merely reflect children with 
a longer progression of the same disease status in contrast to asymptomatic children in 
whom parasites currently are at a steady state with the immune system. However, the small 
study size has also to be taken into account and more data are needed. Because of the 
unknown population of var genes and to exclude primer bias, we also performed 
quantitative analysis of genomic DNA of all samples. Normalisation of var transcript 
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numbers with genomic var copy numbers did not change the results and we are certain that 
primer bias does not explain the outcome.  
Finally, concern has been raised whether the same distribution of parasites is found in 
peripheral blood as in vital organs, where virulent parasites sequester. Different adhesive 
phenotypes of IE were shown in peripheral IE of pregnant women compared to IE isolated 
of their placenta. 44 But conversely, parasites of peripheral blood of children with severe 
malaria showed a different agglutination pattern than parasites of children with mild 
malaria, indicating a restricted parasite population also in the periphery of children with 
severe malaria. 45  
In conclusion, here we show for the first time in a malaria case-control study conducted in 
an endemic area that the different var subgroups influence clinical outcome. In particular, 
we show a significant increase of var group B transcripts in clinical malaria. In contrast, 
var group C transcripts were significantly more often found in asymptomatic individuals. 
We also show that var group A transcripts are associated with rosetting of parasites. These 
findings confirm together with previous studies the importance of PfEMP1 in disease 
manifestation, and justifies further studies to understand its molecular development. 
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Table 1. Oligonucleotide primers for amplification of var gene regions 
 
*reverse primer which was used in the primary PCR  **forward primers were identical in primary and real-time PCR 
 
 
 
 
Table 2: Clinical assessment of cases and controls (% of children) 
 
var gene 
region 
length of 
amplified 
product 
name primer sequence Ref. 
DBL1αrev *  DBL_FADall_rev 5’-CC(A/T)AT(A/G)(G/T)C(A/G/T)GCAAAACT(C/G/T)C(G/T)(A/T)GC-3’  
upsA1_for ** 5’-AACTTACCATAAATTATCATCAAA-3’  
upsA3_probe 5’-6FAM-AAACCTTTGGTATAGAAAAAAATATT-MGB-3’  
var group A, 
5'UTR 150 bp 
upsAj_rev 5’-TCACCTACAACAAAT(A/G)TAATAAA-3’ (Smith J, pers.comm.) 
17deg_for ** 5’-CTCAT(A/T)TATAATTTTA(C/G)AAAATA(A/T)A(A/T)AAAAC-3’  
upsB1_probe 5’-6FAM-TCTAACAAAAAAAAAAAACAACAATTAC-MGB-3’  
var group B, 
5'UTR 370 bp 
RT-17.2_rev 5’-TTA(A/T)GGGAGTAT(A/T)GT(A/G/T)ATATGGTAGAAT-3’  
RT-5B1.1_for ** 5’-AATATTCATATTCCCACATT(A/G)TCATATAT-3’  
upsC_probe 5’-6FAM-ACATATAATACGACTAAGAAAC-MGB-3’  
var group C, 
5'UTR 230 bp 
5B1.4_rev 5’-ATTATGTGGTAATATCATGTAATGG-3’  
Clinical outcome 
Overview of children and clinical features 
asymptomatic (25 children) mild (26 children) severe (14 children) 
Sex (female/male) 9/16 10/16 7/7 
Age (months) (mean [range]) 41.3 [14-65] 42.2 [12-84] 35.8 [8-60] 
Parasites/µl (geometric mean [range]) 3'715 [40-108'000] 27'241 [160-310'200] 32'928 [240-480'000] 
Temp (˚C) (geometric mean [range]) 36.6 [35.4-37.5] 38.5 [35.6-40] 38.7 [37.1-39.9] 
Medical history of fever in the last 5 days  5 (20%)  22 (85%)  14 (100%)  
Medical history of headache in the last 5 days  0 9 (35%) 6 (43%) 
Medical history of diarrhea in the last 5 days  0 3 (12%)  1 (7%)  
> 1 convulsion/24h  0 0 5 (36%) 
Prostration  0 0 7 (50%) 
Impaired consciousness ; coma ;  
neurological alterations  0 0 1 (7%) ; 4 (29%) ; 4 (29%) 
Anormal respiration  
(shallow, fast, irregular or deep) 0 3 (12%) 8 (57%) 
Severe anemia (hemoglobin <5 g/dl) 0 0 3 (21%) 
Hypoglycemia (glucose <2.2 mmol/l)   0 0 4 (29%)  
Hyperlactatemia (lactate >5 mmol/l)  0 0 0 
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Table 3:  
Odds ratios for disease with increased proportions of var group specific transcripts.  
Odds ratios for disease  
Comparison 
between:  
var group A proportions var group B proportions var group C proportions 
unadjusted 0.94 [0.11-8.0] 0.96 18.95 [3.21-111.87] <0.001 0.01 [0.00-0.22] <0.001 Asymptomatic 
vs clinical (mild 
and severe) adjusted 0.76 [0.07-8.00] 0.82 31.63 [3.68-271.71] <0.001 0.02 [0.00-0.24] <0.001 
unadjusted 1.56 [0.18-13.35] 0.69 10.53 [1.74-63.64] 0.006 0.02 [0.00-0.37] <0.001 
Asymptomatic 
vs mild  
adjusted 1.11 [0.11-11.75] 0.93 21.71 [2.45-192.67] 0.002 0.02 [0.00-0.33] <0.001 
unadjusted 0.17 [0.00-8.90] 0.33 111.47 [2.43-5108.28] <0.001 0.01 [0.00-1.20] 0.004 
Asymptomatic 
vs severe 
adjusted 0.28 [0.00-43.73] 0.59 302.16 [1.44-63248] 0.002 0.01 [0.00-1.13] 0.006 
unadjusted 0.04 [0.00-6.67] 0.13 12.61 [0.26-612.36] 0.15 0.64 [0.00-159.1] 0.87 
Mild vs severe  
adjusted 0.05 [0.00-7.18] 0.15 9.89 [0.20-494] 0.20 1.31 [0.01-380] 0.93 
 
OR [95%CI] P value; Odds ratios are either unadjusted or adjusted in multivariate logistic 
regression for parasitemia; Significant results are shaded in grey 
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Figure legend 
 
Figure 1: 
1A) Box plots of clinical outcome (severe malaria, mild malaria, asymptomatic malaria) 
and proportions of var group specific transcripts over the sum of all amplified var 
transcripts.  
1B) Box plots of parasites mediating rosetting and proportions of var group A, B and C 
transcripts. 
Boxes of box plots contain the middle 50% of data ranging from upper to lower quartile 
while the line in the box indicates the median. Vertical lines extend to a maximum of 1.5 
times the inter-quartile range, points are outliers. 
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4. Discussion 
PfEMP1 is an important virulence factor of P. falciparum not only in acute infections but 
also by contributing to chronic disease. Therefore, it is not surprising that this protein 
family has been discussed as potential vaccine target. 43,72,75 However, few studies have 
analyzed var expression dynamics in vivo and pathological implications of different 
expressed PfEMP1. 12,71,74 Here, we describe 2 studies on var gene expression in vivo. In a 
longitudinal study over a 4-month period, we analyzed the dynamics of var gene 
expression over time. We studied the longitudinal distribution of var transcripts in semi-
immune children by RT-PCR, cloning and sequencing. In a case-control study, we 
evaluated potential differences in the virulence of PfEMP1 encoded by var group A, B or 
C. By using quantitative real-time PCR, we compared the distribution of var gene 
transcripts of var groups A, B and C among children with severe, mild and asymptomatic 
malaria.  
Both studies were carried out in Madang Province, a highly endemic area at the north coast 
of Papua New Guinea (PNG). Analysis of Madang hospital paediatric records of 1994-
1995 showed that 19.2% of all admissions and 15.3% of all deaths in children were 
assigned to malaria. 76 Furthermore, the most common severe manifestations of malaria in 
children were shown to be severe anemia (22%) and coma (16%) and hyperlactatemia was 
the major predictor of death. 76  
4.1. Expression of var group A, B and C genes in clinical malaria 
We found a significant up-regulation of var group B genes in children with clinical malaria 
(severe and mild) while var group C transcripts were hardly detectable in these children. 
No clear trend was evident between mild and severe malaria. Compared to children with 
mild malaria, only a further increase of var group B proportions was observed in children 
with severe malaria. In contrast to previous indications (see Introduction section 1.9.), we 
found no up-regulation of var group A in children with severe malaria but only a slight 
increase in children with mild malaria when compared to children with asymptomatic 
malaria.  
The lack of different proportions of var group specific transcripts in mild and in severe 
malaria could be attributed to the limited dataset of only 14 children with severe malaria.  
However, the fact that we only collected 14 severe malaria cases in 3 months also reflects 
the smaller contribution of severe malaria to morbidity in Madang. Severe malaria 
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morbidity and mortality is less frequent in PNG than in many endemic settings of Africa. 77 
One reason for this reduced morbidity with P. falciparum in PNG might be the 
omnipresence of the less virulent P. vivax which is suggested to induce some degree of 
cross-protection. 78  
Apart of a fairly good access to antimalarial drugs in Madang, these reduced severe 
manifestations could also be attributed to the genetic background of Papua New Guineans. 
Various red blood cell traits such as Southeast Asian Ovalocytosis (SAO) 79, α-thalassemia 
80
, CR1 deficiency 81 and Gerbich-negative phenotype 82 are prevalent and have been 
shown to a various degree to be protective against severe malaria. A high prevalence of 
80% of CR1 deficient individuals in Madang 81 could have accounted for the observed lack 
of up-regulation of var group A genes in severe disease. CR1 is known to be the main 
ligand on erythrocytes for rosetting which was shown to be associated with severe disease 
in Africa but not in PNG. 22,83 We found a significant association between parasites 
conferring rosetting and an up-regulation of var group A genes in these parasites. This is in 
concordance with in vitro observations (personal communication Alex Rowe). It is 
tempting to speculate that rosetting is not associated with severe disease in PNG because 
the main ligand CR1 is missing. 81 Not fully developed rosettes which do not withstand 
physiological shear stress in vivo could explain the non-existent correlation between up-
regulation of var group A genes and severe disease in PNG. However, this implies that the 
rosetting phenotype of PfEMP1 molecules encoded by var group A genes contributes 
significantly to severe disease. But other severe manifestations including binding of IE to 
ICAM1 have been implicated with large var genes and var genes provided with a DBL2β-
C2 domain in cerebral malaria. 38,70 In 3D7, DBL2β-C2 containing var genes belong to var 
group A but also in some cases to the intermediate groups B/A and B/C. 45 Since we 
included var group B/A in group B, we cannot exclude that the observed var group B up-
regulation in severe malaria is due to var B/A gene up-regulation. Further sequence 
analysis will shed light onto this question. 
It has always been discussed whether parasites circulating in the periphery represent the 
disease associated phenotypes. There is controversial data on phenotypes of circulating 
parasites and adhering parasites from human placental studies. Two studies reported 
identical binding phenotypes in the placenta and in the periphery, 84,85 whereas other 
studies showed antigenically distinct parasites. 21,86 By performing agglutination assays, 
Bull et al. 69 found a distinct parasite subset in peripheral blood of children with severe 
malaria compared to children with mild malaria. This indicates that virulent parasites also 
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circulate in the periphery. Since various host tissues express different receptors, the 
presence of different parasite subsets within one host can be expected.  
But one can also speculate that severe disease is maintained by a homogenous parasite 
population expressing multi-adhesive variant surface antigens (VSA) or a parasite 
population expressing a VSA subset which mediates cytoadherence independent of the 
endothelium such as rosetting or platelet-mediated clumping. Although not in PNG, 
rosetting and clumping have both been shown to be correlated with severe disease 10,23 
while multi-adhesive IE have been shown to occur in vitro. 87 
The observation of similar var transcript proportions in mild and in severe malaria raises a 
fundamental question about the definition of severe and mild malaria. Is there a qualitative 
difference between mild and severe disease? The progression of disease might be merely a 
factor of time and a child arriving at the hospital with mild malaria might be severely sick 
a few hours later without treatment. According to our data, there is no significant change in 
var gene transcript composition. However, we observed a large variation of var group 
specific transcript proportions between individuals of clinical cases and individuals with 
asymptomatic infections. We propose that a delay in the clinical picture in relation to the 
transcribed var subset contributed to this large deviance.  
 
4.2. Expression of var group A, B and C genes in asymptomatic children 
In our case-control study, var group C genes were found to be highly up-regulated in 
asymptomatic children. Conversely, on average, only half of var group B transcripts were 
detected in children with asymptomatic malaria compared to children with clinical malaria. 
Also var group A proportions were reduced overall in asymptomatic children, but 6 of 
these 25 children had high var group A proportions.  
In the longitudinal study on older, semi-immune children, we did not perform quantitative 
analyses, but sequence analysis revealed a larger diversity of var group B transcripts 
(5'UTR-DBL1α sequences) than of var group C transcripts. Of the latter, never more than 
3 different transcripts were found per child compared to 11 different var group B 
transcripts. On average, 3.7 different var group B transcripts were detected per child 
compared to 1.5 different var group C sequences. This will be discussed and incorporated 
into the hypotheses below. In this longitudinal study, DBL1α subtype sequences 
characteristic of var group A genes were also isolated, indicating the presence of var group 
A transcripts in semi-immune children. 
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We found a highly dynamic picture of var expression in the longitudinal study with mostly 
new var transcripts at each 2 week interval but some var transcripts recurred for up to 10 
weeks. RT-PCR, cloning and sequencing revealed up to 15, but on average 5 different 
DBL1α sequences per child. When multiple infections were taken into account we 
calculated a mean of 1.7 DBL1α sequences per infection. This might be a good estimation 
of the actual number and reflects the tight control of var gene transcription within a single 
parasite population. It is not known how parasites are able to synchronize their var gene 
expression avoiding the simultaneous expression of many var transcripts despite the 
reported high switching rate. It seems unlikely that elimination of concurrent variants by 
immune responses could account for the observed low diversity because this would require 
rapid effector mechanisms and would lead to an early exhaustion of the var repertoire. 
Other explanations such as an inter-parasite communication by chemotactic signalling have 
not been shown yet and no signalling pathways from the erythrocyte membrane to the 
parasite have been found except of indications of a cAMP dependent signalling pathway 
being involved in initiation to gametocytogenesis. 88 However, low diversity could be 
obtained by an ordered switching mechanism suggesting some sort of epigenetic 
programming to prevent the random switching to different var genes in different parasites. 
However, this is speculative and not much is known about var switching control. 
Although we observed only a small number of expressed var variants per infecting strain, 
we detected on average 5 different var transcripts in semi-immune children due to multiple 
P. falciparum infections. Different VSA subtypes presented at the same time to the 
immune system might be advantageous for the parasite because it might lead to immune 
distraction and the distribution of different VSA subsets among different P. falciparum 
strains reduces the risk of a fast exhaustion of the var gene repertoire. In endemic areas, 
larger anti-VSA antibody repertoires have been shown to occur in asymptomatic children 
compared to matched children with no detectable P. falciparum infections 89 indicating an 
on-going build-up of anti-VSA antibodies of which some might only be short lasting.  
In a mathematical model, Recker et al. 90 showed that the combination of 2 types of 
immune responses against PfEMP1 variants can maintain chronic infection. In this model, 
short-lived immune responses (for instance due to linear, low complexity epitopes) are 
built up against minor, partially cross-reactive epitopes of PfEMP1 variants. But every 
PfEMP1 variant is provided with a major unique epitope which elicits long-lived 
responses. This combination results in a cascade of sequentially dominant PfEMP1 
variants of which the active variant is always the most immunologically distinct variant 
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from the previous. Parasites expressing similar minor epitopes are suppressed by short-
lived antibody responses while the development of long-lived, variant specific immune 
responses limits an aggressive amplification of parasites expressing immunologically 
distinct forms. 91 
This model is independent of different var switching rates but can explain the low number 
of simultaneously expressed var variants in an infecting strain. In this case, immune 
selection would be solely responsible for the observed low diversity.  
 
4.3. Two hypotheses explaining our results 
I will discuss our findings in the context of two hypotheses. 
4.3.1. Hypothesis I: Different switching rates of var groups  
Initially, it is difficult to imagine that the observed shifts of var group specific transcripts 
in clinical and asymptomatic malaria can only be attributed to distinct virulences of the 
PfEMP1 molecules in different clinical presentations. Phylogenetic analyses and basic 
binding studies did not show any major differences in these two var subfamilies 45,92(and 
own observation). We propose that a different transcriptional regulation of var groups such 
as different switching rates accounts for our observations. The different, but within one 
group highly conserved untranslated regions of var genes might support this hypothesis. 
And mathematical models indicated that a combination of innate, clonal and anti-PfEMP1 
immunity could maintain chronic infection when using different var switching rates 
influencing anti-PfEMP1 immunity. 93,94 Moreover, Horrocks et al. 95 showed in isogenic 
parasite clones var genes with identical inherent "on" and "off" rates. However, in their 
experiments these different "on" and "off" rates were not associated with specific var 
groups. Yet, this study collected data with sampling only every 10 generations over 40 
generations.  
We base our hypothesis on following assumptions in relation to distinct var group specific 
switching rates: 
   - var group C has high switch off rates 
 - var group A and B have low switch off rates. Accordingly, in vivo 
parasites expressing these genes are mainly eliminated by the immune 
system 
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 - var group A and B also have increased switch on rates compared to var 
group C, therefore, var group A and B genes have a higher likelihood to 
be switched on first in an infection. 
The following explanations are summarized in Figure 2. Row (1) shows the typical course 
of parasitemia during infection and row (2) our observed proportions of var group specific 
transcripts. Rows (3) and (4) show possible scenarios which could explain our findings. 
The left part depicts an infection in a malaria naïve host while the right part refers to a 
semi-immune host with a modest anti-VSA antibody repertoir.  
According to our assumptions, var group A and B encoded PfEMP1s are prominently 
expressed early in infection (row (3)) while var group C variants do not play a major role 
in acute infections as they tend to be fast switched off again (row (3): small arcs). 
Therefore, hardly any antibodies are mounted against these group C PfEMP1s (row (3) as 
depicted in the small antibody drawing to the right.  
Larger PfEMP1 molecules of var group A and B/A are provided with more adhesive 
domains and were shown to have distinct binding characteristics mediating rosetting or 
binding to ICAM1 in the brain (see above). Therefore, these variants might bind to 
receptors in vital organs or might confer rosetting contributing to the progression to more 
severe manifestations of disease. Due to the conserved structure of var group A variants, 
the small size of this group, and their extended presentation, I propose that these variants 
elicit an effective variant-specific, long-lasting immune response (as depicted in the right 
panel of row (3) and in row (4) with large arcs). This could contribute to the protection 
from severe malaria already observed after only 1 or 2 clinical episodes. 96 According to 
the model of Recker et al. 90 (see above), I also assume that all PfEMP1 variants possess 
minor epitopes eliciting cross-reactive, short-lasting responses shared between different 
PfEMP1 variants (row (4): small arcs in all 3 var groups) and variant-specific epitopes 
mounting long-lasting responses. The existence of cross-reactive antibodies against 
PfEMP1 was shown after immunizing mice with 3 CIDR1 domains. 97 Since var group B 
genes have been shown to undergo numerous small recombination and conversion events 
47,98
 resulting in a potential homogenizing effect, var group B variants might share a 
considerable amount of minor epitopes which could increase the production of primarily 
short-lasting antibodies against these PfEMP1 (row (4): small arcs). The development of 
long- and short-lasting immune responses against var group B variants leads to a 
continuous elimination and turn over of these parasites.  
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Because of increased switch on but low switch off rates of var group A and B genes and 
distinct structural features of a subset of these genes, group A and B encoded PfEMP1 
molecules are predominantly found in parasites causing acute infections. Since in malaria 
naïve hosts, an effective antibody response against PfEMP1 variants does not yet exist and 
parasites do sequester, unrestrained parasite amplification occurs (row (1)). Eventually, 
initial acute infections are either cleared by drug treatment, successful anti-parasitic 
immune response, or by death. 
 
In semi-immune hosts, a modest anti-VSA antibody repertoire has been built up. This 
antibody repertoire might be primarily targeted against var group A and B variants because 
of their preferred exposure in previous infections (row (4), second column). This would 
result in the constant elimination of parasites expressing these variants, and leads to a fast 
and dynamic turn over of parasites expressing var group A and B variants (row (3), right 
panel). Such dynamic turn over was also evident in the longitudinal study. And due to the 
constant elimination of these variants, the presence of var group C encoding parasites 
increases.  
I assume that the combination of previously exposed and cross-reactive var group B 
variants as well as the short presentation of var group C variants results in a strongly 
reduced variant specific immune response against PfEMP1 of var group C. There are also 
indications that var group C genes are more diverse than var group B genes, and higher 
fixation indexes up to 0.53 (P=0.003) have been found between var group C genes of 
different culture strains (Dieter Suter, personal communication). This could further support 
a sequential dominance of var group C derived variants, each variant being the most 
immunologically distinct of the previous expressed one.  
We did observe asymptomatic children with high parasite loads above 50'000 parasites/µl 
and with high proportions of var group C transcripts above 90%. Since these children seem 
not to mount a pro-inflammatory, fever inducing immune response despite of this high 
parasite load, we suggest that some sort of immune unresponsiveness or anergy exists 
against parasites expressing these variants. Distinct binding characteristics of these 
PfEMP1 variants could explain why there are no obstructions in local blood flow in vital 
organs and accordingly, no apparent clinical signs in these children.  
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Figure 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Model of var group specific transcription of a P. falciparum strain in a malaria 
naive host and in subsequent infections of the same host after build-up of a modest 
anti-VSA antibody response. The primary severe infection is cleared by drug treatment 
or by a successful anti-parasitic immune response.  
Small arcs in the "Antibody repertoire" indicate short-lived antibodies against cross-
reactive epitopes, while large arcs indicate long-lived variant specific immune 
responses. For explanations see text. 
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Distinct binding characteristics might lead to an accumulation of parasites in non-essential 
muscle tissue due to binding to CD36, constant removal by non-inflammatory 
phagocytosis activated by CD36 binding to macrophages (see below, 4.5.), or low binding 
abilities leading to a constant removal by the spleen.  
This model could explain our findings of increased proportions of var group A and B 
transcripts in clinical malaria while var group C derived variants are most prominent in 
asymptomatic malaria. It also explains the large variation of our data, particularly of 
proportions of var group B transcripts in children with asymptomatic malaria. These 
children might well be at the beginning of an infection (left part of left panel). The 6 
observed asymptomatic children with large var group A proportions might be explained by 
this delay of disease (see above).  
4.3.2. Hypothesis II: Ordered switching pattern  
Horrocks et al. 95 found some evidence for ordered switching events suggesting that the 
ability to switch to a certain var gene depends on the switching history of this parasite. In 
this second hypothesis, I propose a model which is to a certain degree a programmed 
ordered process and assumes that switching primarily occurs within one var group while 
switching from var group B to var group C is a rare event, in particular at the beginning of 
an infection. On a molecular level, an ordered switching mechanism could be explained by 
epigenetic mechanisms. For instance, var group C genes might be packed in silent 
chromatin after passage through mosquito and liver stages. Accordingly, the machinery for 
var gene transcription is concentrated at the chromosome subtelomers transcribing var 
group B or A genes. It might also be possible that the transcription machinery specific for 
var group C expression is not yet available at the beginning of the asexual erythrocyte 
stage. There is some evidence provided by Peters et al. 74 for an imprinting mechanism of 
var transcription at the beginning of a new infection, who found the same var group B 
gene switched on in different volunteers artificially infected with 3D7. Subsequently 
expressed var genes were also mainly of var group B type.  
Hypothesis II is illustrated below in Figure 3. Letters A, B and C indicate parasites 
expressing variants of var groups A, B or C while numbers after the letter indicate different 
variants within one var group. I assume that at the beginning of an infection, a high 
switching rate is advantageous to guarantee the establishment of a new infection in a host, 
above all in high transmission areas.  
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Figure 3 
A) Malaria naive host
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Figure 3. Switching of var group A, B or C variants during parasite amplification. At the 
beginning of an infection, a var group B gene is active, from which other var genes are 
switched on at high rates. Different var genes within one group are indicated with 
numbers. For simplicity, only 5 merozoites derived from one parasite are indicated, 
however, up to 24 merozoites are normally found.  
A) amplification of parasites expressing var group A, B or C derived PfEMP1 in a 
malaria-naïve host  
B) reduced amplification of parasites in a semi-immune host. A considerable part of 
variants is eliminated by existing immune response 
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A high switching rate leads to the expression of several variants (in this hypothesis 
primarily of var group B type) increasing the chance of at least one not being recognized 
by the host. This was indeed seen in the artificially infected volunteers in whom fast 
switching was observed after the expression of the initial var gene.  
In hosts with a modest anti-PfEMP1 antibody repertoire, a considerable part of parasites 
expressing previously exposed var group B variants is immediately eliminated by immune 
responses. This would increase the proportion of var group C expressing parasites (see 
Figure 3, B)).  
 
Quantitative real-time PCR analysis in 3D7 and FCR3S1.2 culture parasites, showed an 
up-regulation of var group C genes similar to the situation in asymptomatic hosts (own 
observation). This was not expected, as in culture no immune selection is present. Relating 
to hypothesis II, I assume that the initial imprinting of var group B expression after liver 
stage passage is lost in cultured parasites.  
 
As mentioned above, sequence analysis of the longitudinal study revealed a smaller 
number of var group C variants in semi-immune children and in culture parasites than var 
group B variants. Although var group C genes seem to be up-regulated, only very few 
variants of var group C genes are transcribed simultaneously. High switch off rates for var 
group C genes or an ordered switching mechanism could account for that. But, this could 
also simply be ascribed to the lower number of var group C genes per haploid genome 
compared to var group B genes. In 3D7, our var group specific primers targeted 33 var 
group B genes but only 9 var group C genes.  
4.4. Structural differences in PfEMP1 of var group B or C 
Despite of very similar DNA sequences of var group A and B, protein structure differences 
could also contribute to our findings. var group B and C genes most likely have diverged 
early in P. falciparum history, and phylogenetic analyses have shown that DNA exchange 
is reduced between these groups. 45,99 This is in contrast to the ectopic recombination 
currently observed within groups. Small var group specific differences in amino acid 
sequence might have evolved which are not apparent by broad phylogenetic analyses. But 
even minor changes in amino acid sequence have been shown to be able to lead to major 
changes in binding properties or immunogenicity of proteins. 42,100 Therefore, it could be 
possible that both groups show differences in these features. For instance, var group B 
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derived PfEMP1 molecules might elicit more efficient immune responses compared to var 
group C derived PfEMP1. On the other hand, var group C derived PfEMP1 might show 
weaker binding abilities leading to a continuous but partial removal of these parasites by 
the spleen.  
var group C genes are located centrally on chromosomes in more stable regions. One could 
speculate that these var variants are of older origin and thus are adapted to a host-parasite 
co-existence guaranteeing long term transmission of the parasite. This could explain the 
apparently reduced virulence of var group C variants. Presumably, the combination of var 
variants contributing to high parasite loads but also to long term survival might provide the 
highest benefit to the parasite. 
 
. 
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4.5. Outlook 
Despite of the importance of var genes as morbidity and mortality driving factor in malaria 
disease, few studies were performed in vivo. Our studies on var gene expression in 
naturally infected children provide a good insight into the complex and dynamic 
expression of var genes in vivo. We found that var subgroups do not merely reflect 
different recombination assemblies but also lead to differences in disease upon expression, 
and we showed the highly dynamic nature of var transcription in semi-immune children. 
However, the observed transcriptional shifts of var groups contain a set of var genes which 
are unknown apart of their affiliation to the corresponding var group. Subsequent sequence 
analyses of var transcripts will concentrate on these individual genes. Phylogenetic 
analyses and protein structure predictions will be performed to find potential sequence 
conservations of var transcripts of parasites conferring severe disease.  
Based on these initial results, we have to confirm our findings in a larger case-control 
study, enrolling a larger number of children, but also compare var gene expression in 
different geographical locations. Currently, a larger case-control study is carried out in 
Tanzania addressing similar questions on var group specific expression in children with 
severe and mild malaria. To test our hypotheses, var gene expression could be compared in 
young children in longitudinal studies in subsequent acute infections in combination with 
serological studies, analyzing the nature of antibody response in acute and reconvalescence 
phase, the degree of cross-reactivity and duration of antibody response. Since in young 
children, the number of previous clinical episodes and build-up of anti-VSA repertoire 
cannot be easily evaluated, longitudinal studies in infants would be highly interesting 
following var gene expression in malaria naïve hosts. Alternatively and far easier, but not 
longitudinally, var gene expression could also be evaluated in malaria naïve hosts such as 
in tourists returning from an endemic area who contracted malaria or in volunteers of 
malaria vaccine studies. 
When relating to in vitro analysis, more information on regulations of var gene expression 
and var switching is desperately needed. Sophisticated techniques such as elaborate 
transfection protocols, FISH analysis, chromatin immuno-precipitation or yeast-one hybrid 
systems might dissect the regulatory mechanisms and nuclear proteins involved in var gene 
regulations.  
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Another central open question addresses the molecular background of our findings. Do var 
group specific protein structures or distinct expression regulations account for the observed 
var group specific expression pattern in different clinical stages? Potential differences in 
var switching rates will be studied in our laboratory in a longitudinal, chip based approach 
analysing the switching pattern of single var genes. 
Because of technical limits, most studies on var gene expression are based on RNA level to 
date. However, potential post-translational regulations and transport limitations should be 
taken into account. Preliminary MS/MS analyses on PfEMP1101 raises hopes that also 
advanced proteomics technologies can be applied. Though, the low abundance of PfEMP1 
remains a challenge. 
Most studies on var gene structuring and regulation are based on in vitro analysis of 
culture strains, above all of 3D7 parasites. It is highly tempting to accept these findings as 
a general rule valid for all var genes while disregarding the fact that this strain only reflects 
a small subset of the enormous var diversity. In addition, 3D7 was in culture for a long 
time and might not reflect parasites in vivo anymore under constant survival pressure. 
Therefore, findings of initial in vitro studies should also be challenged in vivo.  
Moreover, most original findings on binding abilities of PfEMP1 variants were done by 
static binding assays on individual recombinantly produced domains. 36,38,40,42,87,102 
However, static binding conditions do not reflect physiological shear pressure in blood 
vessels in vivo while the analysis of single var domains disregards potential tertiary protein 
structures which are also influenced by numerous conserved cysteines in the adhesive 
domains yielding disulfide bonds among potentially different parts of the protein. 
Therefore, some technical approaches might have to be reassessed and some dogmas 
should be re-opened for discussion.  
 
To overcome the enormous diversity of var genes, large scale screening approaches on 
binding or serology characteristics of culture and field derived var genes in combination 
with in vivo studies on PfEMP1 pathology might reveal distinct var genes relevant for 
disease or conserved immunogenic var epitopes as a potential target for an anti-morbidity 
malaria vaccine. Our studies confirmed the important role of this protein family in 
virulence and survival of P. falciparum and narrowed the more virulent subset of var genes 
down raising hopes that PfEMP1 and thus malaria morbidity can indeed be successfully 
combated. 
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Dynamics of msp2 genotypes and recurring var transcripts 
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Legend to figure "dynamics of msp2 genotypes and recurring var transcripts" 
 
Summary of distribution of var sequences per child, time point and domain. The number of 
different analyzed var sequences is divided by the number of present P. falciparum 
infections. Time points and regions with less than 20 sequences analyzed are marked with 
an asterisk. Recurring msp2 genotypes within one child are indicated as filled boxes in the 
same column. Recurring var sequences within one region are indicated as filled boxes in 
the same column. 
Supplement I: Analysed Sequences of Longitudinal study 77 
DBL1α 
 
L5.06b   (AY462708)    ARSFADIGDIVRGKDLYLGYDDKEKKR----REKLENNLKDIFAKIHEEV----TNGKKG 52 
S5.12f   (AY462715)    ARSFADIGDIIRGRDLYRGNRKKNQKQT--ERDQLESKLKEVFGNIYKELKNGKTNGKKG 58 
L2.06k   (AY462713)    ARSFADIGDIVRGKDLYLGNTHESTQR-----IILENNLKTIFGHIYEEL---IKNGSNG 52 
L3.08a   (AY462772)    ARSFADIGDIIRGKDLYLGDKGN---------DKLEKNLKTIFGDIYKELSRTSTSGRNG 51 
L2.06c   (AY462781)    ARSFADIGDIVRGKDLYIGNKKER--------ARLEENLKKIFKEIHGGL-------KDG 45 
L1.02b   (AY462731)    ARSFADIGDIVRGRDMFRSNEN------------VEKGLRVVFKNIHENLRGPA------ 42 
L7.13a   (AY462745)    ARSFADIGDIVRGRDMFKSNED------------VEKGLKVVFKKIQRKLNGAA------ 42 
L3.02a   (AY462737)    ARSFADIGDIVRGRDMFKRNDK----------DAVQKGLRAVFKKINDNLNEKK------ 44 
L4.13a   (AY462738)    ARSFADIGDIVRGRDMFKSNEK------------VEYGLRKLFKKIHENLRGPA------ 42 
L8.06c   (AY462743)    ARSFADIGDIVRGIDIFKPNDK----------DEVQNGLKKVFKNIHDSLSSDV------ 44 
L1.06L   (AY462746)    ARSFADIGDIVRGRDMFK--SN----------EKVEIGLKKVFDKIYNKLRPEG------ 42 
L6.03c   (AY462732)    ARSFADIGDIVRGKDMFKRTDN----------DEVWKGLRAVFGKIYNGLTPQA------ 44 
L7.08h   (AY462733)    ARSFADIGDIIRGKDMFKRTDK----------DYVENGLKAVFKKIYEGLKNNG------ 44 
S5.12d   (AY462734)    ARSFADIGDIVRGRDMFK--SN----------DNIEKGLRVVFRKIYDGLKKS------- 41 
L3.06d   (AY462735)    ARSFADIGDIVRGRDMFKSNED------------VEKGLQVVFKKIYEGLKGEG------ 42 
S3.07b   (AY462736)    ARSFADIGDIVRGTDMFKPNKD----------DKVEKGLRAIFKNIYEGLKGEG------ 44 
L7.08i   (AY462747)    ARSFADIGDIVRGRDMFKRTDN------------VENGLKKVFDKIYDKLGTQK------ 42 
L3.08c   (AY462729)    ARSFADIGDIVRGRDMFLPNKD----------DKVQKGLQVVFEKINNGLKKIG------ 44 
L1.12i   (AY462730)    ARSFADIGDIVRGRDMFKSN------------DNIEKGLRVVFRKIYDGLKKSG------ 42 
L7.06b   (AY462748)    ARSFADIGDIVRGRDMFKSNNV----------DAVQEGLKVVFKKIYNRSTHHA------ 44 
L6.03d   (AY462739)    ARSFADIGDIVRGIDMFKPNVH----------DKVEKGLREVFKKIHDEMEGEV------ 44 
L2.08g   (AY462740)    --SFADIGDIVRGIDMFKPNVH----------DKVEKGLREVFKKIHDEMEGEV------ 43 
S1.07g   (AY462741)    ARSFADIGDIVRGIDMFKPNVH----------DKVETGFREVFKKIHDGMEDEV------ 44 
L1.12e   (AY462742)    ARSFADIGDIVRGRDMFKSN------------DNVENGLKAVFKKINNGLNDKG------ 42 
L3.12c   (AY462744)    ARSFADIGDIVRGKDMFKPNTV----------DKVHEGLKVVFQKIHDKLKQPE------ 44 
L3.08b   (AY462846)    ARSFADIGDIVRGRDLFYGNPQESAR-----RDKLEENLKRIFGKIYEELTKDKK----- 50 
L6.06e   (AY462830)    ARSFADIGDIIRGKDLYLGD-KQEKD-------NLQNNLKRIFKNIYDNLK--------- 43 
S3.12o   (AY462829)    ARSFADIGDIVRGKDLFLGGPSQEKI-------KLEENLKNIFENIKK------------ 41 
L1.06m   (AY462828)    ARSFADIGDIVRGKDLFLGAPNKEKI-------KLEENLKKIFDNIKN------------ 41 
L1.06c   (AY462834)    ARSFADIGDIIRGKDLYLGKNESEKG----TKEKLRGNLEKIFDKIRN------------ 44 
L8.08g   (AY462851)    ARSFADIGDIVRGKDLFLGKNESEIK----RKEKLQRNLEKIFAQIKN------------ 44 
L6.03b   (AY462831)    ARSFADIGDVIRGRDMFLGNNEKDMT----EKQKLQSNLKKIFGNFME------------ 44 
L5.06e   (AY462850)    ARSFADIGDIIRGRDMFLGNNEKDMT----EKQKLQSNLKKIFEKIRN------------ 44 
S3.12a   (AY462833)    ARSFADIGDIIRGKDLFLGHNHK--------KKPLLDNLEKIFNRFQK------------ 40 
S3.12b   (AY462832)    ARSFADIGDIIRGKDLFLGNNKE--------NEKLQENLKRIFKNIYANLK--------- 43 
PFD1235w (AY462842)    ARSFADIGDIIRGKDLYRRDSRT---------DKLEENLRKIFANIYKELKNGK------ 45 
PF11_0521(AY462836)    ARSFADIGDIIRGKDLYLGNGDY--------KEKVSNNLRAIFNKIYENLN--------- 43 
L5.06d   (AY462839)    ARSFADLGDIIRGKDLYLGHKLG--------NNKLEARLQTMFQNIKE------------ 40 
L1.12b   (AY462840)    ARSFADIGDIIRGKDLYLGHEQG--------NNKLEARLEAMFDNIKK------------ 40 
L2.06f   (AY462844)    ARSFADIGDIIRGKDLFLGHKQR--------KRKLEENLRNIFKNIHDHLT--------- 43 
S3.12c   (AY462843)    ARSFADIGDIIRGKDLYRGGGRG--------RKQLEENLQKIFGNIYNELTRTATSGN-- 50 
L3.08g   (AY462821)    ARSFADIGDIIRGKDLYLGDQQE--------KAKLENNLKNIFAKIHENLNDI------- 45 
PF08_0140(AY462835)    ARSFADIGDIVRGKDLYLGDQQE--------KLYLENNLKKIFVKIHENLND-------- 44 
L1.12c   (AY462837)    ARSFADIGDIIRGKDLFLGTYQE--------KKSLEENLKNIFRKLYKELTKYKE----- 47 
S1.07e   (AY462824)    ARSFADIGDIVRGKDLFLGHSKE--------KEKLEQNLKNLFKQLYEELKKNNK----- 47 
L6.06b   (AY462728)    ----ADIGDIIRGKDLFIGYDKKDRN----EKKQLQQNLKEIFGKIYDNLMKDVRKDK-- 50 
L1.08b   (AY462818)    ARSFADIGDIIRGKDLFLGYDKKDRD----QKKKNQDNLKNIFAKIYENLMEDLTKDN-- 54 
L8.08b   (AY462826)    ARSFADIGDIIRGKDLFIGYNQKDRN----EKKQLQENLKKIFRKIHEGLTTEKR----- 51 
L1.08d   (AY462845)    ARSFADIGDIIRGKDLYLGYDQKEKT----RRENLENKLKEIFGNIYEGLTKEKR----- 51 
L3.12d   (AY462827)    ARSFADIGDIVRGKDLYLGTNEEKKP--------LEENLKEIFKKLYEKLNDPQK----- 47 
S3.12i   (AY462823)    ARSFADIGDIIRGKDLYIGNRKEKE------KVKLQQRLKEIFAKIHNGLPQGK------ 48 
L2.06e   (AY462773)    ARSFADIGDIVRGRDLYGGNK---------KKDKLEKNLKTIFKEIYDKLDG-------- 43 
L7.06a   (AY462775)    ARSFADIGDIVRGKDLYIRNK---------KKDKLQENLKKIFKEIYDKLDG-------- 43 
S3.12k   (AY462774)    ARSFADIGDIVRGRDLYRLDKG--------KRDKLEENLKTTFKKIYDNLFK-------- 44 
L3.12b   (AY462776)    ARSFADIGDIVRGKDLFRGNTK--------EKDRLQSTLKRIFQKIYNNLMEDLKKDP-T 51 
S8.08b   (AY462777)    ----ADIGDIVRGKDLYIRNKR--------EKDRLQSTLKRIFQKIYKNLMEDLRKSSRT 48 
S3.12J   (AY462778)    ARSFADIGDIVRGRDLYGGNSK--------EKVKLEKKLKKIFQKIYNNLMQDLENDKIK 52 
L5.12a   (AY462770)    ARSFADIGDIIRGKDLYLGDN---------GKDKLEENLKTIFGKIYDKLDGK------K 45 
L3.19a   (AY462771)    ARSFADIGDIIRGKDLYRGNN---------GKDKLENNLKEIFKKIYGKLT--------- 42 
L2.06g   (AY462785)    ARSFADIGDIIRGKDLYRGNN---------RKDKLENNLKTIFGIIYEGLT--------- 42 
L6.06a   (AY462780)    ARSFADIGDIVRGKDLFRGNN---------GKDKLQDNLKKIFEKIYNNLN--------- 42 
S1.07f   (AY462787)    ARSFADIGDIIRGKDLFIGNN---------KRDKLEKQLQKYFKKMYEKLTDP------- 44 
L1.12J   (AY462788)    ARSFADIGDIVRGKDLYIGNKG--------EKKKLEEKLKQYFKKIYNDLTKDN------ 46 
L5.08e   (AY462752)    ARSFADIGDIVRGKDLYRRDNKKD---------KLEKNLKEIFQKIQG---R-Y------ 41 
S5.12c   (AY462755)    ARSFADIGDIVRGKDLYIRNKKKD---------KLEDNLQKIFKMIQG---KNP------ 42 
S1.12c   (AY462754)    ARSFADIGDIIRGKDLYRRDNKKD---------KLENNLKKIFKKIQN---K-N------ 41 
L8.08i   (AY462750)    ARSFADIGDIVRGRDLYIRNNKKD---------KLEENLKTIFEKIKG---NNN------ 42 
S3.12n   (AY462779)    ARSFADIGDIVRGRDLYRGDNKKDK----AQKLKLQDNLNKIFNDIK----NTN------ 46 
L7.11a   (AY462751)    ARSFADIGDIVRGKDLYLGGNTKEK----KKREDLEKNLKNIFENIT----KGN------ 46 
S3.12f   (AY462847)    ARSFADIGDIVRGRDLYRGNN--------KRRQQLEDNLKKIFENIK----NEN------ 42 
L5.08b   (AY462753)    ARSFADIGDIVRGKDLFLGHNQ--------RKRKLEENLKQMFENIQS---TI------- 42 
S5.12a   (AY462825)    ARSFADIGDIVRGKDLFLGHSK--------EKEKLEQNLQNIFEKLKS---SN------- 42 
L3.08d   (AY462820)    ARSFADIGDIIRGKDLFLGYNKSDQ----KEKEQLQDNLEKIFRNIQD---KNR------ 47 
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L7.06e   (AY462841)    ARSFADIGDIVRGKDLYLGNKKKNQDI--REKEKLEDNLKTIFANIYKELSRTK------ 52 
L7.06f   (AY462807)    ARSFADIGDIVRGKDLYLGNKKKNQDI--REKEKLEDNLKTIFANIYKELSRTK------ 52 
L8.06g   (AY462808)    ARSFADIGDIVRGKDLYRGNKKEN-----KQRKQLDDSLKEIFENIK----ESD------ 45 
L3.13a   (AY462809)    ARSFADIGDIVRGRDLYGGGGRGK------GKEKLEQKLKDIFGDIYKELSTKN------ 48 
S8.08a   (AY462705)    ARSFADIGDIIRGKDLYRRDKGEE--------TKLEKNLKKIFAKIHDKLDDT------- 45 
S3.12h   (AY462724)    ARSFADIGDIIRGKDLYRRDKGEE--------TKLEKNLRKIFAKIHGGLTG-------- 44 
L6.11a   (AY462795)    ARSFADIGDIIRGKDLYRGNNREN--------DKLEKKLKEYFKKIYEGLKG-------- 44 
L8.06f   (AY462812)    ARSFADIGDIVRGIDLYGGN---NKR-----RKQLDDKLKEIFKKIHENLG--------- 43 
L7.06c   (AY462720)    ARSFADIGDIVRGKDIFIGNKKENKQ-----RQQLDDKLKDIFGKIHEGLS--------- 46 
L1.12h   (AY462704)    -RSFADIGDIVRGKDLYRGNSKEKNR-----RQQLENNLKEIFAKIHEKLTT-A------ 47 
S7.08c   (AY462811)    ARSFADIGDIVRGRDLYRGNTQEKKQ-----REKLDNNLKDIFAKIHGNLR--------- 46 
L7.12b   (AY462719)    ARSFADIGDIVRGRDLFYGNTQEKTK-----REQLDDKLKEAFGKIHSGLT--------- 46 
S3.07d   (AY462810)    ARSFADIGDIVRGRDLYRGNKQEKEQ-----REKLDEKLKEIFKKIHNGLD--------- 46 
MAL6P1.4 (AY462849)    -RSFADIGDIVRGKDLFLGTNEEK--------KPLEENLKEIFKKIYENLG--------- 42 
L2.06b   (AY462797)    ARSFADIGDIVRGRDLYRRDK---GKG-----DHLEKNLKKYFQQIHNDVTSTSG----- 47 
L8.06e   (AY462803)    ARSFADIGDIVRGRDLYRGG----GRG----RKKLDDKLKEIFQQIHSEVTS-SG----- 46 
L5.06f   (AY462805)    ARSFADIGDIIRGRDLYRGGGR--GKG----KEKLEGKLKDIFAKIYNDVTS--G----- 47 
L1.08e   (AY462813)    ARSFADIGDIIRGRDLYSG----NKVK----KKKLDDSLKTIFGKIYEGLTG-G------ 45 
PF08_0103(AY462819)    ARSFADIGDIIRGKDLFIGYDKKDRVQ----KKKLQDSLKNIFGNIYNELTT-SG----- 50 
L7.12c   (AY462814)    ARSFADIGDIVSGRDLYRGN-KKETNQ----REKLEENLRKIFENIYEGLS--------- 46 
L7.08e   (AY462815)    ARSFADIGDIVRGRDLYRGN-KKENKQ----RDKLDENLKKIFGKIHEGLS--------- 46 
L3.08f   (AY462848)    ARSFADIGDIIRGRDLYRGN-SKE-------KDYLQDKLKKYFQKIYDNLN--------- 43 
S1.12a   (AY462798)    ARSFADIGDIVRGKDLYGRN-NRK-------RKQLDENLQKYFENIYYGLSN--E----- 45 
L2.08e   (AY462718)    ARSFADIADIVRGRDLYSGN-SKEKKQ----RKQLDDKLKEVFTNIYNEL---RS----- 47 
L7.08k   (AY462804)    ARSFADIGDIVRGRDLFYGN-PQEKDQ----RKKLQQNLKTIFKKIHGGS---TK----- 47 
L1.12d   (AY462717)    ARSFADIGDIVRGRDLYLGN-PEEIKQ----SHQLDKKLKDIFAKIYEGLSRTRT----- 50 
L5.06a   (AY462703)    ARSFADIGDIVRGRDLFRGYNEKDRKE----REQLQDSLKNIFGNIYEKLLEENQ----- 51 
L1.12f   (AY462789)    ARSFADIGDIIRGKDLYRRDNKKDK---------LEKNLKKIFEKIYDKLLEENQ----- 46 
S3.12e   (AY462714)    ARSFADIGDIIRGRDLFRG-NTYESAQ----RIILENNLKKIFRNIYDKLD---G----- 47 
L3.12a   (AY462759)    ARSFADIGDIVRGRDLYGGS-KKEIKQ----RQLLDENLKTIFGKIYEELTKNEK----- 50 
L3.12e   (AY462727)    ARSFADIGDIVRGRDLYRGN-KKENKQ----RKQLDDSLKKIFGKIHSGLSKG------- 48 
L1.06a   (AY462757)    ARSFADIGDIVRGRDLFRGN-DEEIKQ----RQQLDKKLKEIFKKIYEGLKNG------- 48 
L1.06h   (AY462801)    ARSFADIGDIVRGRDLYGGG-NN--KR----RQQLDENLKTIFKNIYDKLLEENQ----- 48 
S1.07a                 ARSFADIGDIIRGKDLYLGDNGKDR---------LEENLRKIFKKIYDKLDG-K------ 44 
S1.07b   (AY462767)    ARSFADIGDIVRGRDLYRGVNGNDK---------LEKNLKEIFAKIHKEVTS-T------ 44 
L3.08h   (AY462769)    ARSFADIGDIVRGRDLFLGYNEKDRKE----KEQLAKNLKDIFAKIHDDVT--------- 47 
L1.06J   (AY462706)    ARSFADIGDIVRGRDLYLGDNRKDREQ----REQLEKNLKDIFEKIHKEVT--------- 47 
L2.08a   (AY462768)    ARSFADIGDIIRGKDLYRGNNGKDK---------LEENLKRIFQQIHKEVTS-T------ 44 
L2.12a   (AY462725)    ARSFADIGDIIRGKDLFIGYNQKDREE----KNQLQENLKKIFAKIHSEVTN-G------ 49 
L1.12a   (AY462822)    ARSFADIGDIIRGKDLFRGYNEKDQQE----KAKLQQSLKDIFAKIHSEVTK-GG----- 50 
L2.08f   (AY462726)    --SFADIGDIVRGKDLFRGYNEKDQQG----KAKLQQNLKDIFAKIHSDVMK-T------ 47 
S1.12b   (AY462709)    ARSFADIGDIIRGKDLFRGYNEKDRNE----KKQLQQNLKTIFGKIHDDVTN-G------ 49 
L2.06h   (AY462710)    ARSFADIGDIIRGKDLYLGGRGRD---------QLESNLRKIFAKIYKDVTN-G------ 44 
L8.06h   (AY462707)    ARSFADIGDIIRGKDLYRG-NDKEKDQ----RKKLDKNLKTIFGKIYKDVTT-N------ 48 
L5.06c   (AY462783)    ARSFADIGDIVRGKDLYRG----VNG-----NDKLENKLKEIFKKIHEGLT--ST----- 44 
S3.07a   (AY462765)    ARSFADIGDIVRGKDLYRG----NNRE----NDKLESKLKVIFGKIYKDLT--TT----- 45 
L7.08b   (AY462784)    ARSFADIGDIVRGKDLYRGYDQKEKEQ----RDELENNLKTIFGDIYKDVTNGRN----- 51 
S7.08a                 ARSFADIGDIVRGKDLFLG-NTHESAR----REKLENKLKDIFGDIYKELR--KN----- 48 
L1.12g   (AY462711)    ARSFADIGDIVRGRDLYLG-NPQESTQ----RDKLENNLKTIFANIYKDVT---S----- 47 
L1.02a   (AY462762)    ARSFADIGDIVRGKDPFYG-NPQESAQ----RKQLEKNLKDIFKNIYNDVT--RG----- 48 
L1.06g   (AY462806)    ARSFADIGDIVRGEDLFLG-TNEE-------KKPLEENLKEIFKNIYNEVM--RG----- 45 
L2.08c   (AY462790)    ----ADIGDIIRGKDLYLG-DKGEKK-------KLEENLKTIFTQIYNDVT--KG----- 41 
L5.12b   (AY462760)    ARSFADIGDIVRGKDLYLG-NKQEKKQ----RKKLEDKLKDIFKNIYKDVT--RG----- 48 
L5.08c   (AY462749)    ARSFADIGDIIRGRDLYRRDNKKDK------TDKLQEQLKKYFQKIYEELKN-------- 46 
L8.08d   (AY462799)    ARSFADIGDIIRGKDLYLGGNKKEKNR----RDDLEDKLKNIFAKIYDNLVE-------- 48 
L7.08f   (AY462817)    -------------KDLYLGYDDKEKTR----RKKLEEKLQKIFGNIYNELTR-------- 35 
S3.12m   (AY462782)    ARSFADIGDIVRGKDLYLRYNRKDKT------DKLQEQLKKYFQKIHDGLTN-------- 46 
L6.02a   (AY462716)    ARSFADIGDIVRGKDLYLGYDDEEKN----RRKKLQQNLKNIFGNIYKELTS--T----- 49 
S1.08b   (AY462793)    ARSFADIGDIVRGKDLYLGDKEKKQNGKKTEREKLEQKLKDIFEKIHEELK--------- 51 
L6.02b   (AY462756)    ARSFADIGDIVRGRDIFRGNDEEKKQ-----RDKLEENLKNIFGKIHDNLT--------- 46 
L8.08c   (AY462758)    ARSFADIGDIVRGKDLFYG-NPQEKD----QREKLDENLKTIFKNIK------------- 42 
S1.08a   (AY462786)    ARSFADIGDIVRGKDLYLGYDDKEKD----RRRKLEENLKTIFTQIYNDVTS--G----- 49 
S5.12e   (AY462794)    ARSFADIGDIVRGKDLFLG-NDEEKK----RREKLEKNLKEIFKQIHEKLTD--Q----- 48 
L5.08a   (AY462791)    ARSFADIGDIIRGKDLFLGNTYESAQ-----REKLDDKLKKIFGDIYEGLKK--K----- 48 
S1.07d   (AY462764)    ARSFADIGDIVRGKDPFYGNTYESAQ-----REKLESKLKEIFAKIYEGLTT--T----- 48 
S1.12d   (AY462792)    ARSFADIGDIVRGKDLFLGNTYESAQ-----RDKLEKNLKEIFGKIHSEVMK-------- 47 
S3.12g   (AY462712)    ARSFADIGDIIRGKDLFLGNTYESEQ-----RIILENNLKTIFAKIHSEVTN--G----- 48 
L1.06b   (AY462761)    ARSFADIGDIVRGKDPFYGNTHESAQ-----RKVLDKKLKEVFGKIHDDV---------- 45 
L2.06L   (AY462763)    ARSFADIGDIVRGRDLFYGNTHESAQ-----RDQLDKKLKEVFGKIHGGL---------- 45 
L5.06g   (AY462721)    ARSFADIGDIVRGRDLYRGNKKENKQ-----REKLEAKIKEYFQKIYDDLFQ-------- 47 
L2.13a   (AY462722)    ARSFADIGDIVRGRDLFYGNPQESTQ-----RKQLDKKLKVIFGKIHEGL---------- 45 
S1.07c   (AY462766)    ARSFADIGDIIRGKDLFYGNTQESAR-----RDELEKNLKTIFEKIHDKL---------- 45 
L6.03a   (AY462723)    ARSFADIGDIVRGRDLYRRDKGE--------ETKLEKNLKTIFAKIHSEVTKGGN----- 47 
L8.08e   (AY462796)    ARSFADIGDIIRGKDLYRGNNRE--------NDKLEKKLKEYFKKIYEELVK--K----- 45 
L1.06k   (AY462838)    ARSFADIGDIIRGRDMWDKDGG---------STEMENNFKKIFNTIRQKLPE-------- 43 
L5.08f   (AY462800)    ARSFADIGDIIRGRDLYRRDKGE--------ETKLEKNLKEIFKNIYNELTT-------- 44 
L7.08g   (AY462802)    ARSFADIGDIIRGRDLYRRDKGE--------ETKLEKNLKEIFKNIYNELTT-------- 44 
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L5.06b   (AY462708)    ----------EIEARYK----DTTNFFQLREDWWTANRQEIWKAITCDAG-----GSQYF 93 
S5.12f   (AY462715)    ----------EIETRYKGD--EANNFFKLREDWWTANRATIWEAMTCSEHL---KNSAYF 103 
L2.06k   (AY462713)    ----------QIEARYKKDD-EDGNFFQLREDWWYANRATIWEALTCDAR----HDAQYF 97 
L3.08a   (AY462772)    K-------KEEIERRYG----SDENFFQLREDWWDANRATVWYAITCGAG----ESDKYF 96 
L2.06c   (AY462781)    -----------AKKHYQD---GSGDFFQLREDWWYANRIMVWNAITCGAG-----GSQYF 86 
L1.02b   (AY462731)    ------------KNYYADDDG-SGNYSKLREAWWTTNRDQVWKAITCSAPR----DADYF 85 
L7.13a   (AY462745)    ------------KSYYNADE--KGNYYKLREDWWMANRDQVWKAITCKAPT----GADYF 84 
L3.02a   (AY462737)    ------------ITHYNDG---SGNYVKLREDWWTVNRDQVWKALTCSAPY----NAHYF 85 
L4.13a   (AY462738)    ------------KSHYEDGDK-SGNYYKLREHWWIVNRKQLWEAITCIAPR----DAHYF 85 
L8.06c   (AY462743)    ------------RKNYPDDG--FGNYYKLREAWWNANRDKVWNALTCSIPY----YANYV 86 
L1.06L   (AY462746)    ------------K-NYPD-DG-SGNYYKLREAWWNVNRDQVWRAITCEAPQ----KVDYF 83 
L6.03c   (AY462732)    ------------KTHYADEDG-SGNYYKLREAWWKANRDQVWRAITCSAPG----DVNYF 87 
L7.08h   (AY462733)    ------------ANVHYKDDG-SGNYYKLREAWWTVNRDQVWKALTCTAPD----NVNYF 87 
S5.12d   (AY462734)    ------------KITDYDND---PNYYKLRNDWWTVNRDQVWKALTCNAPD----NVNYF 82 
L3.06d   (AY462735)    ------------ANVHYKEDK-DENYYKLRNDWWTANRDQVWKAITCKAPK----GANYF 85 
S3.07b   (AY462736)    ------------VKVHYKENK-DGNYYKLREAWWTANRDQVWRALTCNAPY----DANYV 87 
L7.08i   (AY462747)    ------------KNYYNNTGN-NVDYVKLREDWWTANRDQVWKAITCKAPH----DANYF 85 
L3.08c   (AY462729)    ------------INAYNDGS---GNYSKLREVWWNVNRDQVWRAITCSAPG----DVNYF 85 
L1.12i   (AY462730)    ------------INYYNDEN---GNYYKLREAWWNVNRDKVWEAITCEASK----NANFF 83 
L7.06b   (AY462748)    ------------KNDYTGDH---PNYYKLREDWWNVNREQVWRAITCKASK----NANYF 85 
L6.03d   (AY462739)    ------------KNYYNPDG--SGNYYKLREAWWDVNRNKVWESITCGALP----KSAYF 86 
L2.08g   (AY462740)    ------------KNYYNPDG--SGNYYKLREAWWDVNRNKVWEAITCGALP----KSAYF 85 
S1.07g   (AY462741)    ------------KNDYNPDG--SGNYYKLREAWWNVNRNKVWEAITCDASY----KSGYF 86 
L1.12e   (AY462742)    ------------IRYYDDDG--SGNYYKLREAWWTANRDQVWKAITCGALP----KSAYF 84 
L3.12c   (AY462744)    ------------KDYYNADE--KGNFYKLREDWWTANRDQVWKALTCYAPD----KANYF 86 
L3.08b   (AY462846)    -------KMVEAKKKYKDEN--GGNFFKLREDWRTANRETVWKAITCAAKV----GDTYF 97 
L6.06e   (AY462830)    -------DNEAVKTRYDNDEK-DGNFYQLREDWWALNRKEVWKALTCSVPY----EAYYF 91 
S3.12o   (AY462829)    -------GNTELSTLP---------IEKVREYWWALNRKEVWKALTCSVPY----EAYYF 81 
L1.06m   (AY462828)    -------ENAELSKLS---------LEKVREYWWAIHRKELWEALTCNAPK----GANYF 81 
L1.06c   (AY462834)    -------NDKTLNNLS---------IGQVREDWWALNRKDVWKALTCSAPE----DAKYV 84 
L8.08g   (AY462851)    -------NDRTLNNLS---------IGQVREAWWTANRDQVWKAITCNAPY----KAWYF 84 
L6.03b   (AY462831)    -------SNANLKKHTLE---------RVREYWWALNRNDVWKALTCSAPY----DANYV 84 
L5.06e   (AY462850)    -------DGRIPKNVPIG---------QVREYWWALNREDVWKALTCSADG----SEEYF 84 
S3.12a   (AY462833)    -------IYEDINNLPID---------DIREYWWALNRNDVWEALTCSAPY----YADYF 80 
S3.12b   (AY462832)    -------DHQALKHYKDDTKN----YYQLREAWWALNRNDVWKALTCSAPY----DANYV 88 
PFD1235w (AY462842)    -------KWAEAKEYYQDDGT-G-NYYKLREAWWALNRKDVWKALTCSAPR----DAQYF 92 
PF11_0521(AY462836)    -------DPKLKKHYQKDAPN----YYKLRDDWWNANREDVWKALTCNAPY----EAQYF 88 
L5.06d   (AY462839)    ------------NNNTELGE---LTTAQVREYWWALNRVQVWKAITCKAKE----GDIYS 81 
L1.12b   (AY462840)    ------------NNKKQLGE---LSTAQVREYWWALNREDVWKALTCSADG----SEEYF 81 
L2.06f   (AY462844)    ---------EEAKKKCQDGD---GNYFKLREDWWYANRRQVWNAITCAAKE----EDTYS 87 
S3.12c   (AY462843)    -------KGKTLQKHYKDND---KNFFKLREDWWTANRDQVWKALTCFADG----SEDYF 96 
L3.08g   (AY462821)    ----------EAKTYYNSDT---PDFYKLREDWWALNRRDVWKAITCGAG---------- 82 
PF08_0140(AY462835)    ----------KIKSNYNDSE---GNYFKLREDWWTAIRDQVWKAITCNAPK----DVNYL 87 
L1.12c   (AY462837)    -------NEAVIKSRYSKDD---PYFYQLREDWWNANRDQVWKAITCGADD----NDKYF 93 
S1.07e   (AY462824)    -------ND-AIKTHYEKDG---QNYYKLRNDWWELNRKQVWNAITCGAPK----DAKYL 92 
L6.06b   (AY462728)    ------RRQMEAQERYKKDEE-DGNYYQLREDWWDANRGTVWKAITCKAEQ----NNKYF 99 
L1.08b   (AY462818)    ------IKRQEAEKRYKKDEE-DGNYYQLREDWWDANRGTVWKAITCKAEQ----NNKYF 103 
L8.08b   (AY462826)    -------------SHYNGDGD---NYYKLREDWWYANRKEVWKAITCDASE----DAKYF 91 
L1.08d   (AY462845)    -------------SRYKKDGD-TDNYYKLREYWWALNRDQVWKAITCSAGE----DDIYS 93 
L3.12d   (AY462827)    -------------SSYNDDG--TGNYYKLREYWWNANRNDVWKAITCEAKS----DDKYK 88 
S3.12i   (AY462823)    ------------NSAYLNDG---PNYSKLREDWWNANRYDVWKAITCGAPK----ESKYF 89 
L2.06e   (AY462773)    KKGK------EAKDRYKD--DEANNFFKLREDWWDANRHQVWRAITCSAG-----GGRYF 90 
L7.06a   (AY462775)    KKKE------EAKDYYKD--TDKN-YYKLREDWWNANRIMVWNAITCGAG-----GGKYF 89 
S3.12k   (AY462774)    KKGK------EAEERYNG--DKDPNYYQLREDWWDANREKVWKAIKCNAG-----GGKYF 91 
L3.12b   (AY462776)    KELK-------GKERYKD----TENYFQLREDWWNNNRKMVWYAITCGAA-----GGKYF 95 
S8.08b   (AY462777)    KVDK-------AKERYEG----DKNYYQLREDWWDANRAKVWYAMTCDAA-----GGTYF 92 
S3.12J   (AY462778)    VKNKGKVTKEEAKRRYKDINDIDNNFYKLREDWWDANRAKVWEAITCGHP-----GGTYF 107 
L5.12a   (AY462770)    GHKS-------AKEHYKDESR---NYYQLREDWWNANRKMVWYAITCGAGQ----IDKYF 91 
L3.19a   (AY462771)    -HRR-------AKEHYKDEDDKDPNYYQLREDWWNNNRIMVWRAITCGAGQ----IDKYF 90 
L2.06g   (AY462785)    -DSG-------AKNHYEDATG---NYYQLREDWWNINRKKVWDAITCHVVS----GNNYF 87 
L6.06a   (AY462780)    -NRK-------AKTHYEDKDP-EKNFFKLREDWWNANRQQVWYAITCGAG-----GSQYF 88 
S1.07f   (AY462787)    ----------RAKKHYED--GAPE-FYKLREDWWNANRQEIWKALTCDAPNG---DVHYF 88 
L1.12J   (AY462788)    IKRQ------EAQKRYQD--DKYENYYQLREDWWNANRQEIWKALTRDAPNG---DVHYF 95 
L5.08e   (AY462752)    ----------STLTRLPLDK--------VREYWWALNRQEIWKAITCDAGK----NDKYF 79 
S5.12c   (AY462755)    ----------SKLGALSLDQ--------VREYWWEENREKIWKAITCNAG-----GYSYF 79 
S1.12c   (AY462754)    ----------EDLKSLSLDE--------LREYWWELNRETVWKAITCNAG-----GGKYF 78 
L8.08i   (AY462750)    ----------STLKDLPLDA--------VREYWWDANRATVWKALTCDAHE----GDTYF 80 
S3.12n   (AY462779)    ----------RRLNDLTDDQ--------IREYWWDANREKVWYAITCDAGG----G-TYF 83 
L7.11a   (AY462751)    ----------TELSTLPIEK--------VREYWWELNRKEVWKAITCEAN------GTYF 82 
S3.12f   (AY462847)    ----------TDLNKLTTEK--------VREYWWALNRQTVWKAITCEAY------GTYF 78 
L5.08b   (AY462753)    ----------DQLNGLSLDE--------VREYWWEANRREVWKAITCHAPN----DAQYF 80 
S5.12a   (AY462825)    ----------PQLTNVSLEK--------IREYWWALNRQEIWKAITCDAPD----YAKYF 80 
L3.08d   (AY462820)    ----------DKLSDLSIDK--------VREYWWNANRQEIWKAITCDAPE----DAKYF 85 
L7.06e   (AY462841)    ----------GAQTYYQDDNG--GNYYLLREDWWALNREKVWKAITCEAEV----EDKYS 96 
L7.06f   (AY462807)    ----------GAQTYYQDDNG--GNYYLLREDWWALNREKVWKAITCDAPH----GAQYF 96 
L8.06g   (AY462808)    ----------AKLTKLNDDQ--------IREYWWALNRNDVWKAITCDAPH----GAQYF 83 
L3.13a   (AY462809)    ----------GAQKHYGDDE----NYYKLREDWWTANRQEIWKALTCDAPD----YAQYF 90 
80 
S8.08a   (AY462705)    ----------VVQKHYSDDDKGTKNYYKLREDWWTANRHTVWKALTCDHRL---AGAHYF 92 
S3.12h   (AY462724)    ----------GAKTHYEGDD---PNYYKLRNAWWEANRQEIWKAITCGH-----PGGTYF 86 
L6.11a   (AY462795)    ----------DAQNRYNGDG---DNYYKLREDWWDANRHTVWKAITCGAD----AGNKYF 87 
L8.06f   (AY462812)    ---------THEKKHY-ENDT--ANYYKLREAWWALNRQDVWKALTCD------AHGTYF 85 
L7.06c   (AY462720)    ---------ESAKKHYTDNKD--PNYYQLREDWWTANRATVWKAITCDEDKKL-AGASYF 94 
L1.12h   (AY462704)    ---------NGVKSRY-NDAT--GNYYKLREDWWTANRETVWKAITCDD--RL-AGAHYF 92 
S7.08c   (AY462811)    ---------NGVKDHY-QDAT--GNFFKLREDWWEENRETVWKALTCDEDKKL-SNASYF 93 
L7.12b   (AY462719)    ---------GSAKDHYKDENG--GNYYKLREDWWNANRETIWKALTCEAP----EHASYF 91 
S3.07d   (AY462810)    ---------GKAQARYNGDT---DNFYRLREDWWNANRQEIWKAITCDEENKL-ASASYF 93 
MAL6P1.4 (AY462849)    ---------IQEKNHYNDTP----DYYKLREDWWIANRDQVWKAITCNAG-----GYSYF 84 
L2.06b   (AY462797)    ----SNGE--PLKTRYGSDKD--NDFFKLREDWWTANRETVWKAITCN---AQGN--TYF 94 
L8.06e   (AY462803)    ----SNWK--ALKTRYQNDPK--GDFFQLREDWWTANRSTVWKAITCS---EKLANYKYF 95 
L5.06f   (AY462805)    ----KNLQ--ALRDRY-NDGS--GNFYKLREDWWTANRHTVWEAITCDDD-NKLGGYSYF 97 
L1.08e   (AY462813)    -----------VKERY-TNDG--GDFFQLREDWWTANRETVWKAMTCS---EHLKNSAYF 88 
PF08_0103(AY462819)    ----KNVD--KAKARY-NDPK--GDFFQLREDWWALNREKVWSAITCN---AQ--GNKYF 96 
L7.12c   (AY462814)    ------NN--GVKARY-EGDK--ENFYQLREDWWALNRDQVWKALTCS---DDLKDASYF 92 
L7.08e   (AY462815)    ------KN--GAQKHY-KGDP--E-FFKLREDWWTANRETVWKAITCS---DELKDASYF 91 
L3.08f   (AY462848)    ------GA--QTYYND-NDKD--KNYYQLREDWWIANRDQVWKAMTCSDDDKKLASAHYF 92 
S1.12a   (AY462798)    ----TNGQ--ALQARY-NNDT--PYYYKLREDWWNANRETVWKAMTCS---KELDNSSYF 93 
L2.08e   (AY462718)    ----TNG----VKDHY-KGDT--PDFLKLREDWWTANRATIWEALTCEAP----EHASYF 92 
L7.08k   (AY462804)    ----NNGA---LKPRY-KDDA--PYYYKLREDWWTANRATIWEALTCEA------YGTYF 91 
L1.12d   (AY462717)    ----KNGQ--TLQERY-KGD---PEFFQLREDWWTENRETVWKALTCEVG-----GGTYF 95 
L5.06a   (AY462703)    ----KNGKNVALQARY-KDTT---NFYELREDWWTANRATVWKALTCD-EENKLRDASYF 102 
L1.12f   (AY462789)    ----TNVK--TLQARY-KDTT---NFYELREDWWTVNRDQVWKALICG-APD---DAQYF 92 
S3.12e   (AY462714)    ----KNGK--TLQARY-NDPK--GDFFQLREDWWTANRETVWKAITCD-AHEG---DTYF 94 
L3.12a   (AY462759)    ----TNKE--AAQKRYK-DND--PNFYKLREDWWYANRKKVWDAITCKAN----DGDKYF 97 
L3.12e   (AY462727)    -----------AQTYYN-DDK--ENYYQLREDWWDVNRKKVWDAITCGAP----DEGEYF 90 
L1.06a   (AY462757)    ----SNGK--EAQKHYE-DDT--KNYYQLREDWWDANRETVWKAITCKAD----ENDRYS 95 
L1.06h   (AY462801)    ----TNGK--TLQERYKKDED--KNFFKLREDWWTANRHTVWEAITCSAD----KGNAYF 96 
S1.07a                 ----KGKKQDAKERYK-DDNG--GNYYQLREDWWNNNRKMVWYAITCGAA-----GGEYF 92 
S1.07b   (AY462767)    ----RGKNMQALQTRY-GQDG--PDYYQLREDWWNNNRKMVWRAITCGAA-----GGEYF 92 
L3.08h   (AY462769)    ----RGTNAEELKTRYKGDDN--NNYSKLREDWWNNNRKMVWRAVTCGVI-----GSHYF 96 
L1.06J   (AY462706)    ----KGSN-GKLKARY-GSDK--ENYYQLREDWWEENRETVWKAITCNAG-----GGKYF 94 
L2.08a   (AY462768)    ----SGKNKDALKTRY-QNDT--DNYYKLREDWWNNNRKMVWYAITCGAK-----GSQYF 92 
L2.12a   (AY462725)    ----KNVNKQSLQARYN-DTD---NYFQLREDWWDANRKKVWDAITCKAND----GDKYF 97 
L1.12a   (AY462822)    ----KNVNKQSLQERYK-DTT---NYYLLREDWWALNRNDVWKAITCGAEH----KDKYS 98 
L2.08f   (AY462726)    ----SGSNGQALQTRYNGDKD--PNFFQLREDWWDANRAKVWYAMTCGAPD----NAEYF 97 
S1.12b   (AY462709)    ------RNGEAAKERYK-DD---PNFFQLREDWWDANRATVWKAITCNARD----NAKYF 95 
L2.06h   (AY462710)    ------GKNGELQERYK-DDT--ANYYQLREDWWDANRATVWKAITCEA------NGTYF 89 
L8.06h   (AY462707)    -----GKNAEELKARYEGDKE--NYFFQLREDWWTANRETVWKALTCDAD------GSYF 95 
L5.06c   (AY462783)    ----NGRNGEAAKKYYF-DPK--GNFYQLREDWWYANRETVWKAIRCSAP----TDANYF 93 
S3.07a   (AY462765)    ----RGKTN-GAQTYYN-DNG--GNYYKLREDWWTANRET-------------------- 77 
L7.08b   (AY462784)    ----GKTNGEAAKARYKDDTD--GNYYKLREDWWTANRHTVWKALTCKAP----QDADYF 101 
S7.08a                 ----GKTNGEAAIKRYGGDGD---NYYKLREDWWDANRHTVWEAITC------------- 88 
L1.12g   (AY462711)    ----SGRNGQTLQKRYE-DNG--GNYYQLREDWWTENRETVWKAITCNDDKKL-ANAQYF 99 
L1.02a   (AY462762)    ----NKGKTNGAEARYGNDPD----FLKLREDWWTANRETVWKALTCEAPN----NAQYF 96 
L1.06g   (AY462806)    ----RNGKTNGAEARYKEDPD--KNYSKLREDWWTANRHTVWEAITCDDDNKL-SNASYF 98 
L2.08c   (AY462790)    ----G--KNVALQERYQDDTD--KNYYKLREDWWALNRDQVWKAITCGAP----DDAQYF 89 
L5.12b   (AY462760)    -------KNVALQKRYNGDEA--NNFFKLREDWWTVNRDQVWKAITCSEEL---RGDAYF 96 
L5.08c   (AY462749)    ----GKTNG-EVKRRYE-DNG--GNYSKLREDWWTVNRATVWKAITCGTHDG----DTYF 94 
L8.08d   (AY462799)    ----KKK---EAKDHYE-DKD--GNYFQLREDWWTANRATVWKAITCKADTG----NAYF 94 
L7.08f   (AY462817)    ----GKQNGQTLKTRYE-NDT--ENYFQLREDWWTANRETVWKALTC-DAPGG---ASYF 84 
S3.12m   (AY462782)    ----G------VKERYK-KDG--DNFYQLREDWWEANRETVWKAITCSDRLGG---NNYF 90 
L6.02a   (AY462716)    ----NG-KKSALQERYGND----PNFFKLREDWWDANRETVWKAITCGHP-----GGTYF 95 
S1.08b   (AY462793)    ----NG-KKSALQERYTNDG---PEFFQLREDWWTANRHTVWKAITCDVV-----GFDYF 98 
L6.02b   (AY462756)    ---------EEAKKSYSDT----TNFFQLREYWWELNRETVWEAITCGVH-----GSDYF 88 
L8.08c   (AY462758)    ----RN-N-----EDLKNIP-----LPKVREYWWALNRNDVWKAITCDAK-----AFYYF 82 
S1.08a   (AY462786)    ----RT-NGEAAKKHYEDATG---NFFKLREDWWYANRRQVWKAITCNAK-----GFNYF 96 
S5.12e   (AY462794)    ----RA-K-----ERYKDENG--GNYFQLREDWWTANRHTVWEAITCEVKS----GSQYF 92 
L5.08a   (AY462791)    ----NGKNVDTLQARYKDGKD--PDFFKLREDWWTANRHTVWEAITCNAK-----GYQYF 97 
S1.07d   (AY462764)    ----NG-----VKDRYEGDAK--KNFYKLREDWWTANRHTVWEAITCNAK-----GYQYF 92 
S1.12d   (AY462792)    -------NNGALQARYKGDK---ENFFQLREDWWDANRETVWKAITCEVK----SGSQYF 93 
S3.12g   (AY462712)    ----KNAKKQALQKRYKKDG---PEFFKLREDWWYANRETVWKALTCDDGL---SNSKYF 98 
L1.06b   (AY462761)    --------TSGAQTRYKKDGG---NYFQLREDWWTASRETVWYANTCGAG----TSDKYF 90 
L2.06L   (AY462763)    --------SEEAKGHYGGDE----NYYKLREDWWTANRHTVWKALTCDAR----DNAEYF 89 
L5.06g   (AY462721)    -------NKQDAKERYGSDAP---YYFQLREDWWTANRETVWKALICHAP----NDAEYF 93 
L2.13a   (AY462722)    --------KDPEKTKYNDPKG---NYYLLREDWWTANRATIWEALTCHAG----QNDKYF 90 
S1.07c   (AY462766)    --------DGKIKSNYNNDTK---NYYQLREDWWTANRETVWKAITCKAN----DGDKYF 90 
L6.03a   (AY462723)    -------NAEELKARYKDESG---DYYQLREDWWEANRETIWRALTCRAPH----SAHYT 93 
L8.08e   (AY462796)    -------YREEAKDYYKD-TE---NYFQLREDWWALNRDQVWKAITCDA-H----DSRYR 89 
L1.06k   (AY462838)    ----------EIQKRYTNREN---KHLELRADWWEANRAKVWEAMKCHI----------- 79 
L5.08f   (AY462800)    --------KNGTKERYND-TD---NYFQLREDWWTANRETVWKALTCNADA----SSAYF 88 
L7.08g   (AY462802)    --------KNGTKERYND-TD---NYFQLREDWWTANRATIWEAITCGAPN----NAQYF 88 
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L5.06b   (AY462708)    RATCSDS-GDNEKHS--TLASNKCRCP-KGD-------------QVPTYFDYVP 130 
S5.12f   (AY462715)    RATC----GDEENKS--TRAKDKCRCK-KKDSK-------SETDQVPTYFDYVP 143 
L2.06k   (AY462713)    RPTC------NGGKS--S-TPNKCRCKDKKTGK-------DDTDQVPTYFDYVP 135 
L3.08a   (AY462772)    RKTC-------SNDT--SHTNEKCRCP---------------IYKVPTYFDYVP 126 
L2.06c   (AY462781)    RPTCG-----SGKTA--TRAKDNCRCP---------------TYKVPTYFDYVP 118 
L1.02b   (AY462731)    IKNSDGS-----RD---FTSEGKCGHND---------------NRVPTNLDYTP 116 
L7.13a   (AY462745)    KKKSVDT-----VD---FTNDGKCGHTE---------------GTVPTNLDYVP 115 
L3.02a   (AY462737)    IKSSPDF-----KS---FS-DHKCGHEE---------------SRVLTNLDYVP 115 
L4.13a   (AY462738)    LKSSPDF-----KS---FS-DLKCGHYE---------------GAPPTYLDYVP 115 
L8.06c   (AY462743)    IKKSDDT-----IV---FTDNRKCGHYE---------------GAPPTNLDYVP 117 
L1.06L   (AY462746)    RKDLDGS-----DV---FTSQGYCGRKE---------------APVPTYLDYVP 114 
L6.03c   (AY462732)    RKGLDGK-----II---FSDNGHCGRNE---------------RNVPTNLDYVP 118 
L7.08h   (AY462733)    RKYSDGS-----SN---FSSEGKCGHKE---------------GTVPTYLDYVP 118 
S5.12d   (AY462734)    RKYSDGS-----SN---FSSEGKCGHKE---------------GSPLTNLDYVP 113 
L3.06d   (AY462735)    RKNSDGS-----RG---FTSQGKCGHYE---------------GAPPTNLDYVP 116 
S3.07b   (AY462736)    RRKSDRT-----MD---LTSQGQCGRNENN-------------GYPLTNLDYVP 120 
L7.08i   (AY462747)    RKKSDGT-----QL---FSSQGQCGHTE---------------GTVPTNLDYVP 116 
L3.08c   (AY462729)    RKISGDT-----RT---FENAGKCRRHD---------------NKVPTNLDYVP 116 
L1.12i   (AY462730)    RKISEDT-----RT---FENAGKCRRHD---------------NSVPTNLDYVP 114 
L7.06b   (AY462748)    RKISGDT-----KV---FTSEGQCGHSE---------------TNVPTYLDYVP 116 
L6.03d   (AY462739)    MQSEDNK-----QL---FS-YLKCGHNKK--------------NDPPTNLDYVP 117 
L2.08g   (AY462740)    LQSEDNK-----QL---FL-YPKCGHNNK--------------NDLPTNLDYVP 116 
S1.07g   (AY462741)    MQ---------------------------------------------------- 88 
L1.12e   (AY462742)    MQSEDNK-----QL---FS-NPKCGHSNG--------------GAPLTNLDYVP 115 
L3.12c   (AY462744)    IYKSDNL-----LN---FS-SDRCGHNNN--------------DGPLTNLDYVP 117 
L3.08b   (AY462846)    MESRTNS-----YK---FS-NGQCGHYE---------------DAPPTNLDYVP 127 
L6.06e   (AY462830)    TYKSDNF-----RT---FS-GYWCGH-K-E-------------GSVPTNLDYVP 121 
S3.12o   (AY462829)    TYKSDNF-----RT---FS-GYWCGH-Y-E-------------GAPPTNLDYVP 111 
L1.06m   (AY462828)    VYKLDGP-----K----FS-SDRCGHNY-N-------------GDPLTNLDYVP 111 
L1.06c   (AY462834)    KYFPSNT-----TT---VS-SDKCGH-N-D-------------IDVPTNFDYVP 114 
L8.08g   (AY462851)    MHSEDNK-----QL---FS-DYKCGH-Y-E-------------GSPLTNLDYVP 114 
L6.03b   (AY462831)    RRKSDRT-----MD---FTSQGYCGHSE-T--------------NVPTNLDYVP 115 
L5.06e   (AY462850)    KKPSSHE-----YS---FS-NGQCGHRD-E--------------NVPTYLDYVP 114 
S3.12a   (AY462833)    KKKSGNT-----YN---FTTEGYCGRNE-G--------------APPTNLDYVP 111 
S3.12b   (AY462832)    RRKSDRT-----MD---FTSQGYCGHSE-T--------------NVPTNLDYVP 119 
PFD1235w (AY462842)    IKSSVRD-----QT---FS-NDYCGHGE-H--------------EVLTNLDYVP 122 
PF11_0521(AY462836)    IKPSDKE-----HS---FS-SEYCGHYK-N-------------GDPLTNLDYVP 119 
L5.06d   (AY462839)    KTANG-N-----TT---LW-NDNCGHHV-K-------------QDVPTNLDYVP 111 
L1.12b   (AY462840)    IQSEGAA-----KS---FS-NEYCG-HE-Q-------------GSVPTNLDYVP 111 
L2.06f   (AY462844)    KITDNGT-----TT---HS-YDKCGHHV-D-------------QDVPTNLDYVP 118 
S3.12c   (AY462843)    IQSEKNT-----KS---FT-NPKCG-HD-E-------------NKVLTNLDYVP 126 
L3.08g   (AY462821)    --TSDKY-----FR---H------------------------------------ 90 
PF08_0140(AY462835)    EYNSGKF-----FK---FS-NDQCGHNN-G-------------GAPPTNLDYVP 118 
L1.12c   (AY462837)    KKSSGGL-----YV---FS-GGKCGRNE-T-------------NVP-TNLDYVP 123 
S1.07e   (AY462824)    EKKDGGA-----YG---CT-HTSCHCA--G-------------GDVLTNFDYVP 122 
L6.06b   (AY462728)    RH-TCGG-----GK---NPTHAKCQCVT---------------HDVPTYLDYVP 129 
L1.08b   (AY462818)    RH-TCGG-----GK---NPTHAKCQCVT---------------HDVPTYLDYVP 133 
L8.08b   (AY462826)    RE-KDSN-----GN---TCTVNKCKCVD---------------GDPPTNLDYVP 121 
L1.08d   (AY462845)    KTITYGT-----TA---TSN-GKCGHDD---------------QDVQTYLDYVP 123 
L3.12d   (AY462827)    IIKPDGT-----TK---DSNKGQCRCIT---------------GDPPTNLDYVP 119 
S3.12i   (AY462823)    RPTCSND-----KA---DT-HEKCQCIG---------------GTVPTYFDYVP 119 
L2.06e   (AY462773)    RATCSDE-----KHP--TPTDDKCQCINF---------------SVPTYFDYVP 122 
L7.06a   (AY462775)    RHTCGSG-----K----TPTDDKCHCTNH---------------GVPTYFDYVP 119 
S3.12k   (AY462774)    RNTCGGG-----QNR--TATNHDCQCINF---------------SVPTYFDYVP 123 
L3.12b   (AY462776)    RKTCGIN-----DTW----TEGNCRCAAG---------------DVPTYFDYVP 125 
S8.08b   (AY462777)    HATCGNN-----DSW----TEKKCRCAANI--------------RVPTYFDYVP 123 
S3.12J   (AY462778)    RQTCN-G-----QNK----TQNNCRCRTN---------------DVPTYFDYVP 136 
L5.12a   (AY462770)    RDACSGG-----T----TATNKKCRCATN---------------YVPTYFDYVP 121 
L3.19a   (AY462771)    RDACSGG-----T----TLTQGKCRCPSH---------------KVPTYFDYVP 120 
L2.06g   (AY462785)    RQTCSKG-----Q----GGTQGKCQCIDQ---------------TVPTYFDYVP 117 
L6.06a   (AY462780)    RPTCGSG-----EKG--NATTGRCRCTTN---------------YVPTYFDYVP 120 
S1.07f   (AY462787)    RKTCSMG-----Q----SHVNDKCTCANG---------------DVPTYLDYVP 118 
L1.12J   (AY462788)    RKTCSMG-----Q----SHVNDKCTCANG---------------DVPTYFDYVP 125 
L5.08e   (AY462752)    RQTCNDD----GTSS--HAIH-QCRCENKSG---------EPQDQVPTYFDYVP 117 
S5.12c   (AY462755)    RPTCGSS----GETP--HVTPSQCRCINFS---------------VPTNFDYVP 112 
S1.12c   (AY462754)    RNTCAG-----LTNW--TETHDKCHCINGD---------------VPTYFDYVP 110 
L8.08i   (AY462750)    RATCSDSA--DKKGP--SVAKDHCRCDGDKPG------HDKPNIDPPTYFDYVP 124 
S3.12n   (AY462779)    RATCSD-----ENNP--TQTQNNCQCIG---------------QAVPTYFDYVP 115 
L7.11a   (AY462751)    HATCGR-----GRDA--TLTQNNCRCGDGKKPG---TNADNPNTDPPTYFDYVP 126 
S3.12f   (AY462847)    HATCGR-----GRDA--TLTQGDCRCA---------------NADVPTYFDYVP 110 
L5.08b   (AY462753)    RGTCGDN----EKTA--IQASHKCRCKDENGK--------NETNQVPTYFDYVP 120 
S5.12a   (AY462825)    GQTCGGG----TTAT--IT---QCRC---------------ATNYVPTYFDYVP 110 
L3.08d   (AY462820)    RKTCSND----QEDT--HE---KCRC---------------ATNDVPTFFDYVP 115 
L7.06e   (AY462841)    K-TANG-----------NTTLWNYKCGH-------------DEGIVPTNLDYVP 125 
L7.06f   (AY462807)    RGTCGGG-----NNA--KRAPSHCRCENKLGE---------PQDQVPTYFDYVP 134 
L8.06g   (AY462808)    RGTCGGG-----NNA--KRAPSHCRCENKLGE---------PQDQVPTYFDYVP 121 
L3.13a   (AY462809)    RGTCGSDE----KTA--TRASHKCRCENKIGE---------PQDQVPTYFDYVP 129 
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S8.08a   (AY462705)    RPTCSMN---GS--C--SQANKYCRCNGDQPG------NDKPNTDPPTYFDYVP 133 
S3.12h   (AY462724)    RHTCNGQ----------NKTESNCRC---------------ITHDVPTYSNYVP 115 
L6.11a   (AY462795)    RVTCNDN---GT--L--SQATKQCRCQKK---------DGANADQVPTYFDYVP 125 
L8.06f   (AY462812)    RATCSER---NG-GC--SQANDKCRCPKTSD--------GKANDQVPTYFDYVP 125 
L7.06c   (AY462720)    RPTCGGN---RQ-GP--SQAHDNCRCPN-------------GNDQVPTYFDYVP 129 
L1.12h   (AY462704)    RPTCGSN---EN-TA--IQTSHKCRCKD---------------DQVPTYFDYVP 125 
S7.08c   (AY462811)    HATCDSG---DNRGG--AQATKQCRCTKSS---------GANADQVPTYFDYVP 133 
L7.12b   (AY462719)    RQTCN-----DDGTS--SNANHKCRCKNKKV--------TNETDQVPTYFDYVP 130 
S3.07d   (AY462810)    RATCGG----DEKTG--TQASHKCRCKDKKG--------KNETDQVPTYFDYVP 133 
MAL6P1.4 (AY462849)    RKTCGGD---NEKNS--TLASNKCRCKDEKG--------EHDTDQVPTYFDYVP 125 
L2.06b   (AY462797)    RATCSDR-NG---SF--SQATKQCRCDG---------RNGTNADQVPTYLDYVP 133 
L8.06e   (AY462803)    RATCSDSGDGK--GP--SQARNQCRCKD---------ENGNNTDQVPTYFDYVP 136 
L5.06f   (AY462805)    RATCGDS---T--SP--SVARNKCRCD------------GKDAHQVPTYFDYVP 132 
L1.08e   (AY462813)    RVTCSDK---Q--GE--SIANHKCRCPMT--------SDGKPNDQVPTYFDYVP 127 
PF08_0103(AY462819)    RPTCSG-------GE--SIAHNKCTC-----------INGDP----PTYFDYVP 126 
L7.12c   (AY462814)    RPTCS--DRKG--SC--SQAKDNCRCD------------GSNTDQVPTYFDYVP 128 
L7.08e   (AY462815)    RATCS--DLNG--SF--SQATKQCRCE------------GAN--VVPTYFDYVP 125 
L3.08f   (AY462848)    RATCD--TGQG--P---SVANHYCRCDGR---------NGTNAHQVPTYFDYVP 130 
S1.12a   (AY462798)    RPTCD--TGKG--P---SVAKDHCRCDGR---------NGTNADQVPTYFDYVP 131 
L2.08e   (AY462718)    RATCND-TGQG--P---SQTHNKCRCEKKR-------GTSDNVSIVPTYFDYVP 133 
L7.08k   (AY462804)    RATCGG-DSQG--P---SQARNQCRCEG--------------ANIVPTYFDYVP 125 
L1.12d   (AY462717)    RKTCND-TGQG--P---SQTHNKCRCDG------------SNADQVPTYFDYVP 131 
L5.06a   (AY462703)    RVTCSD---TK--GP--SVANHYCRCGDDKP------DDDKANVDPPTYFDYVP 143 
L1.12f   (AY462789)    RKTACN---G---GK--SSTQGKCHCIAG---------------DVPTYFDYVP 123 
S3.12e   (AY462714)    RQTCND---SG--TL--SHANHKCRCKKN--------DGTNETDQVPTYFDYVP 133 
L3.12a   (AY462759)    RKTACGTR---------TGTQGRCRCAANI--------------DPPTYFDYVP 128 
L3.12e   (AY462727)    RKTACAG----------TRTNDKCRCKGD---------------QVPTYFDYVP 119 
L1.06a   (AY462757)    ANIEHDRT---------GVSHGRCGHEDD---------------NVPTNLDYVP 125 
L1.06h   (AY462801)    RATCNSADGKY--Q---YQTQNQCRCGDDKKPKS---GKPGEVNIVPTYFDYVP 142 
S1.07a                 RKTCG-TG---------TPTNKQCRCTTRV---------------VPT-FDYVP 120 
S1.07b   (AY462767)    RKTCG-SAK--------SPTNKQCRCTTRV---------------VPTYFDYVP 122 
L3.08h   (AY462769)    RPTCN-GGT--------SSTNTQCRCTIET---------------VPTYFDYVP 126 
L1.06J   (AY462706)    RNTCG-EGT--------SPTQPDCRCIGAT---------------VPTYFDYVP 124 
L2.08a   (AY462768)    RQTCG-SG---------EWTKDKCQCVTD----------------VPTYFDYVP 120 
L2.12a   (AY462725)    RKTAC-AGT--------SQTDGRCRCVT----------------DVPTYFDYAP 126 
L1.12a   (AY462822)    KYLAG-RIT--------TVSNEKCGHVDD---------------DVPTNLDYVP 128 
L2.08f   (AY462726)    IKTACGGGT--------TPTNKKCRCVST---------------DPPTYFDYVP 128 
S1.12b   (AY462709)    RGTCGGDNEK---TG--TLTPSQCRCDDKPN------------TDPPTFLDYVP 132 
L2.06h   (AY462710)    RATCGSSGE----TP--HVTPSRCRCSDNPN------------TDPPTYFDYVP 125 
L8.06h   (AY462707)    RATCDSGDNEK--NT--IRTPSHCRCNDDQ---------------VPTYFDYVP 130 
L5.06c   (AY462783)    RQTVCSGGKTP--TQ--G----KCRCID--------------FSVP-TYFDYVP 124 
S3.07a   (AY462765)    ------------------------------------------------------ 
L7.08b   (AY462784)    RQTVCSEGTTP--TN--E----KCQCIN--------------FSVP-TYFDYVP 132 
S7.08a                 ------------------------------------------------------ 
L1.12g   (AY462711)    RGTCGSGNNARR-AP--S----QCRCGNG-----------DVSIVP-TYFDYVP 134 
L1.02a   (AY462762)    RGTCGSDEKNAT-RV--K---DKCRCSD--------------NQVP-TYFDYVP 129 
L1.06g   (AY462806)    RNTCN-DDGTSS-RA--I---HKCRCDDKTSGGKAIKGSGDVNIVP-TYFDYVP 144 
L2.08c   (AY462790)    GGTCVGHGKHST-LA--K---DKCRCEG-------------ANIVP-TYFDYVP 123 
L5.12b   (AY462760)    HATCNGKERTEG-YC--RCNGDKPDGDN-------------PNTDPPTYFDYVP 134 
L5.08c   (AY462749)    HATCSGSHRKGT-F---SQANHYCRCGNDKPGEDNPNTDP------PTYFDYVP 138 
L8.08d   (AY462799)    RTTWS-DNRGG------AQANHYCGCNGD------------------------- 116 
L7.08f   (AY462817)    RPTCGDSESPS-------VAKDHCRCGNDQPGRDKSKAGNGDVNIVPTFFDYVP 131 
S3.12m   (AY462782)    RPTCNGGKR----------TEGYCRCNDGKSSG--GKAGNGDVNIVPTYFDYVP 132 
L6.02a   (AY462716)    R-NTCVGG-----SP--TQD--NCRCTTH---------------DVPTYFDYVP 124 
S1.08b   (AY462793)    RGKACGGQ-----FE--AKN--NCQCING---------------DVPTYFDYVP 128 
L6.02b   (AY462756)    R-RTCAGEQR---TE--TYD--KCHCING---------------DVPTNFDYVP 119 
L8.08c   (AY462758)    RPT-CSTG-----TG--TQG--RCRCVS---------------TDPPTYFDYVP 111 
S1.08a   (AY462786)    RQTACNGG-----SP--TKG--YCRCNGDQ------PNADNPNTDPPTYFDYVP 135 
S5.12e   (AY462794)    RGT-CGTG-----TG--TQG--RCRCPNG-------------NNQVPTYFDYVP 123 
L5.08a   (AY462791)    HATCDSGDNENTATL--ARN--QCRCS---------DKTSGANTDPPTYFDYVP 138 
S1.07d   (AY462764)    RATCSDSDGK-SQYQ--TQN--QCRCQKEDGA--KAGKGSGNVSIVPTYFDYVP 139 
S1.12d   (AY462792)    RATCSDS-DEKNATL--AKN--NCRCEG------------ANANQVPTYLDYVP 130 
S3.12g   (AY462712)    HATCSDSGDEKNPSP--TDG--QCRCK---------------TNVVPTYFDYVP 133 
L1.06b   (AY462761)    RNTCSNDK-----AG--TSG--KCRCND---------------NQVPTYFDYVP 120 
L2.06L   (AY462763)    RKTPCAGK-----TA--TEAIHKCRCSDKS----KAIKAGGNVNIAPTYFDYVP 132 
L5.06g   (AY462721)    RKTACAGG-----KG--TNR--QCHCIA---------------GEVPTYFDYVP 123 
L2.13a   (AY462722)    R-DACSGG-----KG--TNG--QCHCIA---------------GEVPTYFDYVP 119 
S1.07c   (AY462766)    RDACSGGK-----TP--TQG--KCRCGD------------GDVTIVPTYFDYVP 123 
L6.03a   (AY462723)    KSGADGSITKSVMG--------QCRDVS----------------DVPTNFDYVP 123 
L8.08e   (AY462796)    KMGADGSITESAMR--------QCRNVA----------------DVPTNFDYVP 119 
L1.06k   (AY462838)    KDLNDKSGPRSTPS---------SYCGYS---------------DHTPLDDYIP 109 
L5.08f   (AY462800)    RPTCNDTGRGGAQAKDK------CRCNDDKKPGKANDDVN----IVPTYFDYVP 132 
L7.08g   (AY462802)    RGTCG-SGRDATRTPSQ------CRCEKKSGGKAGDVS------IVPTYFDYVP 129 
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L5.06b   (AY462708)    QYLRWFDEWA--- 140 
S5.12f   (AY462715)    QYLRWFEEWAEDL 156 
L2.06k   (AY462713)    QYLRWFDEW---- 144 
L3.08a   (AY462772)    QFLRWFEEWAED- 138 
L2.06c   (AY462781)    QYLRWFEEWAED- 130 
L1.02b   (AY462731)    QFLRWFEEWAED- 128 
L7.13a   (AY462745)    QFLRWFEEWAEDL 128 
L3.02a   (AY462737)    QFLRWFEEWAED- 127 
L4.13a   (AY462738)    QYLRWFEEWAED- 127 
L8.06c   (AY462743)    QFLRWFEEWAED- 129 
L1.06L   (AY462746)    QYLRWFDEWA--- 124 
L6.03c   (AY462732)    QFLRWFEEWAED- 130 
L7.08h   (AY462733)    QFLRWFEEWAED- 130 
S5.12d   (AY462734)    QFLRWFEEWAEDL 126 
L3.06d   (AY462735)    QFLRWFEEWAED- 128 
S3.07b   (AY462736)    QFLRWFEEWAEDL 133 
L7.08i   (AY462747)    QFLRWFEEWAED- 128 
L3.08c   (AY462729)    QFLRWFEEWAED- 128 
L1.12i   (AY462730)    QFLRWFDEWA--- 124 
L7.06b   (AY462748)    QFLRWFEEWAED- 128 
L6.03d   (AY462739)    QYLRWFEEWAED- 129 
L2.08g   (AY462740)    QYLR--------- 120 
S1.07g   (AY462741)    ------------- 
L1.12e   (AY462742)    QFLRWFEEW---- 124 
L3.12c   (AY462744)    QFFRWFEEWAED- 129 
L3.08b   (AY462846)    QFLRWFEEWAED- 139 
L6.06e   (AY462830)    QYLRWFEEWA--- 131 
S3.12o   (AY462829)    QFLRWFEEWAEDL 124 
L1.06m   (AY462828)    QYLRWFDEWA--- 121 
L1.06c   (AY462834)    QFLRWFEEWAET- 126 
L8.08g   (AY462851)    QFLRWFEEWAED- 126 
L6.03b   (AY462831)    QFLRWFEEWAED- 127 
L5.06e   (AY462850)    QFLRWFDEWA--- 124 
S3.12a   (AY462833)    QFLRWFEEWAED- 123 
S3.12b   (AY462832)    QFLRWFEEWAEDL 132 
PFD1235w (AY462842)    QFLRWFEEWAED- 134 
PF11_0521(AY462836)    QFLRWFEEWAED- 131 
L5.06d   (AY462839)    QFLRWFEEWA--- 121 
L1.12b   (AY462840)    QYLRWFEEWAED- 123 
L2.06f   (AY462844)    QHLRWFEEW---- 127 
S3.12c   (AY462843)    QYLRWFEEWAEDL 139 
L3.08g   (AY462821)    ------------- 
PF08_0140(AY462835)    QIC---------- 127 
L1.12c   (AY462837)    QYLRWFEEWAED- 135 
S1.07e   (AY462824)    QYLRWFEEWAEDL 135 
L6.06b   (AY462728)    QYLRWFEEWAED- 141 
L1.08b   (AY462818)    QYLRWFEEWAED- 145 
L8.08b   (AY462826)    QYLRWFEEWAED- 133 
L1.08d   (AY462845)    QYLRWFEEWAED- 135 
L3.12d   (AY462827)    QYLRWFEEWAED- 131 
S3.12i   (AY462823)    QFLRWFEEWAEDL 132 
L2.06e   (AY462773)    QYLRWFEEWAED- 134 
L7.06a   (AY462775)    QYLRWFEEWAED- 131 
S3.12k   (AY462774)    QYLRWFEEWAEDL 136 
L3.12b   (AY462776)    QYLRWFEEWAED- 137 
S8.08b   (AY462777)    QFLRWFEEWAEDL 136 
S3.12J   (AY462778)    QYLRWFEEWAEDL 149 
L5.12a   (AY462770)    QYLRWFEEWAEDL 134 
L3.19a   (AY462771)    QYLRWFEEWAED- 132 
L2.06g   (AY462785)    QYLRWF------- 123 
L6.06a   (AY462780)    QYLRWFEEWAED- 132 
S1.07f   (AY462787)    QFLRWFEEWA--- 128 
L1.12J   (AY462788)    QYLRWFEEWA--- 135 
L5.08e   (AY462752)    QYLRWFEEWAEDL 130 
S5.12c   (AY462755)    QYLRWFEEWAEDL 125 
S1.12c   (AY462754)    QYLRWFEEWAEDL 123 
L8.08i   (AY462750)    QYLRWFEEWAED- 136 
S3.12n   (AY462779)    QYLRWFEEWAEDL 128 
L7.11a   (AY462751)    QYLRWFEEWAED- 138 
S3.12f   (AY462847)    QYLRWFEEWAEDL 123 
L5.08b   (AY462753)    QYLRWFEEWAEDL 133 
S5.12a   (AY462825)    QYLRWFEEWAEDL 123 
L3.08d   (AY462820)    QYLRWFE------ 122 
L7.06e   (AY462841)    QYLRWFEEWQKI- 137 
L7.06f   (AY462807)    QYLRWFEEWAED- 146 
L8.06g   (AY462808)    QYLRWFEEWAED- 133 
L3.13a   (AY462809)    QYLRWFEEWAE-- 140 
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S8.08a   (AY462705)    QYLRWFEEWAEDL 146 
S3.12h   (AY462724)    QYLRWFEEWAEDL 128 
L6.11a   (AY462795)    QYLRWFEEWAED- 137 
L8.06f   (AY462812)    QYLRWFEEWAED- 137 
L7.06c   (AY462720)    QYLRWFEEWAED- 141 
L1.12h   (AY462704)    QYLRW-------- 130 
S7.08c   (AY462811)    QYLRWFEEWAEDL 146 
L7.12b   (AY462719)    QYLRWFEEWAED- 142 
S3.07d   (AY462810)    QFLRWFEEWAEDL 146 
MAL6P1.4 (AY462849)    QFLRWFEEWAED- 137 
L2.06b   (AY462797)    QYLRWFEEWAED- 145 
L8.06e   (AY462803)    QYLRWFEEWAEDL 149 
L5.06f   (AY462805)    QFLRWFEEWAEDL 145 
L1.08e   (AY462813)    QYLRWFEEWAED- 139 
PF08_0103(AY462819)    QYLRWFEEWAED- 138 
L7.12c   (AY462814)    QFLRWFEEWAEDL 141 
L7.08e   (AY462815)    QYLRWFEEWAED- 137 
L3.08f   (AY462848)    QYLRWFEEWA--- 140 
S1.12a   (AY462798)    QYLRWFEEWAEDL 144 
L2.08e   (AY462718)    QYLRWFEEWAED- 145 
L7.08k   (AY462804)    QYLRWFEEWAED- 137 
L1.12d   (AY462717)    QFLRWFEEWAED- 143 
L5.06a   (AY462703)    QFLRWFEEWA--- 153 
L1.12f   (AY462789)    QFLRWFD------ 130 
S3.12e   (AY462714)    QYLRWFEEW---- 142 
L3.12a   (AY462759)    QFLRWFEEWAED- 140 
L3.12e   (AY462727)    QYLRWFEEWAED- 131 
L1.06a   (AY462757)    QFLRWFEEWAED- 137 
L1.06h   (AY462801)    QFLRWFEEWAE-- 153 
S1.07a                 QFLRWFEEWAEDL 133 
S1.07b   (AY462767)    QFLRWFEEWAEDL 135 
L3.08h   (AY462769)    QFPRWFEEWAED- 138 
L1.06J   (AY462706)    QYLRWFDEWA--- 134 
L2.08a   (AY462768)    QYLRWFEEWAED- 132 
L2.12a   (AY462725)    QFVRWFEEWAED- 138 
L1.12a   (AY462822)    QFLRWFEEWAED- 140 
L2.08f   (AY462726)    QYLRWVEEWAED- 140 
S1.12b   (AY462709)    QYLRWFEEWAEDL 145 
L2.06h   (AY462710)    QFLRWFDEWA--- 135 
L8.06h   (AY462707)    QYLRWFEEWAED- 142 
L5.06c   (AY462783)    QFLRWFEEWA--- 134 
S3.07a   (AY462765)    ------------- 
L7.08b   (AY462784)    QFLRWFEEWAED- 144 
S7.08a                 ------------- 
L1.12g   (AY462711)    QYLRWFDEWA--- 144 
L1.02a   (AY462762)    QYLRWFEEWAED- 141 
L1.06g   (AY462806)    QYLRWFEEWAED- 156 
L2.08c   (AY462790)    QFLRWFEEWA--- 133 
L5.12b   (AY462760)    QFLRWFEEWAEDL 147 
L5.08c   (AY462749)    QYLRWFEEWAEDL 151 
L8.08d   (AY462799)    ------------- 
L7.08f   (AY462817)    QFLRWFEEWAED- 143 
S3.12m   (AY462782)    QYLRWFEEWAEDL 145 
L6.02a   (AY462716)    QFLRWFEEWAED- 136 
S1.08b   (AY462793)    QYLRWFEEWAEDL 141 
L6.02b   (AY462756)    QFLRWFEEWAED- 131 
L8.08c   (AY462758)    QYLRWFEEWAED- 123 
S1.08a   (AY462786)    QYLRWFEEWAEDL 148 
S5.12e   (AY462794)    QYLRWFEEWAEDL 136 
L5.08a   (AY462791)    QFLRWFEEWAEDL 151 
S1.07d   (AY462764)    QFLRWFEEWAEDL 152 
S1.12d   (AY462792)    QYLRWFEEWAEDL 143 
S3.12g   (AY462712)    QYLRWFEEW---- 142 
L1.06b   (AY462761)    QYLRWFEEWAED- 132 
L2.06L   (AY462763)    QYLRWFDEWA--- 142 
L5.06g   (AY462721)    QYLRWFEEWAEDL 136 
L2.13a   (AY462722)    QYLRWFEEWAED- 131 
S1.07c   (AY462766)    QFLRWFEEWAEDL 136 
L6.03a   (AY462723)    QYLRWFEEWAED- 135 
L8.08e   (AY462796)    QYLRWFEEWAED- 131 
L1.06k   (AY462838)    QRLRWFEEWAEDL 122 
L5.08f   (AY462800)    QYLRWFEDGQK-- 143 
L7.08g   (AY462802)    QYLRWFEEWAED- 141 
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L4.03b   (AY462639)    ---------LQDSIYWRTEKIKKCLENN-NGNRCKKKNKCKDDCDCFKRWVEHK-QQEWE 50 
L7.08f   (AY462640)    -----VADMLQDSVEWKT-ELSKCINNNTNGNRCR--NGCNRDCKCYESWAKRK-EKEWG 52 
L1.12a   (AY462635)    -----VADMLKDSIHWRTKKIKGCLKNGKK-K-C-GNQQCKVDCECFKRWVKQKKEQEWD 52 
L3.08c   (AY462644)    -----VSDMLKDSVHWK-KKLQRCLENGTKIK-CR--NGCNSDCECFLQWVEQKKEKEWK 52 
L7.08c   (AY462633)    -----VADMLKDSIHWRTKKIKGCLSNGAKIR-CNKKNKCNNDCDCFQKWVEQK-GKEWM 54 
L3.12c   (AY462632)    -----VTDMLQDSISWRTEKIKKCLENNNGNR-CNKKNKCKDDCECFQRWVDKK-KTEWK 54 
L4.03c   (AY462637)    -----VDDMLQDSIYWRTEKLSKCLQNGKTIK-CK--DKCKDDCECFERWVGKK-KTEWD 52 
L3.12b   (AY462629)    -----------DSIHWRTKKLDKCINNSNESKACKNNNKCKDNCDCFEKWVKHK-QQEWD 49 
L3.19a   (AY462628)    -----------DSIHWRTEKLDKCINNSNESKACKNNNKCKDDCDCFKRWVDQK-KKEWM 49 
L4.03a   (AY462627)    -----VADMLHDSIHWRTEKLDKCINNSNESKACKNNNKCKDKCDCFQRWVKQK-KDEWK 55 
L3.08a   (AY462631)    -----VSDMLNDSIHWRTKKLDKCINNSNESKACKNNNKCNKECGCFEKWVGHK-QQEWG 59 
L7.08a   (AY462630)    -----VADMLHDSIHWRTKKIKSCINTTNESKACKNNNKCKTDCGCFQKWVQQK-KDEWD 55 
L2.12a   (AY462636)    -----VADMLNDSIYWRTEKIKGCLENGTKTR-CKKNN-CKDNCGCFQKWVKQK-ETEWT 53 
L3.08b   (AY462638)    -----VPDMLKDSIHWK-KKLEKCLKNG--SK-IKCTDRCKTPCDCFEKWVGQK-EKEWK 51 
L3.12d   (AY462643)    -----VADMLKDSVEWR-NELGSCINKNKENT-CKTPKKCNKECTCFLKWVVKKKE-EWG 53 
L7.08d   (AY462645)    -----VADMLQDSIKWR-DEHGNCINKDNDNT-CKN-KQCNSKCECFAKWVVKKKD-EWS 52 
L6.11a   (AY462641)    -----VDDMLHDSIKWR-KELDNCL-KNENKQ-CIR-K-CNGKCDCFQRWVDQKKE-EWK 50 
L3.12e   (AY462642)    -----VDDMLQDSIYWETQKLEKCL-KNEKKK-CGK-KICNGDCDCFQKWIGQKKEQEWT 53 
L7.08b   (AY462634)    -----VPDMLKDSIHWK-KKLEKCL-KNGTKT-CGN-QKCKGNCDCFQRWIDKKKD-EWE 51 
 
L4.03b   (AY462639)    KIVQHFNTQDISARGGNGNVVGFFS------------LSHDVLLEQVLD----KGVLLTS 94 
L7.08f   (AY462640)    NIVKHFYKQDDIVE------VGFLAEI----------MKHDIVLEGVLQ----KKELLQI 92 
L1.12a   (AY462635)    KIKEHFG--------------KQTDLG---------EWEPNDLLEQVLE----KGVLLTS 85 
L3.08c   (AY462644)    PIKEHFGNQEAFKNKEENSASQMLGEE---------MNSADFVLDGVLKLEFYKDNSENN 103 
L7.08c   (AY462633)    AIKEHFGNQEAFKNKGKNSASQMLGEE---------MSSPDFVLNYLLK----KDELLTS 101 
L3.12c   (AY462632)    AIKEHFGNQEAFKKEGGNSASGMLGKE---------FESPDFVLQTLLK----KDLLLTS 101 
L4.03c   (AY462637)    AIKKHFKTQDGFSNQGGMDSNVFLDRA---------FRSPDVVLEGVLK----KEVLLTS 99 
L3.12b   (AY462629)    AIKQHFKKQKGFDSEGHNDIHSVLN----------LHMTPDFVLEGVLN----KDLLLKS 95 
L3.19a   (AY462628)    AIKQHFRKQK------NIVIEDVF-----------MKLTHDDVLDSVLK----KDLLLKS 88 
L4.03a   (AY462627)    PIKEHFRKQE------GIVLEQGP-----------IKLTHDAVLQTLLK----KDLLLKI 94 
L3.08a   (AY462631)    QIKTHFYKQDG-----FDDFG------------------HDFALNFLLK----KEELLEN 92 
L7.08a   (AY462630)    AIKKHFYKQDI-----RGTVGNGNQGHNGGSGMLGTGLNHDFVLNYLLK----KDELLSS 106 
L2.12a   (AY462636)    QIKDHFRKQK--------DMKDENR----------NDIDPGIILEFLLK----KDELLKS 91 
L3.08b   (AY462638)    PIKQHFYKQD--------DIVKEVR---------LFKLTHDYVLEGVLK----LDVLLTS 90 
L3.12d   (AY462643)    KIIDHFYKQ------------ENIQA---------GMHD--ITLAALLD----KDLLLEI 86 
L7.08d   (AY462645)    NIKNHFNTQG-----------DIVQE---------TGCDPGVTLAALLE----EDELLKI 88 
L6.11a   (AY462641)    NIKIHFGKQED--------MKEEIK----------GMDPG-IILEGVLN----IEDLFQN 87 
L3.12e   (AY462642)    KIKEHFKTQKG--------FGEDVG----------QELPHYMILDGVLK----LEFSKEN 91 
L7.08b   (AY462634)    NIKIHFAKQDF--------GKEGVFL---------GVFGSGYILEGVLE----KEELLKI 90 
 
L4.03b   (AY462639)    LQEA------YGNAKEKEHIKKLLQETG----------VVG---GGE--HKTTIDKLL- 131 
L7.08f   (AY462640)    IQDT------YGNSQETEHIKQLLNEEKKNQ-----VEAAD---GNDSQKKTTMDKLL- 136 
L1.12a   (AY462635)    IKEG------YGNEKDIERIEALLKEEEDKN---EEEDEEA---GADNENKTTIDKLL- 131 
L3.08c   (AY462644)    SAQDKQNSLNAEEAEELKRIRDIIEREENQDAAIAAGGSGI---GGANGKKTTIDKLL- 158 
L7.08c   (AY462633)    LREG------YGKPEDIEHIRKMLDDEEE------ADG-GV---VGEN--KTTMDKLL- 141 
L3.12c   (AY462632)    LQEA------YGNTEDIKHIKEMLDKEEA-------AVLDI---LGGGKDNTTIDKLL- 143 
L4.03c   (AY462637)    LREG------YGNAEDIKHIEALLKEEEN-----------V---VAVTENKNTIDKLL- 137 
L3.12b   (AY462629)    LQEA------YGNAKDIKHIEELLEKEKKRE---EEEAEAG---VVGGKDNTTIDKLL- 141 
L3.19a   (AY462628)    LREA------YGNEKDIDRIEKMLEQ-------------AG---VVGGEDNTTIDKLL- 125 
L4.03a   (AY462627)    IQDV------HGDTDDIERIEALLDD----D---AAAVAAA---IASGEDNTTMDKLL- 136 
L3.08a   (AY462631)    LQEA------YGKPEDIEHIKKLLNDEA------AAGALVV---DSGGENNTTMDKLL- 135 
L7.08a   (AY462630)    IKEA------YGDTDDIKRIEELLQETG------VGG---V---ASGGKDNTTMDKLL- 146 
L2.12a   (AY462636)    LREA------YGNAKDIERIEALLNEDE-TK---SQAEDAG---ASGGKENTTMDKLL- 136 
L3.08b   (AY462638)    IKGG------YGKPEDIKRIEALLKETG----------------VGGGKDNTTIDKLL- 126 
L3.12d   (AY462643)    IEGTYG------NAEDIKHIKDLLDEE--ETA--VAAAIAV----GEN--NTTIDKLL- 128 
L7.08d   (AY462645)    IEGTYG------KSKETEHIREMLQETGVANG--VASASGVSGTCGANGKNSTIDKLL- 138 
L6.11a   (AY462641)    IKDTYG------DVKEIDHIKKLLKEE-------EAVAVLL----GGGENNTTIDKLL- 129 
L3.12e   (AY462642)    TEEDKEN---NVSAKEIDLINKMLEED-------ETAAADV----ADNENNTTIDKLL- 136 
L7.08b   (AY462634)    IEGTYG------KSKETEHIKKLLEEE-------TTVD-------ADNENNTTIDKLL- 128 
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DBLβ 
 
L1.02b   (AY462659)    RRQHMCTSNLEYLQTKDG--PLNKRDGKLVNNSFLGDVLLSAKMDAEKIKELYKGQNNIK 58 
MAL6P1.4 (AY462658)    RREHMCTSNLENLDVDSV--TENDK----ASHSLLGDVQLAAKTDAAEIIKRYKDQNNIQ 54 
L1.11b   (AY462655)    -RQHMCTSNLENLDVG-S--VTKG--GKAIH-SLLGDVLLSAKMDADEIIKRYKHQNNIT 53 
L1.11c   (AY462656)    --QHMCTSNLEHLETGQS--PLKNSDGKVVNNSFLGDVLLSAKMDAAEIINRYKNQNSIG 56 
L2.06a   (AY462657)    -RQHMCTSNLEKLDVE-S--VTKN--DKASH-SLLGDVLLTAKMDADEIINRYKKQNNIE 53 
L2.06b   (AY462660)    -RQHMCTSNLEKIDVKS---VTGNSN---VNDSFLGDILLAAKYEAENIKKLYVENNDRK 53 
MAL6P1.316(AY462661)   -RQHMCTSNLEYLETDQG--PLKNSDGKFVNHSFLGDVLLAANHEAKKIKELYTKDNG-- 55 
L5.06a   (AY462654)    RREHMCTSNLEYLINGNHQAILNVEKGKIN-HSFLGDVLLAAKKEAEFIKS---KVTNN- 55 
L7.02a   (AY462653)    RREHMCTSNLEYLLKARGGQFGQVESGKCN-HSFLGDVLLAAKMEAEDIKS---RLNNN- 55 
PF11_0008(AY462650)    --EHMCTSNLEYLLHVNKGPLLKVEPDKIN-HSFLGDVLLAAKYEAEFIKTNYTRLNGQ- 56 
PF13_0003(AY462651)    -REHMCTSNLEYLLKGNSDQIMKVGNNKIN-HSFLGEVLLAAKYEAEFIKTNYTRLNGQ- 57 
L1.02a   (AY462652)    RRQHMCTSNLEYLLHVNKGPLLKVEPDKIN-HSFLGDVLLASKFEGEYIKTNYKRLNGQ- 58 
S3.07a   (AY462663)    RRQHMCTSNLENLDLSKEG---LSNSSIAS-NSLLGDVLLAAKFEADFIKSNYNKQKNPK 56 
L1.08a   (AY462648)    RRQHMCTSNLEYLINGNHQAILNVENGKIN-HSFLGDVLLAAKYQAEDTIKDYQPKNDDQ 59 
PF11_0521(AY462649)    -RQHMCTSNLEYLINGGHQAILNVKNGKIN-HSFLGDVLLAAKYQAQHTMKDYKSKNDKE 58 
L7.12d   (AY462664)    RREHMCTSNLEHLNTGTK----GLSDGTLASHSLLGDVLLAAKYEAKNIKELY-EKNKDQ 55 
S1.07a   (AY462665)    RRQHMCTSNLEHLNTGNK----GLSDGTLASHSLLGDVLLAAKYEANYIKQRYNDRTKAH 56 
L7.12a   (AY462647)    RRQHMCTSNLEKLN------VDKVITNGKVNNSFFVEVLLAANKEAERTKNHYKKP---- 50 
L7.12b   (AY462646)    ----MCTSNLEKLN------VDKAITNGKVNNSFFVEVLLAANKEAERTKNHYKKP---- 46 
L8.13a   (AY462662)    RREHMCTSNLEKIHDK----FVTQNTNDHVNDTFLVDVLLAAKEEAEDIKKKYKEIKDKN 56 
L1.11a                 ----------------------TDGNPKLVNNSFLGDVLLSAKYEAQRTKEDYEPVS--- 35 
 
L1.02b   (AY462659)    NVTDP---KHQETICRALRYSFADLADIIRGRDMWDKDKGSTDMEKYFVPIFKEIREQLP 115 
MAL6P1.4 (AY462658)    -LTDPIQQKDQEAMCRAIRYSFADLGDIIRGRDMWNKDSGSTEMEKHLISIFEKINEKLP 113 
L1.11b   (AY462655)    GNIKQ---KDKEAMCRAVRYSFADLGDIIRGRDLWDLDDGSKKMEGHLKKIFGKIKQELP 110 
L1.11c   (AY462656)    DSIDA---KHKESICRAVRYSFADLGDIIRGRDMWNKDSGSKDMEKYLVNIFDKIKKHP- 112 
L2.06a   (AY462657)    DVTDP---NDQATVCRALRYSFADLGDIIRGRDLWE-NGEAKQLQKDLVTIFRHIHSSL- 108 
L2.06b   (AY462660)    DLNDE---NDKATVCRAMKYSFADIGDIIRGRDIWDREPGMKHAKKHLKDVFDNIRKSLN 110 
MAL6P1.316(AY462661)   -LNDL---KDKETVCRAMKYSFADLGDIIRGRDMWDNGTGMKHAKKHLKDVFDNIRKSLK 111 
L5.06a   (AY462654)    --------DNGSAICRAMKYSFADIGDIIRGRDLWEHG-DQTKLQGHLQIIFGKIKENLD 106 
L7.02a   (AY462653)    --------GNSSSICRAIKYSFADLGDIIRGKDLWEHK-DFKKLEEHLVKIFEKIKTELK 106 
PF11_0008(AY462650)    --------NDNGAKCRAMKYSFADIGDIIRGKDLWGIQ-DFKDLQTKLVTIFGKIKEEIP 107 
PF13_0003(AY462651)    --------NDNGAKCRAMKYSFADIGDIVRGRDLWEHN-DFKKLERDLVKIFGKIKEGIT 108 
L1.02a   (AY462652)    --------NNNEDKCRAMKYSFADIGDIIRGRDLWERNGDMVKLQGHLETVFENIRKSLK 110 
S3.07a   (AY462663)    AATDL---KDEEGICRAMKYSFADIGDITRGKDFWEKNGDAKRLQGHLKEIFGKIKEKLH 113 
L1.08a   (AY462648)    G------------ICRAVRYSFADIGDIIKGTDLWDRDRGENKTQRNLETIFGKIKEGIT 107 
PF11_0521(AY462649)    G------------ICRAIRYSFADIGDIIKGTDLWDKDGGEIKTQNHLVTIFDKIKAQLP 106 
L7.12d   (AY462664)    --------SGHEVICRAVRYSFADIGDIIKGTDLWIDDVGEKKTQGNLVKIFEKIKEKLD 107 
S1.07a   (AY462665)    GF------KDEETICRAIKYSFADIGDIIKGTDLWDQNNGEQTTQRKLREVFDKIKQKLP 110 
L7.12a   (AY462647)    --------DEHPTACRAIRYSFADIGDIIRGRDLWERNRDMVKLETNLKKIFKNIKDKLP 102 
L7.12b   (AY462646)    --------DEHPTACRAIRYSFADIGDIIRGRDLWERNRDMVKLETNLKKIFKNIKDKLP 98 
L8.13a   (AY462662)    GLK-----DDQVTTCRAIKSSFADLGDIIRGRDLWDRDNGSTEMEKHLITIFGKIK-ELK 110 
L1.11a                 ---------DEQSICRAVRYSFADLADIIRGRDMWDKDDGAQKMERILKSIFKNIYETIG 86 
 
L1.02b   (AY462659)    EK-EQKKYS----NDGAYLDLRRDWWEANRHQVWRAMKC------------AIEKDNITK 158 
MAL6P1.4 (AY462658)    EK-EQKKYS----NDGKYLDLRKDWWEANRYKVWKAMKC------------ATKNSKIP- 155 
L1.11b   (AY462655)    QQ-IKEKYK---KDEDPYKQLREDWWEANRRQVWKAIKC------------ALKNGSFP- 153 
L1.11c   (AY462656)    -E-IQGKYN---TDGPPYKKLREDWWEANRHQVWKAIKC------------ALKDGSFP- 154 
L2.06a   (AY462657)    -N-GKGKYEGDYKKKPAYKQLREDWWEANRHQVWEAMKCHIG---------HLKDLSIDK 157 
L2.06b   (AY462660)    AK-GISKY---DKDSPDYIKLREDWWEANRHQVWRAMKC------------ATKDINNNK 154 
MAL6P1.316(AY462661)   NK-GNQKYNYDDKKLPPYKELREDWWEANRHQVWRAMKC------------AIKEATIDN 158 
L5.06a   (AY462654)    DT-IKDKYAS--EDK-PYTQLRKDWWEANRKQIWEAMQCP----------KNGVHITCD- 151 
L7.02a   (AY462653)    GT-FGKKYDS--DSNGKHTQLRADWWEANRAKVWEAMKCP----------KNG--IKCD- 150 
PF11_0008(AY462650)    D--IKKKYSS--ENP-PYTTLREHWWEANRAKVWEAMQCP-T-----IPPVT---TSCDT 153 
PF13_0003(AY462651)    DETTKKQYEK--DDT-DNKQLRCDWWEANRDQVWEAMQCKTT-----IPPVT---TSCDT 157 
L1.02a   (AY462652)    GK-GNDKYND--DAP-KYLKLREDWWEANRAKVWEAMQCP-T-----IPPSRGGDIKCAE 160 
S3.07a   (AY462663)    DESMKKIYEE--DKD-LYTKLREDWWEANRDQIWEAMQCP-T---SPSSPPRGNNTIC-- 164 
L1.08a   (AY462648)    DETIRKKYD----SDPKHTKLRFDWWEANRDEIWKAMKCPTK---------PPVTTNCDT 154 
PF11_0521(AY462649)    KD-IKGKYT----G-TKHLELRKDWWEANRDQVWKAMQCGND---------NPCSGESDH 151 
L7.12d   (AY462664)    ET-SKNKYK---KSDDKHLDLRKDWWEANRDQIWEAMTCDLK-----SG-----SFPCS- 152 
S1.07a   (AY462665)    QD-IRGKYPG--NGDPYHLKLRSDWWEANRHQVWKAMKCHIKDLKDKSGPQSTPSSYCGY 167 
L7.12a   (AY462647)    GD-IKEKYKD--DDKGKYRTLREDWWEANRDQVWKAMQCGN-------------DNPCSG 146 
L7.12b   (AY462646)    GD-IKEKYKD--DDKGKYRTLREDWWEANRKQIWEAMKCKTN----------GVDITCDS 145 
L8.13a   (AY462662)    GE-DKYTNDT--DANPRYKKLRADWWTANRRQVWKAMICETP----------SGKNPCSG 157 
L1.11a                 DK--KGKYTN---TDGKYLELREDWWDANRAKVWEAMKCAIKG-----LNVTSSDGKLSD 136 
 
L1.02b   (AY462659)    -------CNGIPIEDYIPQRLRWMTEWAE- 180 
MAL6P1.4 (AY462658)    -------CSGIPIEDYIPQRLRWMTEWAE- 177 
L1.11b   (AY462655)    -----CKSDHTPLHDYIPQRLRWMTEWAE- 177 
L1.11c   (AY462656)    -----CKSDHTPLHDYIPQRLRWMTEWAE- 178 
L2.06a   (AY462657)    SKGHCGYSDHTPLDDYIPQRLRWMTEWAE- 186 
L2.06b   (AY462660)    -------CNGIPIEDYIPQRLRWMTEWAE- 176 
MAL6P1.316(AY462661)   -------CNGIPIEDYIPQRLRWMTEWAE- 180 
L5.06a   (AY462654)    -------SG-VPVDDYIPQRLRWMTEWAE- 173 
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L7.02a   (AY462653)    -------NGETPLDDYVPQRLRWMTEWAE- 172 
PF11_0008(AY462650)    -------TTVTPLVDYIPQRLRWMTEWAE- 175 
PF13_0003(AY462651)    -------TTVTPLVDYIPQRLRWMTEWAE- 179 
L1.02a   (AY462652)    -------SDV-PFDDYIPQRLRWMTEWAE- 181 
S3.07a   (AY462663)    -------SDTTPYDDYVPQRLRWMTEWAE- 186 
L1.08a   (AY462648)    -------TTVTPLVDYIPQRLRWMTEWAE- 176 
PF11_0521(AY462649)    ----------TPLHDYIPQRLRWMTEWAE- 170 
L7.12d   (AY462664)    -------DKTTPHEDYIPQRLRWMTEWAE- 174 
S1.07a   (AY462665)    -------SDHTPLDDYIPQKLRWMTEWAE- 189 
L7.12a   (AY462647)    --------TDVPLEDYIPQRLRWMTEWAE- 167 
L7.12b   (AY462646)    --------DHTPLDDYIPQRLRWMTEWAE- 166 
L8.13a   (AY462662)    --------TDVPLDDYIPQRLRWMTEWAE- 178 
L1.11a                 HCG---YSDHTPLDDYIPQKLRWMTEWAE- 162 
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L2.12b/c               -------------------------------------------------------------  
L2.12a/s (AY462669)    -MVTL--GGGGSSD----ADKYKNAQDAKHLFDIIGKDVYDEVH-KKNAD-YRGELQGRLS 52 
L3.08a/c (AY462667)    -MSTL--GGG-------------TDKSAKHVLDEFGQQVYEQVK-NGEAKTYFDELHGDLS 44 
L3.08l/s (AY462666)    -MSTL--GGG-------------TDKSAKHVLDEFGQQVYEQVK-NGEAKTYFDELHGDLS 44 
L1.12c/c (AY462697)    -MASSTTY--GSV--------------KD-LFENIGKEVQELAK-NDAKQ-YRSQLKGDLS 41 
L1.11b/s               -------------------------------------------------------------  
L3.12c/s (AY462698)    -MEPKADA---SAPVT----ASTTYSSVKDLLEDIGKSIQKQAK-DAAEERSKEKLQGDVL 52 
L2.06a/s (AY462668)    -MAPKAAV---S------APRYDQATSAKDFLDQIGQIVHTKVH-GAAKK-YYDYLHGDLP 49 
L3.08c/s               ----------------------TDYSDAKDFLDKIGEDIYKVAK-NDADD-FREKLKGTLS 38 
L2.08a/c (AY462673)    -MARGRRGGGSSKEKEDEPD-YTNVKDAKELLDKIGQTVH-KKV-HREDANYRGKLYGLLT 57 
L3.06a/s (AY462674)    -MAAGRRGGGGTQEQK---DKYKYVNDAKDLLDQIGEKIQ-DIA-HKAALKYENELHGDLS 55 
L1.12b/s (AY462670)    -MAR—-PGSAGTQEQK---DKYKYVSDAKDLLDQIGEDIY-KKA-KNDANDFRDKLKGTLS 53 
L8.08a/s               ------------------------------------------------------------- 
L7.08d/s (AY462672)    -MVK-QNGGGG--DGRDG---IDHAS-AKHLLDSIGEKVYKEKV-ESDRKTYFDDLHGTLS 52 
L1.12a/s (AY462671)    -MVI--QITGG--EGR-----IEDAT-AKHLLDSIGKKVY-DKV-HSEVDAYRDKLKGTLS 48 
L3.08J/s (AY462675)    -MAPQKPTAPDYNNVTN----------AKDLFDEIGKHIN-PQV-NKEALTYQPELLGYLT 48 
L1.11a/s (AY462700)    -MAPQKPTAPDYNNVNN----------AKDLFDEVGK--YIEKKVRDAALERKGNLKGNLK 48 
L7.12a/s               ---------------------------------NFTK--YIKRKASNNAKRHENVLKANLR 26 
L3.08a/s (AY462701)    -MGPQR---------------ATQDEDAKHMFDRIGGTVQ-QQV-HTAADQYREKLKGHLS 43 
MAL6P1.4 (AY462702)    -MGPP---GGSGGS--------TLDESVKDLFDRIGKEVH-DQV-EKEANQYKEALKGDLS 47 
S1.07a/s (AY462695)    -MVKQVKPDGVIE-----------DTTAKHIFDRIGKIVYETV--EKDALPYENELHGLLT 47 
S1.08c/s (AY462694)    -MVTQVNPGGNVEDATA-----------KNIFDRIGKKVYEEK-VKKVAEQYRSQLHGSLK 48 
L1.12c/s (AY462696)    -MVKQVIVGGVIEDTPA-----------KNIFDRIGKIVYDK---HNEVDEYREKLKGTLS 47 
L1.12d/s               ---------------------------------MIGEDVYDEV--HRKAVDYRNYLQGHLE 26 
L1.11b/c               -MAPGITG---------------TKKTAKEVLDEIGETIQKGVH-RSAVDYIN-DLQGDLS 43 
PF08_0140              -MVPPVRSPRAAGPAPAPASASTTYGSVKDLLEDIGKSIQKQAK-DAAEKRSNGELQGDLS 59 
L8.19a/c (AY462685)    -MAPQS-GGGSPQD-----------ESAKHALDRIGEEVY-KEVKSEAEQRSKGELKAGVL 47 
S1.08e/s               ------------------------------------------------------------- 
L7.11a/c (AY462686)    -MAP---GGRQGDGG-----EDIDHQSAKHLLDSIGKIVH-DQVKGEAEKRSNGDLKGSLT 51 
L1.02b/c (AY462688)    -MAP---GGPQGGGTKDEDAKNMFDRIGKKVLDK---------VKEEAQT-YKDDLKGNLA 47 
L7.11a/s (AY462693)    -MGPPAQGGTD--------------KGAKEVLDEFGQQVYNEKVKNEAET-YKEALTGQLS 45 
L1.02c/c (AY462687)    -MARPGSGGGGSSQ------------DAKHVLDEIGQQVH-DQVEKEAKERSNGDLKGNLT 47 
MAL7P1.50(AY462690)    -MASQ-SGGGSPQ-------------DAKHVLDEFGQQVH-KEVKKEAERRSKGELKGLLT 45 
L1.02a/c (AY462689)    -MAPQGVSGGTQ------------DEDAKHVLDEFGEKVY-KEVKNESNG-FKDDLKGNLN 46 
L3.12a/c (AY462681)    -MSTPGGPRGGGGSSGEDGIEHDK--DAKHLLDSIGKIVH-DEVKNGEAKTFKGELEGKLS 57 
PFL0935c (AY462680)    ------------------------------------------------------------- 
L7.12b/c (AY462679)    -MVTPGGGQVGAAGSSGDAEKYKNATNVKDLLDMIGKDVHDKVK-GEAEQRSNGELKGLLS 59 
L1.11a/c               -MAPQ--SGGTQ-------------KDAKNMFDRIGKRVHDEIV-EKEAKNYIDDLKGDLN 47 
L3.08d/s               ------------------------------MFDRIGKIVHDKVKGEAETYF--DELKGDLQ 29 
L3.08i/s               ------------------------------------------------------------ 
L3.08k/s (AY462682)    -MAASTTYSSA--------------TDAKHLLDMIGKDVHDQVKKEADAKNYIDDLKGNLQ 46 
L2.06b/s               -MVT-GSGGSTQD------------EDAKHVLDKIGQQVYKEVK-NGGAEKYIEALKGNLQ 46 
L1.12b/c (AY462676)    -MTP-SSAGTNGY------------SDAKDFLDKIGQQVYDKVK--EEAATYKDDLKGNLA 45 
L1.12a/c (AY462677)    -MAPQSSGGGRGGGEED----------AKDFLDKIGEKVYKEVK-GEAEKRSNGDLKAYVS 49 
S1.07b/s (AY462678)    -MAPGNAGGGAGSVDKDGIEDTTA----KHLLDSIGKKVHDQVK-KEVEQRSNGDLKGFLT 55 
L3.12a/s               -MAPIGDGG------------ADANKSAKEVLDEFGQKVHDEVK-NDA-KTYEGELKGFLS 46 
L6.02a/s               ------------------------------------------------------------- 
L7.08c/s (AY462684)    -MAPQGSTGGGTQEDPIDET------SAKHVLDSIGKIVHDQVK-S-KSNGFKDELKGDLN 52 
L7.08b/s (AY462692)    -MVAAAKGGGSSQD-------------AKEVLDRIGEKVHEEVK-NGDAKKYIEALRGNL- 45 
L3.08h/s               ---------------------------------------------------------GNLT 4 
L7.08a/s (AY462691)    -MVTQGRQGGKDEEDPIEHN-----KDAKHLFDSIGEKVYREKVQS-DAKTYEGELKGNLS 54 
L2.08a/s (AY462699)    -MAPGSTGTQDD--------------DAKNMFDRIGKEVH-DKVKN-DAKTYEGELKGNLA 44 
S1.08b/s (AY462683)    -MGGGSGGGGSSQ---------EQDESVKHMFDRIGQQVYEQVKKDADAKNYIEKLKGDLN 51 
 
L2.12b/c               ---IKIPQEPN---LLVP--CKLKCGYHTNVTKGH---GREYPCNDRWD-----IRFSDKY 45 
L2.12a/s (AY462669)    SATYPGDKDSSGTKPSSP--CKLKCGYHTNVTKGH---GREYPCNDRWD-----IRFSDKY 103 
L3.08a/c (AY462667)    EATYPGDENPNKTTPPNP--CLLQYDYNSNVTIGG---GREYPCKDRPE-----VRFSDEY 95 
L3.08l/s (AY462666)    EATYPGDENPNKTTPPNP--CLLQYDYNSNVTIGG---GREYPCKDRPE-----VRFSDEY 95 
L1.12c/c (AY462697)    QATYSRNSNGQ-ETPSDP--CELNHEYHTTVTGGF---DKNNPCKNRPN-----VRFSDIY 91 
L1.11b/s               ----------------------LFMNMTLTSTGGF---DTNNPCANRLD-----VRFSDKY 31 
L3.12c/s (AY462698)    RATIREGRMIQ-SGIAEL--CHLDYQWHTNVTSG-----KSNPCEGRAD-----VRFSDVI 100 
L2.06a/s (AY462668)    RATYPKDENPEGSTENNP--CKLDYKYHTNVTIGG---DKEYPCKDRPD-----VRFSDTE 100 
L3.08c/s               QATYPRDKYPKGTTPPNP—-CELLYEYHTNVTKGG---DKEYPCANRSD-----IRFSDTK 89 
L2.08a/c (AY462673)    QAIFSDI---TRVPTENP--CELDHRYHTNVSWG-----VINPCEHKSV-----ERFSEVS 103 
L3.06a/s (AY462674)    KARFSDG---SVVKSNDP--CQLNYEFDTYVTST-----VIEPCEHKKG-----KRLSEVH 101 
L1.12b/s (AY462670)    QATYPRDKYPEGTTPEDP--CDLDYNFHTNVTST-----VIDPCKHNSE-----ERFSDTQ 102 
L8.08a/s               --------------------CELDYQYHTNVTSN-----VIEPCKHNSE-----KRFSDTK 31 
L7.08d/s (AY462672)    EATFSNG---DKVTNHDP--CNLNYKYDTTVTST-----EIEPCKHKSG-----KRLSEVH 98 
L1.12a/s (AY462671)    KATYPKDKYPEGTTPKDP--CELEYKYHTNVTST-----EIDPCEHKKG-----KRLSEVH 97 
L3.08J/s (AY462675)    QAIFS---DRSRVPTGNP--CQLDHTVHTNVTS-----NVIDPCKHNSE-----KRFSDTQ 94 
L1.11a/s (AY462700)    SAKYR---EGYNIEHANTNICHLIHTHDTNVTEG---HGKEYPCANRSD-----IRFSDKQ 98 
L7.12a/s               QAKFRHEFSAYRPNYGNP—-CELDYRFHTNVWNRGAS--ERDPCYRRQP-----KNNSKLE 78 
L3.08a/s (AY462701)    QATFREG---RMIESEKAELCKLNYKYHTNVTKG---RGREDPCLGRYP-----ERFFDTQ 93 
MAL6P1.4 (AY462702)    SATFPTG---RRHEKPQSESCKLNYIYDTNVTSG---GGKENPCYGRQG-----VRFSDTK 97 
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S1.07a/s (AY462695)    NATFEKNPP-GKQTPARP—-CKLNHEYHTNATN-----GRSYPCRKGTE-----KRFSEVS 95 
S1.08c/s (AY462694)    NAIFEDAPD-GQQTPAGP--CQLKYKWHTNATN-----GKSYPCRTGTE-----ERFSQVH 96 
L1.12c/s (AY462696)    QATFEGKP----IKVSVP—-CGLEYQYHTNVTKG---HGREHPCRKGTE-----KRFSEVH 94 
L1.12d/s               NTIFEKLPS-DKQALSDP--CDLNHEYHTTATEG---HNKENPCEKRSN-----VRFSDTK 76 
L1.11b/c               KVHFKDG----EIDTHDI--CNLDHTKHTNV-----SWGVIHPCDNRLA-----NLFSEES 88 
PF08_0140              KARFKDQ----KNTTTNP—-CQLNYRNHSNVRS---SFENDNPCYGREE-----KRFSDSR 106 
L8.19a/c (AY462685)    FATFSGEE---LAAFSDP--CGLIKNEGENLIR-----ARGHPCKKDTNG-NDVDRFSVKE 97 
S1.08e/s               ------------------------------------------------------------- 
L7.11a/c (AY462686)    SVTLLGESVG----FSDP--CKLINDKVVKLID-----ARGDPCKKDTNG-NDVDRFSDKQ 100 
L1.02b/c (AY462688)    SSSILGE----LAAFSDP--CNLIKNEGEKLLA-----LRDNPCGNGSGKGEDVSRFSKER 97 
L7.11a/s (AY462693)    QVSINSETIT----FTDP--CTSEYDKHTTSAN-----GNTKPCGND-GKEDDSKRFSKNR 94 
L1.02c/c (AY462687)    ISTIFDTETTG---TDDP—-CSSDYTTRFDARGD--------PCKKDGTG-NDVERFSVKQ 94 
MAL7P1.50(AY462690)    SAKLSGGEIAGT—-TD-P--CSSDYTKHFE---ANSNR---YPC-GNT----NVDRFPDND 90 
L1.02a/c (AY462689)    TASGSSGETLGSIDT-----CYLVNQYYTERLNGNSNR---YPC-GTRT--EEVKRFSDKQ 96 
L3.12a/c (AY462681)    QAS-ILGESAGT---DDP--CTFK---YDELTGAARGE—-RYPCKELSGKM-FENPFSDTL 106 
PFL0935c (AY462680)    -----MGERASSNKT-----CTLVKEYYEHFNGDANSN—-RYPCKELNGKM-GENRFSDTL 48 
L7.12b/c (AY462679)    QAS-ILGETAFT---DKP--CNFDYDKLINGSGSGGNR---HPCKNLKG-STIEGRFSNTL 110 
L1.11a/c               KANNSSDETIS---SLDP—-CELQSEYTELINGSGSGVAARGDPCENLS-RKVEPRFSDTL 102 
L3.08d/s               KAVTTIWQTV---DTDKP-—CDLVEQYRSKANGGGGKGER—YPCKELGV-KVEVKRFSNSV 83 
L3.08i/s               -------------------------------------------------------------    
L3.08k/s (AY462682)    HAAKGSDETVG---TDDP--CTFKYDKLIGANDGNR-----HPCTNLKGN-ANEERFSDTL 96 
L2.06b/s               -EAKGIGE---LASSLDT--CTLIKDKRHE-LLRARD----DPCTNLSG--KLEPRFSDTL 94 
L1.12b/c (AY462676)    SSSILGVESASTA---DP--CNFEYHKLIG--ANDGNR--HPCESLSGKDAKKEERFSNTL 97 
L1.12a/c (AY462677)    FASIFGEEKART---LDP--CNLKSEYTKLIEANRNR----YPCTNLSG--KVEPHFSNTL 99 
S1.07b/s (AY462678)    STTIFGGERAIT---LDP--CNLKSEYTKLIEANSNR----YPCKNLKG-ITNEERFSNTL 106 
L3.12a/s               STTIFGGVRDRT---LEP--CKLKSEYTKLIKDNSNR----YPCGNES---VSQKRFSVKQ 95 
L6.02a/s               -----------------------EYYEHFNGDANSNR—---HPCGN-RTGKEEVNRFSDTL 35 
L7.08c/s (AY462684)    TANNSSGE---LASSIDP—-CTLVEQYRSKANGGDTDKR--HPCRKDGTGKEEVNRFSDTL 106 
L7.08b/s (AY462692)    TDSTILGET—VAFSDT----CDLVKQYISKVGGNSER—---HPCGNGTGDAKKEERFSNTL 97 
L3.08h/s               SSTFFGGETVSS---LHP--CGLDYTKRLK---GK-----RYPCANRQT-----VRFSDEY 47 
L7.08a/s (AY462691)    FASIFDTETTG---TDDP--CGLDYIKRLN---GNNN---RHPCANRSP-----VRFSDEY 99 
L2.08a/s (AY462699)    SSSIWK-ESAY---TTDT--CQLVYDYYTKRLNGK-----RYPCANRSP-----VRFSDES 89 
S1.08b/s (AY462683)    TANGHSSETL---GTTDT--CTLVYKYYDDVNGGGAAPGERYPCGTGKE-----ERFSDTL 102 
 
L2.12b/c               GGQCTNVKIHGNSKGGNG--TEVGACAPFRRLHLCDHHLSHMQADK---IMNKHNLLLEV 100 
L2.12a/s (AY462669)    GGQCTNEKIHGNSKGENG--TEVGACAPFRRLHLCDHRLSHMQADK---IMNKHNLLLEV 158 
L3.08a/c (AY462667)    GGQCTDSKIKGN-EDNKG-----GACAPFRRLFLCDQHLSHMKAEK---INNKHNLLLEV 146 
L3.08l/s (AY462666)    GGQCTDSKIKGN-EDNKG-----GACAPFRRLFLCDQHLSHMKAEK---INNKHNLLLEV 146 
L1.12c/c (AY462697)    GGQCTDSKIRGN-DT-----NNGGACAPFRRLFLCDHHLSHMQADQ---IDSKDNLLLEV 142 
L1.11b/s               GGQCTDTKIHGN-EN-----NEFGACAPFRRLFLCDHHLSHMKVEK---INTKDNLLLEV 82 
L3.12c/s (AY462698)    GGQCTNSKIKGN-EVKYG--KDIGACAPFRRLFLCDHHLSYMNAGK---TNTTDNLLLEV 154 
L2.06a/s (AY462668)    GAQCDKSKIGGS-NS-----NKDGACAPYRRSSLCDHHLSYMNAGK---TNTTDNLLLEV 151 
L3.08c/s               GAECDYRKIDGN-KG-----KTGGACAPYRRSSLCDHHLSYMNAGK---TNTTDNLLLEV 140 
L2.08a/c (AY462673)    GGECDEKKIKGS---------NGGACAPFRRLHVCDKNLEQIKPHT---ITATHNLLVDV 151 
L3.06a/s (AY462674)    SSECDRKKIKDSENN------TAGACAPFRRLHICDENLEQIKPHT---ITATHNLLAEV 152 
L1.12b/s (AY462670)    GAECDNNKIRGSDKK-----SNGGACAPFRRLHLCDKNIQQIKTEN---ITT-HNLLLDV 153 
L8.08a/s               GAECDKSKIRGSNGK-----SEG-ACAPYRRLHVCDRNLEQIDPAK---ITTTHNLLADV 82 
L7.08d/s (AY462672)    RGECDNRKIKDSNVK-------EGACAPYRRLHVCDKNIQQIKAEQ---ITT-HNLLADV 147 
L1.12a/s (AY462671)    SSECDNRKIRDCDKKN----NSVGACAPYRRLHVCDKNIQQIKTEN---ITT-HNLLLDV 149 
L3.08J/s (AY462675)    GAECDRKKIKDNKG-------KEGACAPYRRLSLCDTNLEQIKTEN---ITT-HNLLVDV 143 
L1.11a/s (AY462700)    GAECDKSKIKDGND-------EGGACAPYRRSHLCDQHLSHMKEDK---IDSKDNLLLEV 148 
L7.12a/s               GAVCTNSKIKGNENKI----IDIGACAPYRRIHLCDYNLEHIHEGN---VLTTDDLLGNV 131 
L3.08a/s (AY462701)    GSECATSKIEGNVGKKTNKGKSEGACAPYRRLHLCDQNLEHIDPDK---IESTHNLLVDV 150 
MAL6P1.4 (AY462702)    GAKCYSYKIE-------DNDSSIGFCAPYRRLHLCVQNLEQIKPDQ---ITSTHNLLVDV 147 
S1.07a/s (AY462695)    GGECDKNKIRGSKGDNE------GACAPYRRLNLCVRNLENISDFN---NINNDTLLADV 146 
S1.08c/s (AY462694)    GGECDDSKIKGNKGSNEN---SEGACAPYRRLNLCVRNLENISALD---KINNDTLLADV 150 
L1.12c/s (AY462696)    GGECANSKIKGNKGSKEN---SEGACAPYRRLHLCDYNLENINDYK---NINNDTLLVDV 148 
L1.12d/s               GAECDKSKIKGNKDNKDIGGKSEGACAPYRRLHLCDHNLENISDFD---HINNDTLLADV 133 
L1.11b/c               ASQCSTSRISGN-------ANNSGSCAPYRKLQLCDYNLERITDTN---TTNTNNLLVDV 138 
PF08_0140              SGQCTYNRIKDSKEG----DNKVGACAPYRRLHICDHNLENINDYK---NINNHTLLVDV 159 
L8.19a/c (AY462685)    QAEYDNKKMK----CS-N----GDACAPFRRLHLCNKNIQQIKTEN-IT---THNLLVDV 144 
S1.08e/s               --------------------------------------IKLIVKD---------NLLLEV 13 
L7.11a/c (AY462686)    GAECNKSKIK----DS-DKKNKGGACAPYRRLHVCDKNMEKIATS--MT---KHDLLLDV 150 
L1.02b/c (AY462688)    VDEYDEKKIKDN--KS-KGGNNEGECAPYRRLSLCNKNFPNMNSND-SS-KAKNDLLVDV 152 
L7.11a/s (AY462693)    IAEYDEKKIR---------GSNDGACPPYRRLSLCNKNMVNMIPNN-NDGKAKHDLLADV 144 
L1.02c/c (AY462687)    GAECGNSKIHGNS-KG-GTGTEVGACAPYRRLNLCNKNLENINKYD-NT-KAKHDLLAEV 150 
MAL7P1.50(AY462690)    GAECDNSKIKGN--KG-KEDNSEGACAPYRRLSLCNKNFQNNNNDH-SS-NAKHDLLLDV 145 
L1.02a/c (AY462689)    GAQCDKKKIK-------DSDSNGDACAPFRRLNLCNKNMVKMDTNN-NDGKATHTLLAKV 148 
L3.12a/c (AY462681)    GGQCTNEKMRS-------GGK--GACAPYRRLHLCHHNLETINN---TTSTTSDTLLAEV 154 
PFL0935c (AY462680)    GGQCTNKKIEG-------NKNNCGACAPYRRLHLCHHNLESID----TTSTTSDTLLAEV 97 
L7.12b/c (AY462679)    GGQCTDSKMRS-------GGE--GACAPYRRLHLCHHNLESIETNNYDSDNAKHNLLAEV 161 
L1.11a/c               GGQCTDSKMRS-------GGK--GACAPYRRLHLCSHNLESID----TTSMTTHKLLAEV 149 
L3.08d/s               SGQCTNKKIEGNKYI---EGKDVGACAPYRRLHLCHHNLESIQTNNYNSSNAKHNLLAEV 140 
L3.08i/s               ---------------------------------LCSHNLETID-TKSTTSDT---LLLEV 23 
L3.08k/s (AY462682)    GGQCTDSKIKGNKYNR-KTRKDCGACAPYRRLHLCHHNLETINNTTSTTSDT---LLAEV 152 
L2.06b/s               GGQCTKEKIEGNKYIK-G--KDVGACAPYRRLHLCHHNLETINNTTSTTHD----LLAEL 147 
L1.12b/c (AY462676)    GGQCTNKKMRSG---------GEGACAPYRRLHLCSHNLESIETNNYDSNNARHKLLAEV 148 
90 
L1.12a/c (AY462677)    GGQCTKEKISG-------STNTCGACAPYRRLHLCHHNLESIPTNNYNSSNARHNLLAEV 152 
S1.07b/s (AY462678)    GGQCTKEKISG-------STNTCGACAPYRRLHLCDHNLETIETNNYDSNNARHNLLAEV 159 
L3.12a/s               QAEYDNKKMKC-------SNG--GACAPYRRLHLCHHNLESIQTKNYNSSNARHNLLAEV 146 
L6.02a/s               GGQCTDHRIKGNN-----RNVTGGACAPLRRLHLCHHNLESIQTNNYDSGKAMHTLLAEV 90 
L7.08c/s (AY462684)    GGQCTDHRIKGND-----RNKTGGACAPLRRLHLCDYNLESINTDKIDSGNAKHDLLAEV 161 
L7.08b/s (AY462692)    GGQCTDHRIKGND-----RNVTGGACAPFRRLHVCDRNLENIN--DYSKINNKDNLLLEV 150 
L3.08h/s               GGQCPHNRIKDNE----TVDNNCGACAPYRRLHLCDYNLEKMGRT----STTKHDLLAEV 99 
L7.08a/s (AY462691)    GGQCTHNRIKDNE----TVDNKCGACAPYRRLHLCDYNLEKMGTTK---SKARHNLLAEV 152 
L2.08a/s (AY462699)    RSQCTYNRIKDNK----SEDNACGACAPFRRLSVCDYNLEKMGTKK---IDNTHKLLAEV 142 
S1.08b/s (AY462683)    GGQCTYNRIKDSN----KNDNK-GACAPYRRLHLCDYNLESINNYN---SNARHKLLAEV 154 
 
L2.12b/c               CYAAKYEGKSLVEKHKKFKEENSDFNIN--ICTVLARSFADI- 140 
L2.12a/s (AY462669)    CYAAKYEGKSLVEKHKKFKEENSDFNIN--ICTVLARSFADI- 198 
L3.08a/c (AY462667)    CLAAKYEGESLKGYHDKYNATYSDSRSQ--LCTVLARSFADI- 186 
L3.08l/s (AY462666)    CLAAKYEGESLKGYHDKYNATYSDSR----------------- 172 
L1.12c/c (AY462697)    SLAAQYEGKLLVERHRECKKTHEDFKTN--ICDVLARSFADI- 182 
L1.11b/s               LLAAKYEGESIRN---EYDQKKDDYKLG--LCTALARSFADI- 119 
L3.12c/s (AY462698)    CLAAQYEGESIIK---NYPQDHNNNEV---ICTALARSFADI- 190 
L2.06a/s (AY462668)    CMAAKHEGASITRYHDQHKRTNP--DSK--ICTELARSFADI- 189 
L3.08c/s               CLAALHEGQSITGRYPQHQETNEGTASQ--LCTVLARSFADI- 180 
L2.08a/c (AY462673)    CMAAQFEGASIKGYYPKYQEKYKDTGS--TMCTMLARSFAD-- 190 
L3.06a/s (AY462674)    CMAAQFEGASIKGYHPQYDVQYPGSGS--TMCTVLARSFADIG 193 
L1.12b/s (AY462670)    CLAAKFEGQSITGYHPQYEVQYPSSGS--TICTALARSFADI- 193 
L8.08a/s               CQAAKFEGQSIAGYYAQYEAQYPGSGS--TICTALARSFADI- 122 
L7.08d/s (AY462672)    CMAAKFEGQSISGYHPKYEIQYPGSGSGFTLCTMLARS----- 185 
L1.12a/s (AY462671)    CLAAKFEGQSITGYHPQYEVQYPSSGS--TMCTMLARSFADI- 189 
L3.08J/s (AY462675)    CMAAKYEGTSLKGYHDQHQLTYPGYHS--QLCTELARSFADI- 183 
L1.11a/s (AY462700)    SLAAQYEGQSIRVDHDKYKLDNDNSGS--KLCTELARSFADI- 188 
L7.12a/s               LVMAKNEGASIVNSNAHNGVLN--------VCTVLARSFADI- 165 
L3.08a/s (AY462701)    CLAAQYEGKSIR---TQYEQKKDDYKS--GLCTVLARSFADI- 187 
MAL6P1.4 (AY462702)    LLAAKYEGQSITQDYPKYQATYDDSPS--KMCTMLARSFADI- 187 
S1.07a/s (AY462695)    CLAALHEGDSIRSDHYKYKLTN--SSS--QICTMLARSFADIG 185 
S1.08c/s (AY462694)    CLAALHEGAAIRGDHGKYQETNNDVNA--NICTMLARSFADIG 191 
L1.12c/s (AY462696)    CLAALHEGASLQGYHDKYKETN--DSS--QLCTMLARSFADI- 186 
L1.12d/s               CLAAKFEAESLEKYRDQYQLSNRDLHI--NICTVLARSFADI- 173 
L1.11b/c               LLAAKYEGDSLSKYIKEHPEIIPNSN----ICTVLARSFADIG 177 
PF08_0140              CLSAKHEGEMIANKLKEYDKSNYESR----ICTVLARSFADI- 197 
L8.19a/c (AY462685)    CMAANYEAQSLIRDHPQYQEKYGDS----QICTVLARSFADI- 182 
S1.08e/s               SLAAKYEGEYLRINHPQYQEKYGDS----QICTVLARSFADI- 51 
L7.11a/c (AY462686)    CLAAKYEGDSLKHYSKKLNLTYTDSP--SQLCTELARSFADI- 190 
L1.02b/c (AY462688)    CLAAKYEGESITLNYPKYEAIYEGSG--HTPCTMLARSFADI- 192 
L7.11a/s (AY462693)    CYAAKHEGESLKNYHPQYKLTYGDS----QICTVLARSFADI- 182 
L1.02c/c (AY462687)    CHAAKYEGASITLHYPQYQNKYDDSG--STMCTMLARSFADI- 190 
MAL7P1.50(AY462690)    CMAANYEAQSLITYHDKHE--LTNVG--SQICTVLA------- 177 
L1.02a/c (AY462689)    CYAAKYEGDSIKTHYPLYQHKYGDSD--SQICTVLARSFADI- 188 
L3.12a/c (AY462681)    CMAAYYEGDLIKTHYTQHEQTNPDTK--SQLCTVLARSFADI- 194 
PFL0935c (AY462680)    CYAAKFEGETLTTQHGQHQQTNPGTA--SQLCTVLARSFAD-- 136 
L7.12b/c (AY462679)    CMAAKYEGDLIKTHHRQHQLTYPDSA--SELCTVLARSFADI- 201 
L1.11a/c               CMAAKYEGDSITRYHPQHQETNPGTA--SQLCTVLARSFADI- 189 
L3.08d/s               CYAAKYEGDSIKKYHDEHQGTN--KV--SNICTVLARSFADI- 178 
L3.08i/s               CMAAKYEGQSITGYYPIYQTKYNDYG--SPICTVLARSFAD-- 62 
L3.08k/s (AY462682)    CYAAKEEGASISGRYRQYVTKYKDYG—-STMCTVLAR------ 191 
L2.06b/s               CMAAKYEAESLEKYRDQYEAQYPGSG--STMCTVLARSFA--- 185 
L1.12b/c (AY462676)    CYAAKYEAESLIHDHAQYRVKNTDFN--TTICTVLARSFADI- 188 
L1.12a/c (AY462677)    CMAAKYEGDLIKTHYTKYKESNPGTA--SQLCTVLARSFADI- 192 
S1.07b/s (AY462678)    CMAAKYEGDLIKTHYTPYQLTNEGTA--SQLCTVLARSFADI- 199 
L3.12a/s               CMAAYYEGDLIKTRYTPYQHTNEGTA--SQLCTELARSFADI- 186 
L6.02a/s               CMAAKYEGESIKVDYVKYRGNNPDFN--TTICTELARSFADI- 130 
L7.08c/s (AY462684)    CMAAKYEGNSINTHYTIHKETNPGTA--SQLCTVLARSFADI- 201 
L7.08b/s (AY462692)    CMAAYYEGQSIKDDHAHYQSKNSDFK--TNICTELARSFADI- 190 
L3.08h/s               CMAAKYEGNSINTHYTPHQVTYSDS--AAELCTVLARSFADI- 139 
L7.08a/s (AY462691)    CLAAKYEGESLKNYHAQYQAKNTDF--KTNICTELARS----- 188 
L2.08a/s (AY462699)    CMAAKYEAESLEKYRDQYDAKYHDT--GFTICTALARSFAD-- 181 
S1.08b/s (AY462683)    CYAAKHEGDLINTHYTPHQQKYKDTGTASQLCTVLARSFADIG 197 
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L2.06d/s (AY462590)    --TCATATATAATTTTACAAAATATATAAAACATAAAAAA------ATAATATATATA-- 50 
L3.08g/s (AY462591)    --TCATATATAATTTTACAAAATATATAAAACATAAAAAA------ATAATATATGTA-- 50 
L2.08a/s (AY462592)    --TCATATATAATTTTACAAAATATATAAAACATAAGAAA------ATAATATATATA-- 50 
S1.12e/s (AY462593)    TCTCATTTATAATTTTACAAAATATATAAAACATAAGAAA------ATAATATATATATA 54 
L3.08b/s               --TCATATATAATTTTACAAAATATATAAAACATAAAAAA------ATAATATATATA-- 50 
S1.07a/s (AY462594)    -CTCATTTATAATTTTACAAAATATATAAAACATAAAAAA------ATAATATATATA-- 51 
S1.08c/s (AY462595)    -CTCATATATAATTTTACAAAATATATAAAACATAAGAAA------ATGATATATATA-- 51 
PF08_0106(AY462596)    -CTCATTTATAATTTTACAAAATATATAAAACATAAAAAA------ATAATATATAAA-- 51 
S1.08g/s (AY462597)    CCTCATTTATAATTTTACAAAATATATAAAACATAA-AAA------ATAATATATGTA-- 51 
PF08_0140(AY462598)    -CTCATATATAATTTTACAAAATATATAAAACATAAAAAA------ATAATATATAAA-- 51 
S5.12a/s (AY462599)    -CTCATTTATAATTTTACAAAATATATAAAACATAAAAAA------ATAATATATATA-- 51 
L3.06a/s (AY462600)    --TCATATATAATTTTACAAAATATATAAAACATAAAAAA------ATAATATATATA-- 50 
S1.08d/s (AY462601)    ---------TAATTTTACAAAATATATAAAACATAAAAAA------ATAATATATATATA 45 
S3.12a/s (AY462602)    -CTCATTTATAATTTTACAAAATATATAAAACATAAAAAA------ATAATATATGTA-- 51 
L2.06f/s (AY462603)    ------------TTTTACAAAATATATAAAACATAAGAAA------ATAATATATATA-- 40 
S1.12c/s (AY462604)    TCTCATTTATAATTTTACAAAATATATAAAACATAAAAAA------ATAATATATATA-- 52 
L7.11b/s (AY462605)    TCTCATATATAATTTTACAAAATATATAAAACATAAAAAA------GTAATATATAAA-- 52 
S1.07c/s (AY462606)    -CTCATATATAATTTTACAAAATATATAAAACATAAAAAA------ATAATATATAAA-- 51 
L3.08a/s (AY462607)    --TCATTTATAATTTTACAAAATATATAAAACATAAAAAA------ATAATATATATA-- 50 
S1.07b/s (AY462608)    -CTCATTTATAATTTTACAAAATATATAAAACATAAGAAA------ATAATATATATA-- 51 
S3.12d/s (AY462609)    -CTCATTTATAATTTTACAAAATATATAAAACATAAAAAA------ATAATATATGTA-- 51 
L6.02b/s (AY462610)    TCTCATTTATAATTTTACAAAATATATAAAACATAAGAAA------ATAATATATATA-- 52 
MAL7P1.50(AY462611)    -CTCATATATAATTTTACAAAATATATAAAACATAAAAAATAAAA-ATAATATATGTA-- 56 
L6.02c/s (AY462612)    -CTCATTTATAATTTTACAAAATATATAAAACATAAAAAAATAAAAATAATATATGTA-- 57 
S5.12b/s (AY462613)    -CTCATTTATAATTTTACAAAATATATAAAACATAAGAAAAT------AATATATAAA-- 51 
L1.12a/s (AY462614)    TCTCATTTATAATTTTACAAAATATATAAAACATAAAAAAA------TAATATATATA-- 52 
S1.08b/s (AY462615)    -CTCATATATAATTTTACAAAATATATAAAACATAAAAAAAA-----TTATATATGTA-- 52 
S3.12c/s (AY462616)    -CTCATTTATAATTTTACAAAATATATAAAACATAAAAAAA------TAATATATGTA-- 51 
L3.08f/s (AY462617)    --TCATTTATAATTTTACAAAATATATAAAACATAAAAAAA------TAATATATGTA-- 50 
L3.08l/s (AY462618)    -CTCATTTATAATTTTACAAAATATATAAAACATAAAAAAAA-----TAATATATATATA 54 
S3.12e/s (AY462619)    -CTCATATATAATTTTACAAAATATATAAAACATAAAAAAA------TAATATATATATA 53 
S1.08f/s (AY462620)    -CTCATATATAATTTTACAAAATATATAAAACATAAAAAAA------TAATATATATA-- 51 
S1.12a/s (AY462621)    -CTCATTTATAATTTTACAAAATATATAAAACATAAAAAAA------TAATATATGTA-- 51 
L2.06e/s (AY462622)    -CTCATATATAATTTTACAAAATATATAAAACATAAGAAAA------TAATATATATA-- 51 
L3.08e/s (AY462623)    --TCATTTATAATTTTACAAAATATATAAAACATAAAAAA------GTAATATATAAA-- 50 
L1.11a/s (AY462624)    TCTCATATATAATTTTACAAAATATATAAAACATAAAAAA------ATAATATATATA-- 52 
S1.07d/s (AY462625)    -CTCATATATAATTTTACAAAATATATAAAACATAAAAAA------ATAATATATGTA-- 51 
L7.11a/s (AY462626)    TCTCATTTATAATTTTACAAAATATATAAAACATAAAAAA------ATAATATATATA-- 52 
L3.12b/s               ------------------------------------------------------------ 
MAL6P1.316             -CTCATTTATAATTTTACAAAATATATAAAACATAAGAAA------ATAATATATGTA-- 51 
 
L2.06d/s (AY462590)    --------ATTAAATATTTAAATAAAG-GAATACATGAAATATA--ATATTTTTCATAAA 99 
L3.08g/s (AY462591)    --------ATTAAATATTTAAATAAAG-GAATACATAATATATATAATATTTTTCATAAA 101 
L2.08a/s (AY462592)    --------ATTAAATATTTAAATAAAA-GAATACATAATATATATAATATTTTTCATAAA 101 
S1.12e/s (AY462593)    --------ATTAAATATTTAAATAAAA-GAATACATGAAATATA--ATATTTTTCATAAA 103 
L3.08b/s               --------ATTAAATACATAAAGAAAG-GAATACATGAAATATA--ATATTTTTCATAAA 99 
S1.07a/s (AY462594)    --------ATTAAATATTTAAATAAAA-GAATACATGATATATA--ATATTTTTCATAAA 100 
S1.08c/s (AY462595)    --------ATTAAATATATAAATAAAG-GAATACATGAAATATA--ATATTTTTCATAAA 100 
PF08_0106(AY462596)    --------ATTAAATATAAAAATAAAG-GAATACATGATATATA--ATATTTTTCATAAA 100 
S1.08g/s (AY462597)    --------ATTAAATATTTAAATAAAG-GAATACATCAAATATA--ATATTTTTCATAAA 100 
PF08_0140(AY462598)    --------ATTAAATATAAAAATAAAG-GAATACATGAAATATA--ATATTTTTCATAAA 100 
S5.12a/s (AY462599)    --------ATTGAATAAGTAAATAAAGAGAATACATGAAATATA--ATATTTTTCATAAA 101 
L3.06a/s (AY462600)    --------ATTAAATATAAAAATAAAG-GAATACATAATATATATAATATTTTTCATAAA 101 
S1.08d/s (AY462601)    --------ATTAAATAGATAAATATTT-GAATACATGAAATATA--ATATTTTTCATAAA 94 
S3.12a/s (AY462602)    --------ATTAAATATTTAAATAAAG-GAATACATGATATATA--ATATTTTTCATAAA 100 
L2.06f/s (AY462603)    --------ATTAAATATAAAAATAAAG-GAATACATGAAATATA--ATATTTTTCATAAA 89 
S1.12c/s (AY462604)    --------ATTAAATATATAAATAAAG-GAATACATGAAATATA--ATTTTTTTCATAAA 101 
L7.11b/s (AY462605)    --------ATTAAATATAAAAATAAAG-GAATACATGAAATGTA--ATATTTTTCATAAA 101 
S1.07c/s (AY462606)    --------ATTAAATATAAAAATAAAG-GAATACATCAAATATA--TTATTCTTTATTA- 99 
L3.08a/s (AY462607)    --------ATTAAATATATAAATAAAG-GAATACATGAAATATA--ATATTTTTCATAAA 99 
S1.07b/s (AY462608)    --------ATTAAATATTTAAATAAAA-GAATACATGATATATA--ATATTTTTCATAAA 100 
S3.12d/s (AY462609)    --------ATTAAATATATAAATAAAA-GAATACATGATATATA--ATATTTTTCATAAA 100 
L6.02b/s (AY462610)    --------ATTAAATATATAAATAAAA-GAATACATGAAATATA--ATATTTTTCATAAA 101 
MAL7P1.50(AY462611)    --------ATTAAATATTTAAATAAAG-GAATACATGAAATATA--ATATTTTTCATAAA 105 
L6.02c/s (AY462612)    --------ATTAAATATTTAAATAAAA-GAATACATGAAATATA--ATATTTTTCATAAA 106 
S5.12b/s (AY462613)    --------ATTAAATATATAAATAAAA-GAATACATAATATATATAATATTTTTCATAAA 102 
L1.12a/s (AY462614)    --------ATTAAATATATAAATAATG-GAATACATGAAATATA--ATATTTTTCATAAA 101 
S1.08b/s (AY462615)    --------ATTAAATACATAAAGAAAG-GAATACATGAAATATA--ATATTTTTCATAAA 101 
S3.12c/s (AY462616)    --------ATTAAATACATAAATAAAG-GAATACATAATATATATAATATTTTTCATAAA 102 
L3.08f/s (AY462617)    --------ATTAAATATATAAATAAAA-GAATACATAATATATATAATATTTTTCATAAA 101 
L3.08l/s (AY462618)    TATATATAATTAAATAGATAAATAAAG-GAATGCATAAAATATA--ATATTTTTCATTAT 111 
S3.12e/s (AY462619)    TATAT--AATTAAATATATAAATAAAG-GAATACATAATATATATAATATTTTTCATAAA 110 
S1.08f/s (AY462620)    --------ATTAAATATATAAATAAAA-GAATACATGAAATATA--ATATTTTTCATAAA 100 
S1.12a/s (AY462621)    --------ATTAAATATATAAATAAAA-GAATACATGAAATATA--ATATTTTTCATAAA 100 
92 
L2.06e/s (AY462622)    --------ATTAAATATAAAAATAAAA-GAATACATGAAATATA--ATATTTTTCATAAA 100 
L3.08e/s (AY462623)    --------ATTAAATATAAAAATAAAG-GAATACATGAAATATA--ATATTTTTCATAAA 99 
L1.11a/s (AY462624)    --------ATTAAATATTTAAATAAAG-GAATACATGAAATATA--ATATTTTTCATAAA 101 
S1.07d/s (AY462625)    --------ATTAAATATATAAATAAAA-GTATACATGAAATATA--ATATTTTTCATAAA 100 
L7.11a/s (AY462626)    --------ATTAAATATTTAAATAAAG-GAATACATGAAATATA--ATATTTTTCATAAA 101 
L3.12b/s               ------------------------------------------------------------ 
MAL6P1.316             --------ATTAAATATATAAATAAAG-GAATACATAATATATATAAAATTTTTCATTAA 102 
 
L2.06d/s (AY462590)    AT-GTAATT-GTTGTTTTTTTTTTT-GTT--------AGAATA-TTTAAATTTATTATAA 147 
L3.08g/s (AY462591)    AT-GTAATT-GTTGTTTTTTTTTT--GTT--------AGAATA-TTTAAATTTATTATAA 148 
L2.08a/s (AY462592)    AT-GTAATT-GTTGTTTTTTTTTT--GTT--------AGAATA-TTTAAATTTATTATAA 148 
S1.12e/s (AY462593)    AT-GTAATT-GTTGTTTTTTTTTTTGTT---------AGAATA-TTTAAATTTATTATAA 151 
L3.08b/s               AT-GTAATT-GTTGNTTTTTTTTTTTTTTTTTTTGGTAGAATA-TTTAAATTTATTATAA 156 
S1.07a/s (AY462594)    AT-GTAATT-GTTGTTTTTTTTTTGTT----------AGAATA-TTTAAATTTATTATAA 147 
S1.08c/s (AY462595)    AT-GTAATT-GTTGTTTTTTTTTGTT-----------AGAATA-TTTAAATTTATTATAA 146 
PF08_0106(AY462596)    AT-GTAATT-GTTGTTTTTTTTTTTGTT---------AGAATA-TTTAAATTTATTATAA 148 
S1.08g/s (AY462597)    AT-GTAATT-GTTGTTTTTTTTTTGTT----------AGAATA-TTTAAATTTATTATAA 147 
PF08_0140(AY462598)    AT-GTAATT-GTTGTTTTTTTTTT--GTT--------AGAATA-TTTAAATTTATTATAA 147 
S5.12a/s (AY462599)    ATAGTAATTAGTTGTTTTTTTTTTT-GTT--------AGAATAGTTTAAATTTATTATAA 152 
L3.06a/s (AY462600)    AT-GTAATT-GTTGTTTTTTTTTT--GTT--------AGAATA-TTTAAATTTATT-TAA 147 
S1.08d/s (AY462601)    AT-GTAATT-GTTGTTTTTTTTTTT-GTT--------AGAATA-TTTAAATTTATTATAC 142 
S3.12a/s (AY462602)    AT-GTAATT-GTTGTTTTTTTTTTT-GTT--------AGAATA-TTTAAATTTACTATAA 148 
L2.06f/s (AY462603)    AT-GTAATT-GTTGTTTTTTTTTT--GTT--------AGAATA-TTTAAATTTATTATAA 136 
S1.12c/s (AY462604)    AT-GTAATT-GTTGTTTTTTTTTT--GTT--------AGAATA-TTTAAATTTATTATAA 148 
L7.11b/s (AY462605)    AT-GTAATTGTTGTTTTTTTTTTT--GTT--------AGAATA-TTTAAATTTATTATAA 149 
S1.07c/s (AY462606)    -T-ATAATT---------TTTTTT--GTT--------AGAATA-TTTAAATTTACTATAA 137 
L3.08a/s (AY462607)    AT-GTAATT-GTTGTTTTTTTTTT--GTT--------TGAATA-TTTAAATTTACTATAA 146 
S1.07b/s (AY462608)    AT-GTAATT-GTTGTTTTTTTTTTT-GTT--------AGAATA-TTTAAATTTATTATAA 148 
S3.12d/s (AY462609)    AT-GTAATT-GTTGGTTTTTTTTT--GTT--------AGAATA-TTTAAATTTACTATAA 147 
L6.02b/s (AY462610)    AT-GTAATT-GTTGTTTTTTTTTTTTGTT--------AGAATA-TTTAAATTTATTATAA 150 
MAL7P1.50(AY462611)    AT-GTAATT-GTTGTTTTTTTTTT--GTT--------AGAATA-TTTAAATTTATTATAA 152 
L6.02c/s (AY462612)    AT-GTAATT-GTTGTTTTTTTTTTT-GTT--------AGAATA-TTTAAATTTATTATAA 154 
S5.12b/s (AY462613)    AT-GTAATT-GTTGTTTTTTTTT---GTT--------AGAATA-TTTAAATTTATTATAA 148 
L1.12a/s (AY462614)    AT-GTAATT-GTTGTTTTTTTTTTT-GTT--------AGAATA-TTTAAATTTATTATAA 149 
S1.08b/s (AY462615)    AT-GTAATT-GTTGTTTTTTTTTTT-GTT--------AGAATA-TTTAAATTTATTATAA 149 
S3.12c/s (AY462616)    AT-GTAATT-GTTGTTTTTTTTTT--GTT--------AGAATA-TTTAAATTTATTATAA 149 
L3.08f/s (AY462617)    AT-GTAATT-GTTGTTTTTTTTTT--GTT--------AGAATA-TTTAAATTTATTATAA 148 
L3.08l/s (AY462618)    AT-GT---------TTTTTTTTTTTTGTT--------AGAACA-TTTAAATTTATTATAA 152 
S3.12e/s (AY462619)    AT-GTAATT-GTTGTTTTTTTTTTT-GTT--------AGAATA-TTTAAATTTATTATAA 158 
S1.08f/s (AY462620)    AT-GTAATT-GTTGTTTTTTTTTTT-GTT--------AGAATA-TTTAAATTTATTATAA 148 
S1.12a/s (AY462621)    AT-GTAATT-GTTGTTTTTTTTTT--GTT--------AGAATA-TTTAAATTTATTATAA 147 
L2.06e/s (AY462622)    AT-GTAATT-GTTGTTTTTTTTTTT-GTT--------AGAATA-TTTAAATTTATTATAA 148 
L3.08e/s (AY462623)    AT-GTAATT-GTTGTTTTTTTTTTT-GTT--------AGAATA-TTTAAATTTATTATAA 147 
L1.11a/s (AY462624)    AT-GTAATT-GTTGTTTTTTTTTTTTGTT--------AGAATA-TTTAAATTTATTATAA 150 
S1.07d/s (AY462625)    AT-GTAATT-GTTGTTTTTTTTTTT-GTT--------AGAATA-TTTAAATTTATTATAA 148 
L7.11a/s (AY462626)    AT-GTAATT-GTTGTTTTTTTTTTT-GTT--------AGAATA-TTTAAATTTATTATAA 149 
L3.12b/s               ------------------------------------------------------------ 
MAL6P1.316             AT-----TT------TTTTTTTGTTTGTT--------AGAATA-TTTGAATATATTATAA 142 
 
L2.06d/s (AY462590)    AAGTATTAATATA-------TATTTTTTT--AAAAATATATATATAAAACTAATAATTAT 198 
L3.08g/s (AY462591)    AAGTATTAATATA-------TATTTTTTT--AAAAATATA----TAAAACTAATAATTAT 195 
L2.08a/s (AY462592)    AAGTATTAATATA-------TATTTTTTT--AAAAATATATATATAAAACTAATAATTAT 199 
S1.12e/s (AY462593)    AAGTATTAATATA-------AA-TTTTTTT-AAAAATATATATATAAAACTAATAATTAT 202 
L3.08b/s               AAGTATTAATATA-------T--TTTTTTT-AAAAATATATATATAAAACTAATAATTAT 206 
S1.07a/s (AY462594)    AAGTATTAATATA-------TATTTTTTTT-AAAAATATATATATAAAACTAATAAGTAT 199 
S1.08c/s (AY462595)    AAGTATTAATATA-------TATTTTTTTT-AAAAATATATATATAAAACTAATAATTAT 198 
PF08_0106(AY462596)    ATGTATTAATATA-------TA-TTTTTTT-AAAAATATATATATAAAACTAATAATTAT 199 
S1.08g/s (AY462597)    AAATATTAATATA-------TA-TTTTTTT-AAAAATATATATATAAAACTAATAAGTAT 198 
PF08_0140(AY462598)    ATGTATTAATATA-------TATTTTTTTT-AAAAATATATATATAAAACTAATAATTAT 199 
S5.12a/s (AY462599)    ATGTATTAATATA-------AATTTTTTTT-TTTTAAAAATATATAAAACTAATAATTAT 204 
L3.06a/s (AY462600)    AAGTATTAATATA-------TATTTTTTTA-AAAAATATATATATAAAACTAATAATTAT 199 
S1.08d/s (AY462601)    AAGTATTAATATA-------AATTTTTTTT-----AAAAATATATAAAACTAATAAGTAT 190 
S3.12a/s (AY462602)    AAATATTAATATA-------TATTTTTT---AAAAATATATATATAAAACTAATAATAAT 198 
L2.06f/s (AY462603)    AAGTATTAATATA-------AATTTTTTTA-AAAAATATATATATAAAACTAATAATTAT 188 
S1.12c/s (AY462604)    AAATATTAATATA-------TATTGTTTT--AAAAATATATATATAAAACTAATAATTAT 199 
L7.11b/s (AY462605)    AAATATTAATATA-------TATTTTTTT--AAAAATATATATATAAAACTAATAATTAT 200 
S1.07c/s (AY462606)    AAATATTAATATA-------TATTTTTTT--AAAAATATATATATAAAACTAATAATTAT 188 
L3.08a/s (AY462607)    AAATATTAATATA-------AATTTTTTTT-AAAAATATATATATAAAACTAATAAGTAT 198 
S1.07b/s (AY462608)    AAATATTAATATA-------TATTTTTTT--AAAAATATATATATAAAACTAATAATTAT 199 
S3.12d/s (AY462609)    GAATATTAATATA-------TATTTTTTTT-AAAAATATATATATAAAACTAATAATTAT 199 
L6.02b/s (AY462610)    AAATATTAATATA---------TTTTTTTT-AAAAATATATATATAAAACTAATAATTAT 200 
MAL7P1.50(AY462611)    AAATATTAATATA-------TATTTTTTT--AAAAATATATATATAAAACTAATAATTAT 203 
L6.02c/s (AY462612)    AAATATTAATATA-------AATTTTTTTT-AAAAATATATATATAAAACTAATAATTAT 206 
S5.12b/s (AY462613)    AAATATTAATATA-------AATTTTTTTT-AAAAATATA----TAAAACTAATAAGTAT 196 
L1.12a/s (AY462614)    AAGTATTAATATA-------TATTTTTTTT-AAAAATATATATATAAAACTAATAAGTAT 201 
S1.08b/s (AY462615)    ATGTATTAATATA-------TTTTTTTTTT-AAAAATATATATATAAAACTAATAATTAT 201 
S3.12c/s (AY462616)    AAGTATTAATATA-------TATTTTTTT--AAAAATATATATATAAAACTAATAATTAT 200 
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L3.08f/s (AY462617)    AAATATTAATATA-------AATTTTTTTTTTTTTAAAAATATATAAAACTAATAATTAT 201 
L3.08l/s (AY462618)    AACTAAATATATAATTTTTTTTTTCTTTTTTAAAAATATATATATAAAACTAATAATAAT 212 
S3.12e/s (AY462619)    AAGTATTAATATA-----TATTTTTTTTTTTAAAAATATATATATAAAACTAATAATTAT 213 
S1.08f/s (AY462620)    ACCTATTAATATA--------TATTTTTTTTAAAAATATATATATAAAACTAATAATTAT 200 
S1.12a/s (AY462621)    AAGTATTAATATA--------TATTTTTTT-AAAAATATATATATAAAACTAATAATTAT 198 
L2.06e/s (AY462622)    AAGTATTAATATA---------TATTTTTTTAAAAATATATATATAAAACTAATAATTAT 199 
L3.08e/s (AY462623)    AAGTATTAATATA-------TATTTTTTTA--AAAATATATATATAAAACTAATAATTAT 198 
L1.11a/s (AY462624)    AAGTATTAATATA-------TATTTTTTTT--AAAA---ATAAGTAAAACTAATAATTAT 198 
S1.07d/s (AY462625)    AAATATTAATATA-------AATTTTTTTT--AAAA---ATATATAAAACTAATAAGTAT 196 
L7.11a/s (AY462626)    AAGTATTAATATA-------TATTTTTTTAAAAATATATATATATAAAACTAATAATTAT 202 
L3.12b/s               ----TCTCATTTA-------TAATTTTACA-------AAATATATAAAACTAATAATTAT 42 
MAL6P1.316             AGCTATTTGAATA----------TTTGATT----AAAAAATATATAAAACTAGTTATGAT 188 
 
L2.06d/s (AY462590)    TAT---TATATACATATTAAATATTATTTATA--TATATA------TAT-ATAT-TATAT 245 
L3.08g/s (AY462591)    TAT---TATATACATATTAAATATTACTTAT---TA-ATA------TAT-ATAT-TATAT 240 
L2.08a/s (AY462592)    TAT---TATATACATATTAAATATTATTTATT--AATATA------TATTATATATATAT 248 
S1.12e/s (AY462593)    TAT--ATACAAACATATGAAATATTGTTTTTT--TA-----ACATATATATATATAATAT 253 
L3.08b/s               TAT---TATATACATATTAAATATTATTTATT---A-----ATATATATA---------- 245 
S1.07a/s (AY462594)    TAT--ATACAAACATATGAAATATTATTTATT---A-----ATATATATA---------- 239 
S1.08c/s (AY462595)    TAT---TATATACATATGAAATATTATTTATT--AATATATATATATATATATATTATAT 253 
PF08_0106(AY462596)    TAT---TATATACATATTAAATATTATTTATA--AA------TATATATA---------- 238 
S1.08g/s (AY462597)    TAT---TATATACATATGAAATATTATTTATT--AA------TATATATA---------- 237 
PF08_0140(AY462598)    TAT---TATATACATATTAAATATTATTTATT--AATATA------TATTA----TATAT 244 
S5.12a/s (AY462599)    TAT---TATATACATATTAAATATTATTTATT--AATATA------TATTA----TATAT 249 
L3.06a/s (AY462600)    TAT---TATATACATATGAAATATTATTTATT--AATATA------TATTA----TATAT 244 
S1.08d/s (AY462601)    TAT---TATATACATATTAAATATTATTTATT--AATATA------TATTA----TATAT 235 
S3.12a/s (AY462602)    TAT---TATATACATATTAAATATTATTTATT--AATATA------TAT----------- 236 
L2.06f/s (AY462603)    TAT---TATATACATATTAAATATTATTTATT--AATATA------TATTA----TATAT 233 
S1.12c/s (AY462604)    TAT--ATACAAACATATGAAATATTATTTATT--AATATA------TATTA----TATAT 245 
L7.11b/s (AY462605)    TAT--ATACAAACATATGAAATATTATTTATT--AATATATATATATATAA----TATAT 252 
S1.07c/s (AY462606)    TAT---TATATACATATTAAATATTATTTATT--AATATA------TATTA----TATAT 233 
L3.08a/s (AY462607)    TAT---TATATACATATTAAATATTACTTATT--AATATA------TATTA----TATAT 243 
S1.07b/s (AY462608)    TAT---TATATACATATTAAATATTATTTATT--AATATA------TAT----------- 237 
S3.12d/s (AY462609)    TAT---TATATACATATTAAATATTATTTATT--AATATA------TATTA----TATAT 244 
L6.02b/s (AY462610)    TAT---TATATACATATGAAATATTATTTATT--AATATA------TATTA----TATAT 245 
MAL7P1.50(AY462611)    TAT---TATATACATATTAAATATTATTTATT--AATATA------TATTA----TATAT 248 
L6.02c/s (AY462612)    TAT---TATATACATATGAAATATTATTTATT--AATATA------TATTTA---TATAT 252 
S5.12b/s (AY462613)    TAT---TATATACATATTAAATATTATTTATT--AATATA------TATAT----TATAT 241 
L1.12a/s (AY462614)    TAT---TATATACATATTAAATATCATTTATT--AATATATAT---TAT---------AT 244 
S1.08b/s (AY462615)    TAT---TATATACATATTAAATATTATTTATT--AATATATATA--TATT--------AT 246 
S3.12c/s (AY462616)    TAT---TATATACATATTAAATATTATTTATT--AATATATATA--TATAA------TAT 247 
L3.08f/s (AY462617)    TAT---TATATACATATTAAATATTATTTATT--AATATATATA--TATA---------- 244 
L3.08l/s (AY462618)    TACATACATATACATATTAAATATTATTTATT--AATATATATATAAATATATAT-ATAT 269 
S3.12e/s (AY462619)    TAT--ATACAAACATATGAAATATTATTTATT----AATA------TATAT--------- 252 
S1.08f/s (AY462620)    TAT--ATACAAACATATGAAATATTATTTATT--AATATA------TATAT---TATATA 247 
S1.12a/s (AY462621)    TAT---TATATACATATTAAATATTGTTTTTTT-AACATA------TACATA--TATATA 246 
L2.06e/s (AY462622)    TAT--ATACAAACATATGAAATATTATTTATT--AATATA------TATAT--------- 240 
L3.08e/s (AY462623)    TAT---TATATACATATTAAATATTACTTATT--AATATA------TAT----------- 236 
L1.11a/s (AY462624)    TAT---TATATACATATTAAATATTATTTCCT--AATATA------TATTGT-------- 239 
S1.07d/s (AY462625)    TAT---TATATACATATTAAATATTATTTATT--AATATA------TATTA------TAT 239 
L7.11a/s (AY462626)    TAT---TATATACATATTAAATATTACTTATT--AATATA------TATTA------TAT 245 
L3.12b/s               TAT---TATATACATATTAAATATTATTTTTTT-AACATATACATATATTGTAATATTAT  98 
MAL6P1.316             TAT--ATACATA-ATATAAATTTTTTTTTTTTTTTTTGTACATATACATATATATATATA 245 
 
L2.06d/s (AY462590)    ATATATTATAA-TATTACTAC-TAT-------TATAATTACTAT--ATATATACA--AAT 294 
L3.08g/s (AY462591)    ATATATTATAA-TATTACTAC-TAT-------TATAATTAATAT--ATATATATA--AAT 289 
L2.08a/s (AY462592)    ATATATTATAA-TATTACTAC-TAT-------TATAATTAATAT--ATATATATA--AAT 297 
S1.12e/s (AY462593)    ATATATTATAA-TATTACTAC-TAT-------TATAATTAATAT--ATATATACA--AAT 302 
L3.08b/s               --ATATTATAA-TATTACAAC-TAT-------TATAATTAATAT--ATATATATA--AAT 290 
S1.07a/s (AY462594)    ---TATTATAA-TATTACTAC-TAT-------TATAATTACTAT--ATATATACA--AAT 283 
S1.08c/s (AY462595)    ATATATTATAA-TATTACTAC-TAT-------TATAATTA------ATATATACA--AAT 298 
PF08_0106(AY462596)    ---TATTATAA-TATTACAAC-TAT-------TATAATTAATATATATATATATA--AAT 284 
S1.08g/s (AY462597)    ---TATTATAA-TATTACTAC-TAT-------TATAATTAATATATATATATAAA--TAT 283 
PF08_0140(AY462598)    ATATATTATAA-TATTACTAC-TAT-------TATAATTACTAT--ATATATACA--AAT 293 
S5.12a/s (AY462599)    ATAT--TATAA-TATTACTAC-TAT-------TATAATTA------ATATATATA--AAT 292 
L3.06a/s (AY462600)    ATAT--TATAA-TATTACAAC-TAT-------TATAATTAATAT--ATATATATA--AAT 291 
S1.08d/s (AY462601)    A-ATATTATAA-TATTACTAC-TAT-------TATAATTAATAT--ATATATACA--AAT 282 
S3.12a/s (AY462602)    ATAT--TATAA-TATTACTAC-TAT-------TATAATTAATAT--ATATATATA--AAT 283 
L2.06f/s (AY462603)    ATAT--TATAA-TATTACTAC-TAT-------TATAATTAATAT--AT----ATA--AAT 276 
S1.12c/s (AY462604)    ATAT--TATAA-TATTACAAC-TAT-------TATAATTAATAT--ATATATATA--AAT 292 
L7.11b/s (AY462605)    ATAT--TATAA-TATTACTAC-TAT-------TATAATTACTAT--ATATATACA--AAT 299 
S1.07c/s (AY462606)    ATAT--TATAA-TATTACTAC-TAT-------TATAATTACTAT--ATATATACA--AAT 280 
L3.08a/s (AY462607)    ATAT--TATAA-TATTACTAC-TAT-------TATAATTAATAT--ATATATATA--AAT 290 
S1.07b/s (AY462608)    --ATATTATAA-TATTACTAC-TAT-------TATAATTACTAT--ATATATATA--AAT 282 
S3.12d/s (AY462609)    --ATATTATAA-TATTACTAC-TAT-------TATAATTAATAT--ATATATATA--AAT 289 
L6.02b/s (AY462610)    --ATATTATAA-TATTACTAC-TAT-------TATAATTAATAT--ATATATATA--AAT 290 
MAL7P1.50(AY462611)    ATATATTATAA-TATTACTAC-TAT-------TATAATTACTAT--ATATATACA--AAT 297 
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L6.02c/s (AY462612)    ATATATTATAA-TATTACTAC-TAT-------TATAATTAATAT--ATATATATA--AAT 301 
S5.12b/s (AY462613)    ATATATTATAA-TATTACAAC-TAT-------TATAATTAATAT--ATATATACA--AAT 290 
L1.12a/s (AY462614)    ATATATTATAA-TATTACTAC-TAT-------TATAATTACTATATATATATACA--AAT 295 
S1.08b/s (AY462615)    ATATATTATAA-TATTACTAC-TAT-------TATAATTA------ATATATATA--AAT 291 
S3.12c/s (AY462616)    ATATATTATAA-TATTACAAC-TAT-------TATAATTACTATATATATATATA--AAT 298 
L3.08f/s (AY462617)    --ATATTATAA-TATTACAAC-TAT-------TATAATTACTAT--ATATATACA--AAT 289 
L3.08l/s (AY462618)    ATA--------------------------------------------------------- 272 
S3.12e/s (AY462619)    ----ATTATAA-TATTACTAC-TAT-------TATAATTACTAT--ATATATATA--AAT 295 
S1.08f/s (AY462620)    TA-TATTATAA-TATTAGAAC-TAT-------TATAATTACTAT--ATATATATA--AAT 295 
S1.12a/s (AY462621)    TAATATTATAA-TATTACTAC-TAT-------TATAATTA--AT--ATATATATA--AAT 293 
L2.06e/s (AY462622)    ----ATTATAA-TATTACTAC-TAT-------TATAATTACTAT--ATATATACA--AAT 283 
L3.08e/s (AY462623)    --ATATTATAA-TATTACTAC-TAT-------TATAATTAATAT--ATATATATA--AAT 281 
L1.11a/s (AY462624)    -AATATTATAA-TATTACTAC-TAT-------TATAATTACTAT--ATATATACA--AAT 286 
S1.07d/s (AY462625)    ATATATTATAA-TATTACTAC-TAT-------TATAATTACTATATATATATATA--AAT 290 
L7.11a/s (AY462626)    ATATATTATAA-TATTACTAC-TAT-------TATAATTAATAT--ATATATATA--AAT 294 
L3.12b/s               A-ATAGTACAACTATTAATATATATATATATATATATACAATATTTATATATATTGTAAT 158 
MAL6P1.316             ATATATTATAA-CATTACAAA-TAT-------TATAATAAATATTTATATATATAAAAAT 298 
 
L2.06d/s (AY462590)    ATATATATAATAC-TTATATATATATAT----TCCAACACA-ATAC--TATTATTATTAT 346 
L3.08g/s (AY462591)    ATATATACAATAC-TTATATATACATAT----TTCAACAAA-A--A--CAATATTATTAT 339 
L2.08a/s (AY462592)    ATATATATAATAC-TTATATATATATAT----TCCAACACA-ATAC--TATTATTATTAT 349 
S1.12e/s (AY462593)    ATATATATAATAC-TTATATATATATAT----TCCAACACA-ATAC--TATTATTATTAT 354 
L3.08b/s               ATATATATAATAC-TTATATATATATATATATTCCAACACA-ATAC--TATTATTATTAT 348 
S1.07a/s (AY462594)    ATATATATAATAC-CTATATATATATAT----TCCAACACA-ATAC--TATTATTATTAT 337 
S1.08c/s (AY462595)    ATATATATAATAC-TTATATATATATATAT--TTCAACA-A-ATA---TAATATCATTAT 350 
PF08_0106(AY462596)    ATATATATAATAC-TTATATATATATAT----TTCAACA-A-ATA---TAATATCATTAT 336 
S1.08g/s (AY462597)    ATATATATAATAC-TTATATATATATAT----TTCAACACA-ATAC--TATTATTATTAT 337 
PF08_0140(AY462598)    ATATATATAATAC-TTATATATATATATATATTCCAACACA-ATAC--TATTATTATTAT 349 
S5.12a/s (AY462599)    ATATATATAATAC-TTATATATATAT----ATTCCAACACA-ATACAATATTATTATTAT 346 
L3.06a/s (AY462600)    ATATATATAATAC-TTATATATATATATATATTCCAACACA-ATAC---AATATTATTAT 346 
S1.08d/s (AY462601)    ATATATATAATAC-TTATATATATAT----ATTTCAACAAA-A-ACAATATTATTATTAT 336 
S3.12a/s (AY462602)    ATATATATAATAC-TTATATATATAT----ATTCCAACA-A-ATACAATATTATCATTAT 336 
L2.06f/s (AY462603)    ATATATATAATAC-TTATATATATAT----ATTCCAACACA-ATACAATATTATTATTAT 330 
S1.12c/s (AY462604)    ATATATATAATAC-TTATATATATAT----ATTTCAACACA-ATAC--TATTATTATTAT 344 
L7.11b/s (AY462605)    ATATATATAATAC-TTATATATATAT----ATTTCAACA-A-ATAT---AATATCATTAT 349 
S1.07c/s (AY462606)    ATATATATAATAC-TTATATATATAT----ATTTCAACA-A-ATAT---AATATCATTAT 330 
L3.08a/s (AY462607)    ATATATATAATAC-TTATATATATAT----ATTTCAACACA-ATAC--TATTATTATTAT 342 
S1.07b/s (AY462608)    ATATATATAATAC-TTATATATATATAT----TCCAACACA-ATAC--TATTATTATTAT 336 
S3.12d/s (AY462609)    ATATATATAATAC-TTATATATATATAT----TTCAACA-A-ATA---TAATATCATTAT 341 
L6.02b/s (AY462610)    ATATATATAATAC-TTATATATATATATATATTCCAACACA-ATAC--TATTATTATTAT 348 
MAL7P1.50(AY462611)    ATATATATAATAC-TTATATATATATATAT--TCCAACACA-ATAC--TATTATTATTAT 351 
L6.02c/s (AY462612)    ATATATACAATAC-TTATATATATATATATATTCCAACACA-ATAC--TATTATTATTAT 357 
S5.12b/s (AY462613)    ATATATACAATAC-TTATATATATATATATATTCCAACACA-ATAC--TATTATTATTAT 346 
L1.12a/s (AY462614)    ATATATATAATAC-TTATATATATATAATTTTTCCAACACA-ATAC--TATTATTATTAT 351 
S1.08b/s (AY462615)    ATATATATAATAC-TTATATATATATA----TTCCAACACA-ATAC--TATTATTATTAT 343 
S3.12c/s (AY462616)    ATATATATAATAC-TTATATATATATA----TTTCAACACA-ATAC--TATTATTATTAT 350 
L3.08f/s (AY462617)    ATATATATAATAC-TTATATATATATA----TTCCAACACA-ATAC--TATTATTATTAT 343 
L3.08l/s (AY462618)    ------------------------------------------------------------ 273 
S3.12e/s (AY462619)    ATATATATAATAC-TTATATATATATAT----TCCAACACA-ATAC--TATTATTATTAT 349 
S1.08f/s (AY462620)    ATATATATAATAC-TTATATATATATAT----TCCAACACA-ATAC--TATTATTATTAT 347 
S1.12a/s (AY462621)    ATATATATAATAC-TTATATATATATAT----TTCAACACA-ATAC--TATTATTATTAT 345 
L2.06e/s (AY462622)    ATATATACAATAC-TTATATATATATAT----TCCAACACA-ATAC--TATTATTATTAT 337 
L3.08e/s (AY462623)    ATATATATAATAC-TTATATATATATATATATTCCAACA-A-ATAT---AATATCATTAT 337 
L1.11a/s (AY462624)    ATATATATATAA---TACTTATATATATATATTTCAACA-A-AAAC---AATATTATTAT 339 
S1.07d/s (AY462625)    ATATATATAATAC-TTTTATATATATAT----TCCAACACA-ATAC--TATTATTATTAT 342 
L7.11a/s (AY462626)    ATATATATAATAC-TTATATATATAT------TTCAACA-A-AAAC---AATATTATTAT 342 
L3.12b/s               ACATAAATTATACCTTACATATATATATACA-TTCACAAAA-GTGT--TATTATTCTTAT 215 
MAL6P1.316             ATATATATA-TATATAATATTTATATATATATCATAATAAATATATTAAATCTTACATAT 357 
 
L2.06d/s (AY462590)    TCTACCATATCAC--AATACTCCCATAACATA-CATAC--------ATATATACCCCCAC 395 
L3.08g/s (AY462591)    TCTACCATATCAC--TATACTCCCATAACATA-CATAT--------ATACATAC------ 382 
L2.08a/s (AY462592)    TCTACCATATCAC--TATACTCCCATAACATA-CATAC--------ATACATACCCCCAC 398 
S1.12e/s (AY462593)    TCTACCATATCAC--AATACTTCCATAACATA-CATACATACATATATACATACCCCTAC 411 
L3.08b/s               TCTACCATATCAC--AATACTCCCATAACATA-C-------------------------- 375 
S1.07a/s (AY462594)    TCTACCATATCAC--AATACTCCCATAACATA-CATACATAC------------------ 376 
S1.08c/s (AY462595)    TCTACCATATCAC--TATACTCCCATAACATA-CATACAATCACCC---CACACCACACC 404 
PF08_0106(AY462596)    TCTACCATATAAC--AATACTTCCATAACATA-CATACAATCACCC---CACACCACACC 390 
S1.08g/s (AY462597)    TCTACCATATCAC--AATACTTCCATAACATA--ACATA--------------------- 372 
PF08_0140(AY462598)    TCTACCATATCAC--AATACTCCCATAACATA-CATAC--------ATACATATATACAT 398 
S5.12a/s (AY462599)    TCTACCATATCAC--AATACTCCCATAACATA-CATAT--------ATAC---------- 385 
L3.06a/s (AY462600)    TCTACCATATCAC--AATACTCCCATAACATA-CGCA---------ATACGCCA------ 388 
S1.08d/s (AY462601)    TCTACCATATTAC--AATACTCCCATAACATA-CGAA---------ATACGCCA------ 378 
S3.12a/s (AY462602)    TCTACCATATCAC--AATACTCCCATAACATA-CGCA---------ATACGCCA------ 378 
L2.06f/s (AY462603)    TCTACCATATTAC--AATACTCCCATAACATA-CATAC--------ATACATAC------ 373 
S1.12c/s (AY462604)    TCTACCATATCAC--TATACTCCCATAACATA-CGCA---------ATACGCCA------ 386 
L7.11b/s (AY462605)    TCTACCATATCAT--AATACTCCCATAACATA-CGCA---------ATACGCC------- 390 
S1.07c/s (AY462606)    TCTACCATATCAC--TATACTCCCATAACATA-CGCA---------ATACGCCACCACCA 378 
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L3.08a/s (AY462607)    TCTACCATATCAC--AATACTCCCATAACATA-CGCA---------ATACGCCA------ 384 
S1.07b/s (AY462608)    TCTACCATATCAC--TATACTCCCATAACATA-CGCA---------ATACGCC-ACCA-- 381 
S3.12d/s (AY462609)    TCTACCATATCAC--TATACTCCCATAACATA-CGCA---------ATACGCC-ACCA-- 386 
L6.02b/s (AY462610)    TCTACCATATCAC--AATACTCCCATAACATA-CGCA---------ATACGCC-ACCA-- 393 
MAL7P1.50(AY462611)    TCTACCATATCAC--TATACTCCCATAACATA-CGCA---------ATACGCC-ACCA-- 396 
L6.02c/s (AY462612)    TCTACCATATCAC--TATACTCCCATAACATA-CGCA---------ATACGCC-ACCA-- 402 
S5.12b/s (AY462613)    TCTACCATATCAC--TATACTCCCATAACATA-CATACATATATACATACCCCTACCAAA 403 
L1.12a/s (AY462614)    TCTACCATATCAC--TATACTCCCATAACATA-CGCA---------ATACGC-CACCACC 398 
S1.08b/s (AY462615)    TCTACCATATCAG--AATACTCCCATAACATAACATA---------ACATACATACCCCC 392 
S3.12c/s (AY462616)    TCTACCATATCAC--AATACTCCCATAACATA-CGCA---------ATACGC-CACCACC 397 
L3.08f/s (AY462617)    TCTACCATATCAC--TATACTCCC------------------------------------ 365 
L3.08l/s (AY462618)    -CATCCAAATATTACAATACTCCCATAACATA--ACAT--------A-ACATACATAT-- 319 
S3.12e/s (AY462619)    TCTACCATATCAC--AATACTCCCATAACATA-CATAT--------ATACATACATAC-- 396 
S1.08f/s (AY462620)    TCTACCATATCAC--AATACTCCCATAACATA-CATAC--------ATACATACATA--- 393 
S1.12a/s (AY462621)    TCTACCATATCAC--TATACTCCCATAACATA-CATAA--------ATATATATATAA-- 392 
L2.06e/s (AY462622)    TCTACCATATTAC--AATACTCCCAAAACATA-CATAC--------ATACCCCTAC---- 382 
L3.08e/s (AY462623)    TCTACCATATCAC--TATACTCCCATAACATAACATAA-------CATACAT-------- 380 
L1.11a/s (AY462624)    TCTACCATATCAC--AATACTCCCATAACATA-CATA--------CATACCC-------- 380 
S1.07d/s (AY462625)    TCTACCATATCAC--TATACTCCCATAACATA-CATACATATATACATACCCCCACGT-- 397 
L7.11a/s (AY462626)    TCTACCATATCAC--TATACTCCCATAACATA-CATATATACATACATACCCCCACGT-- 397 
L3.12b/s               TCTACCATATTAT--AATACTCCCATAACATAACATAA-------CATACATACCCCCAC 267 
MAL6P1.316             ATATACATTTCAACAAATACATTCTTATTCTACTATATTACA----ATAATCTCATAACA 415 
 
L2.06d/s (AY462590)    G------TACGTACCAAAACACCACCAAACCATGTATGC-CACGATATAAACCA-----C 442 
L3.08g/s (AY462591)    ------------ACCAAA-----AGCAAACCACTTACGC-CAC-----TTACCA-----C 412 
L2.08a/s (AY462592)    G------TACGTACCAAAACACCACCAAACCATGTATGC-CACGATATAAACCA-----C 445 
S1.12e/s (AY462593)    CAAACACCTACCAAACACCTACCACTCCACCGCCCACACGAACCATGCAAACC------- 464 
L3.08b/s               -----CCCTACCAAACACCTACCACTCCACCGCCCACACTTACCATGCAAACC------- 425 
S1.07a/s (AY462594)    -----CCCTACCAAACACCTACCACTCCACCGCCCACACTTACCATGCAAACC------- 422 
S1.08c/s (AY462595)    ACACCACCTACCAAACACCTACCAC-----CGCCCACACGAACCATGCAAACC------- 452 
PF08_0106(AY462596)    ACACCACCTACCAACCACCTACCAC---------TTCAAGAACCATGCAAACC------- 434 
S1.08g/s (AY462597)    -----ACATAC-ATACCCCTACCAC-----CGCCCACACGAACCATGCAAACCACGTATA 419 
PF08_0140(AY462598)    ACCTA--CATACCCCTACCAAACACGTA-CCACGTATGA-CATAATGTAGTCTGGA-CGA 453 
S5.12a/s (AY462599)    ------------CCCTACCAAACACCTA-CCACGTATGG-CATAATGTAGTCGGGA-AGA 428 
L3.06a/s (AY462600)    --------CCACCACAACCACCTACCAAACCATGTATGC-CACGATATAAACCACG-TAT 436 
S1.08d/s (AY462601)    --------CCACCACCGCCAA-CACGAA-CCATGCACGC-CACAAAATTGTATG------ 419 
S3.12a/s (AY462602)    --------CCACCACCGCCCA-CACTTA-CCATGCAAAC-CCACAAATATATT------- 418 
L2.06f/s (AY462603)    --------ATACCCCTACCAA-A---CA-CCACTTA----CCACGTATGCATGA------ 408 
S1.12c/s (AY462604)    --------CCACCACTCCCCA--AACGAACCATGCAAAC-CCACAAATATATGT---ATG 430 
L7.11b/s (AY462605)    ------------------------------------------------------------ 
S1.07c/s (AY462606)    --------CCGCCCACACGAACCATGCAAACAC-TAAAC-CACCACTTACCATGCA-AAC 425 
L3.08a/s (AY462607)    --------CCACCACCGCCCA-CACGAA-CCATGCAAGA-CCCCACAAATATATGT-ATG 430 
S1.07b/s (AY462608)    -----------CCACCGCCAA-CACGAA-CCATGCACGC-CACAAAAT---TGT---ATG 419 
S3.12d/s (AY462609)    -----------CCACCGCCAA-CACGAA-CCATGCAAAC-CCACAAATATATGT---ATG 427 
L6.02b/s (AY462610)    -----------CCACCGC------------------------------------------ 398 
MAL7P1.50(AY462611)    -----------CCACTCCCCA-AACGAA-CCATGCAAGC-TCCAAAATATATGT---ATG 437 
L6.02c/s (AY462612)    -----------CCACCGCCCA-CACTTA-CCACG---------------TATGT---ATG 429 
S5.12b/s (AY462613)    CACCTACCACTCCACCGCCCA-CACGAA-CCATGCAAAC-CCTCACATATATTT---ATG 457 
L1.12a/s (AY462614)    ACCG----CCAACACGAACCATG--CAAACCACGTATAC-CACGATATAAAC-C----AC 446 
S1.08b/s (AY462615)    ACGT----ACGTACCAAAACACCACCAAACCATGTATGC-CACGATATAAAC-C----AC 442 
S3.12c/s (AY462616)    ACCG----CCCACACTTACCATG--CAAACCACGTATAC-CACG-TATGTATGC----AT 445 
L3.08f/s (AY462617)    ------------------------------------------------------------ 
L3.08l/s (AY462618)    --------AACCACGTATCT---ACCAAACCACTTGC---CACTATATATGCCA--CGAT 362 
S3.12e/s (AY462619)    --------ATACAATCACCCCACACCACACCACTTGCGC-CACTTACCATGCAAA-CCAC 444 
S1.08f/s (AY462620)    -----------CATACAATCA-CCCCACACCACAC--------CACTTACGCCA------ 425 
S1.12a/s (AY462621)    --------GGTTATATACTAC-TGGTAAACTACACTG----ACCATGTATTCCA------ 431 
L2.06e/s (AY462622)    -----------CAAACACC----ACCAAACCA-------------TGTATGCCA--CGAT 410 
L3.08e/s (AY462623)    -----------ACACCAAAC-----CAAACCACTTACGC-CACTT-----ACCA-----C 411 
L1.11a/s (AY462624)    -----------CTACCAAACACCACCAAACTATGTATGC-CACGATATAAACCA-----C 421 
S1.07d/s (AY462625)    --------ACGTACCAAAACACCACCAAACCATGTATGC-CACGATATAAACCA-----C 441 
L7.11a/s (AY462626)    --------ACGTACCAAAACACCACCAAACCATGTATGC-CACGATATAAACCA-----C 441 
L3.12b/s               G------TACGTACCAAAACACCACCAAACCATGTATGC-CACGATATAAACCA-----C 313 
MAL6P1.316             TAGA-TTATTATATATATATATTGATAAAACTATTATTATTATTAT-TATTTTA----TC 467 
 
L2.06d/s (AY462590)    GTATGTATGCAT-------GTATGACATAATGTAGTGGTGGAGTT-AACAAAAATGGCGC 495 
L3.08g/s (AY462591)    GTATGCATG----------ACATAATGTAGTCTGGACGAAGAAT---ATAAAAATGG--- 454 
L2.08a/s (AY462592)    GTATGCATG---------------ACATAATGTAGTGGTGGAGTT-AGCAAAAATGGCGC 488 
S1.12e/s (AY462593)    -CACAAATATATGT--ATGACATGACATAATGTAGTCCGGAGA--ATACAAAAATGGGGC 518 
L3.08b/s               -CACAAATATATGT—ATGACATGACATAATGTAGTCACGAA---—AAAC-AAAATGGCGC 480 
S1.07a/s (AY462594)    -CACAAATATATGT--ATGACATGACATAATGTAGTCATGAAT---AACCAAAATGGTGA 477 
S1.08c/s (AY462595)    -CTCACATATATGT--ATGACATGACATAATGTAGTGGGGGGAGTTAACCAAAATGGTGA 508 
PF08_0106(AY462596)    -CACAAA-AT-TGT--ATGACATGACATAATGTAGTCAGGAAC---AAACGAAATGGCAG 485 
S1.08g/s (AY462597)    CCACGTATGTATGC--ATG-TATGACATAATGTAGT---GCAC---CAACAAAATGGTGG 472 
PF08_0140(AY462598)    AGAATAT------------------------------------------AAAAATGGTTC 500 
S5.12a/s (AY462599)    AGAAGAAGAA--------------------------------GAATACAAAAAATGGATC 487 
L3.06a/s (AY462600)    GCATGACATAATGTAGTCACG----------------------AACAACCACAATGGCGG 498 
S1.08d/s (AY462601)    ACATGAC-----------ATAATG--------TAGTCGCGAACCATAAACAAAATGG--G 460 
96 
S3.12a/s (AY462602)    -TATGAC-----------ATAATG--------TAGTGGTGG-----TGTTAAAATGGCGC 454 
L2.06f/s (AY462603)    -CATAAT-----------GTAGTG--------CACCAATAA-----CG--AAAATGGCGC 442 
S1.12c/s (AY462604)    ACATGAC-----------ATCATG--------TAGTGGTGGAGT-TAACAAAAATGGCTC 472 
L7.11b/s (AY462605)    ------------------------------------------------------------ 
S1.07c/s (AY462606)    ACTAAACCACCAAACCATCAAACC---------CCACCAAATTGTATAACATCATGTTGT 484 
L3.08a/s (AY462607)    ACATGAC-----------ATA--------------------------------ATGTAGT 462 
S1.07b/s (AY462608)    ACATGACATA------ATGTAATGGTGG-TGTTAAAATGGCG----CCAGGTAATGCTGG 470 
S3.12d/s (AY462609)    ACATGACATA------ATGTAGTGGTGG-AGTTAACAA-------------AAATGGTGC 469 
L6.02b/s (AY462610)    ------------------------------------------------------------ 
MAL7P1.50(AY462611)    ACATGACATA------ATGTAATGGGGGGAATTAACCA-------------AAATGGCGT 480 
L6.02c/s (AY462612)    ACATAATG---------------------------------------------------- 439 
S5.12b/s (AY462613)    ACATAATGTA------GTGCACCAA-------TAACGA-------------AAATGGCGC 494 
L1.12a/s (AY462614)    GTATG---TATGT----ATGTATGACATCATGTTGTCGG----------TACAATGGTTA 498 
S1.08b/s (AY462615)    GTATG---TATG-------ACATGACATCATGTTGTCGG----------TACAATGGGGG 491 
S3.12c/s (AY462616)    GTATGACATAATG----TAGTATGGAAGAAGAATA-------------CAAAAATGGCGG 501 
L3.08f/s (AY462617)    ------------------------------------------------------------ 
L3.08l/s (AY462618)    ATATACCACGTAT----GCATGACATAATGTAGT-CACGAACGATAAACAAAAATG---- 415 
S3.12e/s (AY462619)    GTATACCACGTAT----GTATGT-ATGACATAATGTAGTCCCGAACAAACAAAATGGCTC 501 
S1.08f/s (AY462620)    -CTTACCACGTAT----GCATG-----ACATAATGTAGTCACGAACGACCACAATG---- 472 
S1.12a/s (AY462621)    -CATATTGTATG-------ACATG-----ACATAATGTAGTCGATGAGTTAAAATG---- 475 
L2.06e/s (AY462622)    ATAAACCACGTAT------GTATG-ACATCATGTAGTGGTGGAGTTAAAAAAAATG---- 461 
L3.08e/s (AY462623)    GTATG---------------CATGACATAATGT--------------------------- 431 
L1.11a/s (AY462624)    GTATG---------------CATGACATAATGTAGTCATGAAT---AACGAAAATGGCGC 465 
S1.07d/s (AY462625)    GTATGTAT-----------GTATGACATCATGTTGTCG----------CAACCATGGGGC 482 
L7.11a/s (AY462626)    GTATGCAT-----------GTATGACATCATGTAGTGGTGGAGT-TAACAAAAATGGGGC 491 
L3.12b/s               GTATG---------------CATGACATAATGTAGTCGGGA-----AGAAAAAATGGCAG 354 
MAL6P1.316             ATATCACAATACTCCCATAACATACATACATATATACATACATACATACATACATACCCC 527 
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upsC-type 5’UTR-ATG 
 
L4.03a/c (AY462581)    -CACATACAATACGACTAAGAAACCAAATAACATCACAACAAACATATTGACTACCATTA 59 
L7.11a/c (AY462582)    TCACATATAGTACGACTAAGAAACAAAATAACATCACAACAAACATAGTGACTACCATTA 60 
L1.11c/c (AY462583)    --ACATATAGTACGACTAAGAAACAAAATAACATCACAACAAACATAGTGACTACCATTA 58 
S1.12a/c (AY462584)    -CACATATAATACGACTAAGAAACAAAATAACATCATAACAAACATAGTGACTACCATTA 59 
L1.11b/c (AY462585)    --CCATATAGTACGACTAAGAAACAAAATAACATCACAACAAACATAGTGAATACCATTA 58 
L7.12b/c (AY462586)    TCACATATAGTACGACTAAGAAACAAAATAACATCACAACAAACATAGTGACTACCATTA 60 
PFD0615c (AY462587)    -CACATATAGTACGACTAAGAAACAAAATAACATCACAACAAACATAGTGACTACCATTA 59 
L6.02a/c (AY462588)    -CACATATAATACGACTAAGAAACAAAATAACATCATAACAAACATAGTGACTACCATTA 59 
L5.08a/c (AY462589)    -CACATATAATACGACTAAGAAACAAAATAACATCACAACAAACATAGTGACTACCATTA 59 
 
L4.03a/c (AY462581)    CATGATATTACCACATAATTCATACCATTATATAATATTACTACATGGAACCGATAACCA 119 
L7.11a/c (AY462582)    CATGATATTACCACATAATTCATACCATTATATAATATCACTACATGATAGTGATAACCA 120 
L1.11c/c (AY462583)    CATGATATTACCACATAATATAAAGCATTATATAATAT---------ACACCAATACGTA 109 
S1.12a/c (AY462584)    AATGGTATTACCACACAATTCATACCACTATATAATATTACTACATGATAGTGGTAACTA 119 
L1.11b/c (AY462585)    CATGATATTACCACATAATTCATACCACTATATAATATTACTACATGATAGTGATAACCA 118 
L7.12b/c (AY462586)    CATGATATTACCACATAATTCATACCATTATATAATATTACTACATGGTAGTGATAACCA 120 
PFD0615c (AY462587)    CATGATATTACCACATAATTCATACCACTATATAATATTACTACATGATAGTGATAACCA 119 
L6.02a/c (AY462588)    CATGATATTACCACATAATATAAAGCATTATATAATAT---------ACACCAATACGTA 110 
L5.08a/c (AY462589)    CATGATATTACCACATAATTCATACCACTATATAATATTACGACATGGTAGTGATAACTA 119 
 
L4.03a/c (AY462581)    CTATATCATATACACCACTACATATTAATA----CTATCGGAGATATTATGTGCACAAAT 175 
L7.11a/c (AY462582)    TTATATCATATACACCACTACATAATAATA----GTAGCGGCGGTATAATGTACATGTAT 176 
L1.11c/c (AY462583)    TTATG-----------ACTACATAGTAATA----GTAGCGACGGTATCATATACACGAAT 154 
S1.12a/c (AY462584)    CTATATCATATACACCATTATATAGTAATA----GTAGCGGCGGTATCATGCACACGTAT 175 
L1.11b/c (AY462585)    CTATATCATATACACCATTATATAGTAATA----GTAGTGGCGGTATAATGTACATGTAT 174 
L7.12b/c (AY462586)    CTATATCATATACACCACTATATAGTAATA----ATAGCTGTGGTAATATGTACACGTAT 176 
PFD0615c (AY462587)    TTATATCATATACACCACTATCTAATAATA----GTAGCGGAGGTATTATGTGCACAAAT 175 
L6.02a/c (AY462588)    TTATG-----------ACTACATAGTAATA----GTAGCGGCGGTATCATGCACACGTAT 155 
L5.08a/c (AY462589)    CTATATCATATACAACACTACTAACTATCACTACATAGTAACAGTAGTAGTTACAATCAA 179 
 
L4.03a/c (AY462581)    ATATTATAATAATGGCACCCACAACCACGA-----CATCCTGGGAATATATATTTTCGTT 230 
L7.11a/c (AY462582)    ATATTGTAACAATGGTAGCGACAACCACGG-----CATCATGGTAATATAGATTTTCGTT 231 
L1.11c/c (AY462583)    ATATAGAAATATTAGTAGTCACAATCAAGAAGTAACATCATGGTAATATAGATTTTCATT 214 
S1.12a/c (AY462584)    ATATTGTAACAGTGGTAGCTACAATCACTG-----CATCATGGTAATATAGATTTTCGTT 230 
L1.11b/c (AY462585)    ATATTGTAATAGTGGTAGCTACAATCACTG-----CATCATG------------------ 211 
L7.12b/c (AY462586)    ATATTGTAATAGTGGTAGCCAAAATCAGGA-----TATCATGGTAATGTAGATTTTCATT 231 
PFD0615c (AY462587)    ATATTATAATAGTGGTAGCCACAACCACGG-----TATCATGGTAATATAGATTTTCATT 230 
L6.02a/c (AY462588)    ATATTGTAACAGTGGTAGCGACAACCGCGG-----CATCATGGTAATATAGATTTTCATT 210 
L5.08a/c (AY462589)    GAAGTAACATCATGGTAATGTATATTTCCG------TTCATTTCATTGTAATGTTTTGAT 233 
 
L4.03a/c (AY462581)    TATATTTTCTTTATCATTTGTTGCCCAT-ACACTATTAATATGTATTTATGTTATAATGG 289 
L7.11a/c (AY462582)    TATATCTTCCTTATTGTTTGTTGTGCAT-ACACTATTAATATACATTTATGTTATAATGG 290 
L1.11c/c (AY462583)    CATATCTTCCTTATTGTTTGTTGTCCAT-ACACCATTAATATGTATTTATGTTATAATGG 273 
S1.12a/c (AY462584)    TATATCTTCTTTATTGTTTGTTGTCCAT-ACACTATTAATATGTATTTATGTTATAATGG 289 
L1.11b/c (AY462585)    ------------------------------------------------------------ 
L7.12b/c (AY462586)    CATATCTTCCTTATCGTTTGTTGTGCAT-ACACTATTAATATACATTTATGTTATAATGG 290 
PFD0615c (AY462587)    CATATCTTCCTTATTGTTTGTTTTCCAT-ACACTATTAATATGTATTTATGTTATAATGG 289 
L6.02a/c (AY462588)    CATATCTTCCTTATCGTTTGTTGTGTAT-ACACTATTAATATGTATTTATGTTATAATGG 269 
L5.08a/c (AY462589)    GATAATGATGTTGTGTTTTGTTATAGATTGTGATAACAAGATATATGAATCCCATATTAG 293 
 
L4.03a/c (AY462581)    AAAACTATGGTAACAATGTATGAATG-ACCCTCATAAATTAATAACACACACCTCAAAAC 348 
L7.11a/c (AY462582)    TAGACTATGTTAACAATGTATGAATG-ACTATCGTAAATTAATAATAGATACATGAAAAC 349 
L1.11c/c (AY462583)    TAGACTATGTTAACAATGTATGAATG-ATCATCGTAGATTAATAATAAATTCATGAAAAC 332 
S1.12a/c (AY462584)    TAAACTATGTTAACAATGTATGAATG-ATCATCGTAGATTAATAATAGATGCATGGAAAC 348 
L1.11b/c (AY462585)    ---ACTATGTTAACAATGTATGAATG-ACCATCATAAATTAATAACAGACGCATCAAAAC 267 
L7.12b/c (AY462586)    TAGACTATGTTAACAATGTATGAATG-TCCATCATAAATTAATAATAGATGCATAAAAAC 349 
PFD0615c (AY462587)    TAGACTATGTT---AATGTATGAATG-ACCATCATAAATTAATAACAGACGCATCAAAAC 345 
L6.02a/c (AY462588)    TAGACTATGTTAACAATGTATGAATG-ACCATCGTAGATTAATAATAGATACATGAAAAC 328 
L5.08a/c (AY462589)    --AGTAATAATGTGCATGGATGACAGTGGTAATATATACTAGCAGTGTATGAAAAAAAAT 351 
 
L4.03a/c (AY462581)    A-ATGT------ATATGT------------GTGCATTTACAACA-TAATGTATTCCGGGG 388 
L7.11a/c (AY462582)    T-GTGT------ATATGTAT--------GTGTGCATTTACAACA-TAATGTAGTCCGGAG 393 
L1.11c/c (AY462583)    A-ATGTGTATGTATATGTAT--------GTGTGTATTTATGACA-TAATGTAATCGGAAA 382 
S1.12a/c (AY462584)    C-GTGTATATGTATATGTATATATATATGTGTGCATTTATGACA-TAATGTAGTCGGGAA 406 
L1.11b/c (AY462585)    A-ATGT------ATATGT------------GTGCATTTACAACA-TAATGTAGTCCGGAG 307 
L7.12b/c (AY462586)    A-ATGT------ATATGTATATGTAT--GTGTGCATTTACAACA-TAATGTAGTCATGAA 399 
PFD0615c (AY462587)    A-ATGT------ATATGT------------GTGCATTTATGACA-TAATGTAGTCGTGAA 385 
L6.02a/c (AY462588)    A-ATGTGTATGTATATGTAT--------GTGTGCATTTATGACA-TCATGTAGTCACGAA 378 
L5.08a/c (AY462589)    ATATGTATAA--CAATGTATATGTTTATGTATGCATTTATGACA-TAATGTAATCGGA-- 406 
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Legend to multiple sequence alignments 
Multiple alignments (ClustalW) are shown for DBL1α, CIDR1α, DBLβ, NTS-DBL1α, 
and for 400bp of 5' UTR to ATG of upsB- and upsC-type. Sequence names indicate 
“timepoint.child.sequence”: “L” for 4 months and “S” for 1 month longitudinal study (e.g. 
“S3.12b”: 1 month study, time point 3 (=week 4), child 12, sequence b). Names of 5’UTR 
sequences are marked with ”c” for central upsC-type and “s” for subtelomeric upsB-type 
upstream sequences. The sequences specifically mentioned in text are highlighted in 
yellow and green. The accession numbers of the sequences are shown in brackets. 
Sequences which were isolated from 3D7 culture strain are named according to plasmoDB 
annotations. The following sequences were isolated from both, children and 3D7: the 5' 
UTR sequence L3.08l/s of upsB-type (identical sequence in PF08_0103), and the DBL1α 
sequences L8.06f (PFL1970w), L7.12c (PFD0995c) and S3.12a (PF08_0141). 
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Supplement II: Study Forms of Malaria Case-Control Study 
Study enrollment form – severe malaria case control study, 
Modilon Hospital, Madang, PNG   Feb-May 2003
Date (Day, Month, Year) Bleed code
Identification                  d          d               m           m             y            y
ID number
Kristen nem
Nem bilong papa
Nem bilong mama
Kolim nem bilong ples bilong yu 
(nem bilong liklik ples)
Kolim nem bilong as ples tru na 
province bilong papa bilong yu
Hamas christmas bilong yu
Sex (F=female, M=male)
History of disease (ask child or parents)
Yu bin sik tude o long las wik Y/N
Wanem kain sik i kamap Yu gat skin hot o skin col Y/N
Yu gat het pen (ask child) Y/N
Yu gat kus Y/N
Yu gat traut Y/N
Yu gat pekpek wara Y/N
Yu gat guria/ai tanim/hamas, wataim
Hap i dai (unconscious) Y/N
Arapela kain sik Y/N
Sapos yes, yu pin pilim olsem wanem
Yu bin go long Helt Senta long las wik Y/N
Yu bin kisim marasin o sut long 
las wik Y/N
Sapos yes, hamas dei bipo
Sapos yes, wanem nem bilong 
marasin na bilong wanem sik:
Health book, date of 
last antimalarial treatment
Severe malaria case-control stadi. Tok orait
Signed:
(0=Tude, 1=Asde, 2=Asde bipo, 3=Tripela dei i go pinis, 4=Foapela dei i go pinis, 5=Fivepela dei o 
moa i go pinis (hamas dei?))
Sapos yes, 
wanem dei sik i kamap
Mi tok orait na long laik bilong mi yet pikinini bilong mi bai givim blut long dispela stadi "severe malaria case-
control study" bilong PNGIMR. Ol i givim gutpela tok save long mi na long wanem kain wok bai ol i wokim 
wantaim dispela samples. Na mi save tu olsem sapos mi no laik pikinini bilong mi givim blut, em bai mi no 
mas sign. 
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ID number Kristen nem
Clinical assessment:
MUAC cm
Axillary temperature ˚C
Level of consciousness
blantyre score 1-5
Y/N
Prostration Y/N
Convulsions /24h
Respiratory rate/depth
                         /min / 
1 =normal, 2 =deep, 3 =shallow, 4 =irregular, 5 =fast
Chest indrawing/flaring nostril
                          Y/N / Y/N
color face / temp.skin limbs
                            /
Abnormal bleeding Y/N
Hemoglobinuria Y/N
9 =not done
Other signs
Laboratory parameters:
Parasites P.f. P.v. / P.m. Per/200WBC
Hemoglobin value g/dl
Lactate mmol/L
Blood glucose mmol/L
Comments
CSF analysis result
1=done, positive for Meningitis, 2=done, negative for Meningitis, 9=not done
Any other disease suspected
Any other disease 
(laboratory) confirmed
1 =hyperextension neck, 2 =limb rigidity, 3 =tooth grinding, 
4 =upward deviation eyes, 5 =other, specify
Abnormal 
neurological features
 1 =normal, 2 =pallor, 3 =other /  1 =normal temp, 2 =hot, 
3 =cold, clammy skin
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Checklist for enrolment of children in Malaria Case-Control Study 
 
Severe malaria criteria: 
 
- Coma Blantyre coma score ≤ 3     
 => wait 30 min after generalized convulsion 
- Prostration Inability to sit without support or inability to feed... 
- Convulsions > 1/24h - generalized or focal, limbs, facial muscle, jerky 
deviation eye, excess salivation, irregular breathing 
patterns 
- Respiratory distress Chest in-drawing, grunting, irregular, abnormally deep 
respiration, flaring nostrils 
- Hyperlactatemia Lactate > 5 mmol/L 
- Hypoglycemia Glucose < 2.2 mmol/L  
- Severe anaemia Haemoglobin < 5 g/dl 
 
- Hemoglobinuria (Make sure not by Glucose-6-phosphate dehydrogenase 
deficiency after primaquine treatment) 
- Collapse cold clammy skin (Systolic blood pressure [mm Hg] < 60 if 
younger than 5 years, or < 80 if older than 5 years)  
- Abnormal bleeding Spontaneous bleeding gums, nose, gastrointestinal tract....  
- Jaundice Yellow sclera, mucosal surface mouth 
 
Blantyre Coma Score:
Response Findings Score
best motor response localizes painful stimulus (pressure with blunt end of pencil on 
sternum/breast bone or supraorbital ridge)
2
withdraws limb from painful stimulus (pressure with horizontal pencil on 
nail bed of finger or toe)
1
no response or inappropriate response 0
best verbal response cries inappropriately with painful stimulus or if verbal speaks 2
moan or abnormal cry with painful stimulus 1
no vocal response to painful stimulus 0
eye movement watches or follows (follow mother's face) 1
fails to watch or follow 0
 
Symptoms of acute, mild malaria: 
- P. falciparum parasites  
- Headache 
- Fever, chills 
- Muscle aches 
- Diarrhoea, nausea 
 
Age-matched children: 
- less than 6 months old children:  +/- 1 month 
- older than 6 months:  +/- 20% of age (e.g. 5 years old child: 4-6 
years old child is age-
matched) 
Exclusion criteria: 
- Anti-malarial treatment in the last 2 weeks 
- Co-infection with any other disease 
- Severe malnutrition (MUAC < 12 cm)
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Summary
The 
 
Plasmodium falciparum
 
 virulence factor PfEMP1
is responsible for both antigenic variation and cytoad-
herence of infected erythrocytes in malaria. Approxi-
mately 50 
 
var
 
 genes per parasite genome code for this
highly polymorphic surface protein. We showed
recently that chromosome-central and subtelomeric
 
var
 
 genes are controlled by different promoters. Here,
we report that transcriptional repression of 
 
var
 
 genes
located in different chromosomal regions occurs by
different mechanisms. Subtelomeric 
 
var
 
 gene tran-
scription is repressed 4–8 h before that of chromo-
some-central 
 
var
 
 genes. Both repression events
coincide with the shifted expression of two distinct
nuclear proteins binding specifically to conserved
sequence motifs, 
 
SPE1
 
 and 
 
CPE
 
, present in the
respective promoter. Furthermore, a reiterated and
highly conserved subtelomeric 
 
var
 
 promoter element
(
 
SPE2
 
) interacts with a nuclear factor exclusively
expressed during S-phase. Promoter analysis by tran-
sient transfection suggested direct involvement of
these interactions in 
 
var
 
 gene repression and silenc-
ing, and identified regions implicated in transcrip-
tional activation of 
 
var
 
 genes.
Introduction
 
Cytoadherence of parasite-infected red blood cells
(iRBCs) to host endothelial cells constitutes a major viru-
lence determinant in 
 
Plasmodium falciparum
 
 malaria. This
adhesion is mediated through a large parasite-encoded
antigen, termed 
 
P. falciparum
 
 erythrocyte membrane pro-
tein 1 (PfEMP1), which is deposited on the surface of
infected erythrocytes during the advanced intraerythro-
cytic cycle (Leech 
 
et al
 
., 1984; Biggs 
 
et al
 
., 1991; Roberts
 
et al
 
., 1992). PfEMP1-mediated binding of iRBCs to
endothelial cells occurs via host surface receptors such
as ICAM-1, CD36 and CSA (Baruch 
 
et al
 
., 1996; Gardner
 
et al
 
., 1996; Reeder 
 
et al
 
., 1999). As a consequence,
iRBCs sequester in microvasculatory capillaries of various
organs and thus contribute to the severe morbidity and
mortality associated with malaria tropica (Pongponratn
 
et al
 
., 1991; Berendt 
 
et al
 
., 1994). Sequestration in the
brain is involved in cerebral malaria with frequent fatal
outcomes (Turner 
 
et al
 
., 1994; Newbold 
 
et al
 
., 1997),
whereas binding to CSA and hyaluronic acid in the pla-
centa poses a risk to both pregnant women and the foetus
(Fried and Duffy, 1996; Beeson 
 
et al
 
., 2000). PfEMP1 has
also been shown to downregulate dendritic cell function
(Urban 
 
et al
 
., 1999) and to be involved in rosetting (Rowe
 
et al
 
., 1997; Chen 
 
et al
 
., 1998a), another determinant of
disease severity. Owing to its exposure on the surface of
iRBCs, PfEMP1 is recognized by variant-specific antibod-
ies, and these play a pivotal role in protection from clinical
disease (Bull 
 
et al
 
., 1998). However, antigenic variation of
PfEMP1 allows the parasite to escape existing immune
responses and, hence, to establish chronic infections.
PfEMP1 is encoded by the 
 
var
 
 gene family, which com-
prises 
 
ª
 
50 highly diverse genes per haploid genome
(Baruch 
 
et al
 
., 1995; Smith 
 
et al
 
., 1995; Su 
 
et al
 
., 1995;
Gardner 
 
et al
 
., 2002). The majority of 
 
var
 
 genes are
located in the subtelomeric region of nearly all chromo-
somes, but are also found in central clusters on chromo-
somes 4, 6, 7, 8 and 12 (Rubio 
 
et al
 
., 1996; Fischer 
 
et al
 
.,
1997; Hernandez-Rivas 
 
et al
 
., 1997; Thompson 
 
et al
 
.,
1997; Gardner 
 
et al
 
., 2002). We showed recently that,
despite the tremendous sequence diversity observed in
 
var
 
 gene coding regions, 
 
var
 
 gene promoters are highly
conserved and exist in two distinct forms (Voss 
 
et al
 
.,
2000). With the completion of 
 
P. falciparum
 
 genome
sequencing, a third type of 
 
var
 
 upstream sequence
became apparent, and the three classes have been
termed upsA, upsB and upsC (Gardner 
 
et al
 
., 2002). The
type of promoter associated with a particular 
 
var
 
 gene is
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strongly correlated with its chromosomal location. 
 
var
 
genes residing in internal domains are associated with
the upsC (5B1-type) promoter. The most telomerically
located 
 
var
 
 genes are almost exclusively controlled by a
upsB (
 
var
 
17-type) promoter. Another subset of subtelom-
eric 
 
var
 
 genes is flanked by the upsA promoter. However,
compared with the upsB type, these telomere-associated
 
var
 
 genes are located towards the centromere but are
transcribed towards the telomere. Episomally located
upsB and upsC promoters were able to drive reporter
gene expression (Deitsch 
 
et al
 
., 1999; Voss 
 
et al
 
., 2000),
and various studies have shown that 
 
var
 
 genes can be
transcribed from both locations (Fischer 
 
et al
 
., 1997;
Hernandez-Rivas 
 
et al
 
., 1997; Scherf 
 
et al
 
., 1998; Voss
 
et al
 
., 2000). Apparently, every 
 
var
 
 gene represents a
single transcriptional unit capable of 
 
in situ
 
 activation.
Nevertheless, 
 
var
 
 gene expression occurs in a mutually
exclusive manner, i.e. only one 
 
var
 
 gene is actively tran-
scribed while the remaining copies remain silenced
(Chen 
 
et al
 
., 1998b; Scherf 
 
et al
 
., 1998). Switching in 
 
var
 
gene expression takes place through 
 
in situ
 
 gene activa-
tion (Scherf 
 
et al
 
., 1998). Mutually exclusive transcription
among various expression sites has also been reported
to participate in antigenic variation of the variant surface
glycoproteins in 
 
Trypanosoma brucei
 
 (reviewed by Borst
and Ulbert, 2001). However, the main mechanisms used
for antigenic variation in protozoan and bacterial patho-
gens involve DNA rearrangements such as translocation
of silenced genes into active expression sites by duplica-
tive or reciprocal recombination (Borst and Greaves,
1987; Donelson, 1995).
Despite its importance in both parasite survival and
virulence, the mechanisms involved in regulation of 
 
var
 
gene expression remain largely unknown. It was shown
by nuclear run-on analysis in monomorphic parasite pop-
ulations expressing a single PfEMP1 variant that 
 
var
 
 gene
transcription is controlled at the transcriptional level
(Scherf 
 
et al
 
., 1998). However, it is still puzzling how par-
asites activate a single 
 
var
 
 gene while keeping all other
copies repressed or silenced. 
 
var
 
 gene promoters main-
tained on episomes were active irrespective of the state
of the endogenous chromosomal promoter (Deitsch 
 
et al
 
.,
1999). In addition, Deitsch 
 
et al
 
. (2001a) reported that
silencing of episomal 
 
var
 
 gene promoter-driven transcrip-
tion involved the co-operative interaction between the
intron and 5
 
¢
 
 flanking sequence of 
 
var
 
 genes. Complete
silencing, however, was only achieved after plasmid tran-
sition through S-phase. Together, these results clearly
suggest the involvement of epigenetic mechanisms in reg-
ulation of 
 
var
 
 gene transcription.
We were interested in identifying structural and func-
tional elements in different 
 
var
 
 gene promoter types and
to gain insight into regulation of 
 
var
 
 gene transcription. We
show that repression of subtelomeric and chromosome-
central 
 
var
 
 gene transcription during intraerythrocytic
development occurs 4–8 h apart. This shifted repression
sharply coincided with the expression of two distinct DNA-
binding activities specifically interacting with sequence
recognition motifs unique to either subtelomeric or central
 
var
 
 gene promoters. Transient transfection experiments
indicated a direct participation of these DNA-binding activ-
ities in 
 
var
 
 gene repression and also revealed regions with
regulatory activities implicated in transcriptional activa-
tion. A third nuclear protein specifically expressed during
S-phase interacted with a reiterated sequence motif in
subtelomeric promoters. The likely involvement of this
activity in silencing of subtelomeric 
 
var
 
 gene transcription
is discussed.
 
Results
 
EMSA screening of subtelomeric and 
chromosome-central 
 
var gene
 
 promoters
 
To investigate 
 
var
 
 gene promoters for the presence of
elements possibly involved in the regulation of 
 
var
 
 gene
transcription, we tested a series of restriction fragments
derived from the promoters of 3D7 
 
var
 
 genes 4A3 (upsB)
and 5B1 (upsC) (Voss 
 
et al
 
., 2000) in gel retardation
assays (Fig. 1). Initially, most of these fragments
appeared to interact with nuclear proteins. However, it
became evident that there was interference of a non-
specific ssDNA-binding protein, which we identified as 
 
P.
falciparum
 
 replication protein A (RPA) (Voss 
 
et al
 
., 2002),
with labelled single-stranded (ss) probes. Inclusion of
unlabelled ss competitor DNA prevented the formation of
these complexes. Thereafter, we detected three nuclear
activities specifically binding to 
 
var
 
 gene promoter frag-
ments 5B1s(4), 4A3s(1a) and 4A3s(8) (Figs 2 and 3).
Cytosolic control extracts did not contain activities binding
to any of these probes. Competition electrophoretic mobil-
ity shift assays (EMSAs) clearly revealed the specificity of
these interactions. We observed two closely co-migrating
complexes for 4A3s(8) and, in the case of 4A3s(1a) and
5B1s(4), even multiple shifted bands were apparent. In
competition studies, the intensities of these additional
bands decreased and increased concordant to the main
complex, indicating partial dissociation of multisubunit
protein complexes and/or partial proteolysis of the binding
factors, rather than binding of different proteins to the
same recognition sequence.
 
Specificity of 
 
var
 
 promoter-binding activities
 
To fine map the identified sequence elements, we carried
out competition studies using overlapping double-
stranded (ds) oligonucleotides. The complex formed with
5B1s(4) was not competed by 5B1s(4)-1, -2 and -4
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(Fig. 2A). Efficient competition occurred only by a 100-fold
molar excess of 5B1rec (69 bp). Neither the sense nor the
antisense strand of 5B1rec had an effect on complex
formation. The addition of 5B1s(4)-3 caused a reduction
in signal intensity, indicating that a sequence motif con-
tained within 5B1s(4)-3 alone is not sufficient for binding,
but forms part of a recognition element encoded by
5B1rec, which we termed 
 
CPE
 
 (chromosome-central 
 
var
 
gene promoter element). 
 
CPE
 
 is located at position -1426
to -1357 with respect to the initiation ATG of 5B1 and
contains a 4 bp inverted repeat also present in 5B1s(4)-
3. We identified SPE1 (subtelomeric var gene promoter
element 1) (Fig. 2B) in the promoter of 4A3 encompassing
nucleotides -1171 to -1127 by competition of the nuclear
activity binding to 4A3s(8) with 4A3s(8)-1. In contrast,
neither 4A3s(8)-2 nor the sense and antisense strands of
4A3s(8)-1 interfered with binding.
The specific protein interaction involving 4A3s(1a) was
efficiently competed by 4A3s(1b) (data not shown). As
expected, a DNA–protein complex formed with 4A3s(1b)
could be prevented by the addition of 4A3s(1a) (Fig. 3B).
Although both probes were of similar size, the major com-
plexes (C2, C3) formed with 4A3s(1b) showed a clearly
reduced mobility compared with complex C1 formed with
4A3s(1a). These observations suggested an interaction of
the same nuclear factor with identical or related sequence
motifs in both probes, and the binding of multiple proteins
to 4A3s(1b). To investigate this possibility in more detail,
we performed EMSA competition studies using overlap-
ping ds oligonucleotides covering the entire 4A3s(1)
locus. 4A3s(1)-1, -2 and -3 were unable to inhibit complex
formation, whereas competitors 4A3s(1)-1.2, -c1, -c2 and
-c3 completely prevented binding to both probes (Fig. 3A–
C). Sequence comparison revealed the presence of a
conserved sequence motif (SPE2) in all four competitors
consisting of a direct (T/G)GTGC(A/G) repeat spaced by
four nucleotides (Fig. 3D). In 4A3s(1)-1, all but the last two
nucleotides of this motif are present in ds conformation
(see Table 1). Using Klenow enzyme, we generated the
complete recognition motif in 4A3s(1)-1 by refilling the 5¢
overhang. This procedure transformed 4A3s(1)-1, but not
4A3s(1)-2, into an efficient competitor (Fig. 3E). The intro-
duction of two point mutations in either the first
(repmotM1) or the second (repmotM2) repeat of the SPE2
consensus sequence completely eliminated the ability to
prevent protein binding (Fig. 3F). A ds oligonucleotide
coding for a degenerate rep20 tandem repeat (Åslund
et al., 1985) also failed to compete (Fig. 3B). Together,
these findings revealed that the SPE2–protein interaction
occurred in a highly specific manner. The presence of
three binding sites in the 4A3s(1b) probe greatly facilitated
the binding of additional factors (complexes C2 and C3),
and we hardly observed 4A3s(1b) complexes with an
electrophoretic mobility corresponding to the binding of
one protein (C1), despite the fact that the majority of
radiolabelled 4A3s(1b) occurred as free probe. Strikingly,
Fig. 1. var gene promoter fragments analysed in EMSAs. Fragments bound by nuclear proteins are highlighted in black.
A. Restriction map of the chromosome-central var gene 5B1 promoter (upsC) with positions relative to the initiation ATG. The flag depicts the 
position of the transcriptional start site (TSS) of a central var gene (var7b) (Deitsch et al., 1999).
B. Restriction map of the subtelomeric var gene 4A3 promoter (upsB). Fragment 4A3s(1+3a) was an accidental hybrid molecule consisting of 
4A3s(3a) ligated in reverse orientation to the 5¢ end of 4A3s(1).
Horizontal arrows indicate PCR primers used to generate fragments not present in var promoter restriction libraries. A, AvaII; Ap, ApaLI; As, AseI; 
B, BglII; Dd, DdeI; D, DraI; E, EcoRV; N, NdeI; P, PacI; S, SspI; Sa, Sau3AI; T, Tsp509I; X, XbaI.
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Fig. 2. Competitive gel retardation assays and iden-
tification of var promoter elements SPE1 and CPE.
A. Fragment 5B1s(4) formed one major and two 
minor complexes after incubation with nuclear 
extracts (lanes 2 and 3) but not with cytoplasmic 
extracts (lane 4). Complex formation in the presence 
of various specific and non-specific competitors was 
analysed in lanes 5–17. A scheme depicting overlap-
ping competitor DNAs covering 5B1s(4) and the 
nucleotide sequence of CPE is shown. The inverted 
4 bp repeat separated by three nucleotides is high-
lighted in bold.
B. Fragment 4A3s(8) formed one major and one 
closely co-migrating minor complex after incubation 
with nuclear extracts (lanes 2 and 3) but not with 
cytoplasmic extracts (lane 4). Competition experi-
ments were analysed in lanes 5–14. A scheme 
depicting overlapping competitor DNAs covering 
4A3s(8) and the nucleotide sequence of SPE1 is 
shown.
The molar excess of competitors is indicated above 
each lane. Sheared salmon sperm DNA was added 
at a 250-fold weight excess. ss oligonucleotide com-
petitors are denoted by F (forward) or R (reverse). 
n.e., nuclear extract; c.e., cytosolic extract.
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Fig. 3. Interaction of SPE2BP with SPE2 sequence elements.
A. One major and three minor complexes were formed with fragment 4A3s(1a) after incubation with nuclear extracts (lanes 2 and 3) but not with 
cytoplasmic extracts (lane 4). In lanes 5–13, the effect of various competitors on binding was analysed.
B. Radiolabelled 4A3s(1a) and 4A3s(1b) were incubated with nuclear extracts (lanes 2). The complexes formed with 4A3s(1b) (C2 and C3) 
showed reduced mobility compared with C1 formed with 4A3s(1a). Various competitors were analysed in lanes 3–9. The rep20 competitor 
consisted of a degenerate rep20 tandem repeat. 4A3s(1a) was used as a control for competition experiments (lanes 9).
C. Competitors 4A3s(1)-1.2, -c1, -c2, -c3 (black) prevented complex formation with radiolabelled probes 4A3s(1a) and 4A3s(1b). Grey shaded 
rectangles indicate SPE2 consensus sequences at their relative positions in 4A3s(1). The arrow marks the boundary to 4A3s(3a) in the hybrid 
molecule 4a3s(1a) (see Fig. 1).
D. The SPE2 sequences present in various competitors are shaded. Point mutations introduced into repmotM1 and repmotM2 are highlighted in 
bold.
E. The effect of filling in the 5¢ overhangs of 4A3s(1)-1 or 4A3s(1)-2 on SPE2 binding. Klenow-treated ds oligonucleotides 4A3s(1)-1∞K or 4A3s(1)-
2∞K in competition with 4A3s(1a) were analysed in lanes 4 and 6 respectively. Untreated competitors were used in samples 3 and 5. Lanes 12–
15 show the effect of the Klenow-treated competitors on binding to radiolabelled 4A3s(1b). Reduction in complex formation through increasing 
amounts of 4A3s(1)-c2 was analysed in lanes 7–9 and 16–18.
F. The effect of point mutations in either the first (repmotM1) or the second (repmotM2) repeat present in the SPE2 consensus sequence (repmot) 
on protein binding. The faster migrating complexes are most likely caused by proteolysis.
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Table 1. PCR primers and oligonucleotides used in EMSA gel retardation assays.
Transfection constructs
and PCR fragments
Oligonucleotide
name
Used in the
generation of Oligonucleotide sequence
4A3 promoter sequence 4A3-28R All pCAT4A3
derivatives
CTGTATTACATCAGTGCTTGCTATTTGTTTTCCTAGGGCGC
4A3-2202F pCAT4A3-2202 GCATAAGCTTGCAACTAGGTGCAACATTTTAC
4A3-1732F pCAT4A3-1732
PCR 4A3-B
GCATAAGCTTGGATCTAGTCTTTAGGGTTCCCAT
4A3-1517F pCAT4A3-1517 GCATAAGCTTGGATCTATAGCTACTATATAAAGATCTG
4A3-1373F pCAT4A3-1373 GCATAAGCTTGTTAAAGAACATATCTGTTCATCAAGGT
4A3-1210F pCAT4A3-1210 GCATAAGCTTAAAAATCGAAATGGAAGATAC
4A3-1114F pCAT4A3-1114 GCATAAGCTTGGGTTTAGGAATACGTATGCCTTTATG
4A3-1066F pCAT4A3-1066 GCATAAGCTTGAGAGAATACATATGCTCTTG
4A3-804F pCAT4A3-804 GCATAAGCTTCCTTATGCTACATGATATGTCATA
4A3-515F pCAT4A3-515 GCATAAGCTTGAAACATGTATGTTTTTATATGTATGT
4A3-2621F pCAT4A3-D TCCTAAGCTTACTAATTTATGTCCTATAGGTACG
4A3-1180R pCAT4A3-D CGATAAGCTTTTTTGGGTATCTTCCATTTCG
4A3-1347R PCR 4A3-B CAATTTCTTGTATAGACAAGTAGTTTCC
4A3-HpaI_R pVLUC4A3/-D CAGTGCTTGCTATTTGTTTTCAATTGCG
5B1 promoter sequence 5B1EABR All pCAT5B1
derivatives
CTATTGTTCGAAATACTTCGCGTATAATCTCATTATTACACGTACG
5B1-1879F pCAT5B1-1879
PCR 5B1-B
GCATAAGCTTGCATCCTATATGTATATTATATACATTCTCTC
5B1-1681F pCAT5B1-1681
PCR 5B1-C
GCATAAGCTTCATAATTTCATCATTATTAAAGTAGAGAAA
5B1-1508F pCAT5B1-1508 GCATAAGCTTGAAGTATGTATACAAAATAGATG
5B1-1381F pCAT5B1-1381 GCATAAGCTTGTACATATATATTATATATAATAC
5B1-1325F pCAT5B1-1325 GCATAAGCTTATATAACAAAAAAAAATTAATATG
5B1-1228F pCAT5B1-1228 GCATAAGCTTCATAGAAATGTGGTAGATAATATAGATAGA
5B1-1086F pCAT5B1-1086 GCATAAGCTTTATATATGTTCTTCGATTATAATTCTTTT
5B1-2522F pCAT5B1-D GCATAAGCTTCCTTATGCTACATGATATGTCATA
5B1-1483R pCAT5B1-D CGATAAGCTTCATCTATTTTGTATACATAATTC
5B1-1655R PCR 5B1-B GTATTAAAGTAGTAATAATTTCATCTC
5B1-1200R PCR 5B1-C GTATCTTTACACCATCTATTATATCTATC
5B1-HpaI_R pVLUC5B1/-D CACATACATATATCCATATACACAATTGGC
T7-KpnI pVLUC5B1/-D
pVLUC4A3/-D
GGGGTACCTAATACGACTCACTATAGGG
EMSA competitors
and probes
Oligonucleotide
name Competitor Oligonucleotide sequence
5B1s(4)-1F 5B1s(4)-1 ATGTTTTTTTATTAATATAATAATCCTTTTTTTATGTTATTTTA
5B1s(4)-1R AAAAAAATAATTATATTATTAGGAAAAAAATACAATAAAAT
5B1s(4)-2F 5B1s(4)-2 ATGTTATTTTATTTTTTCTATTTTTTTTTTTTTT
5B1s(4)-2R AATAAAATAAAAAAGATAAAAAAAAAAAAAA
5B1s(4)-3F 5B1s(4)-3 ATGTTTTTTTTTTTTTTTTCTTTTGATGTTGTACATATATAT
5B1s(4)-3R AAAAAAAAAAAAAAAAGAAAACTACAACATGTATATATA
5B1s(4)-4F 5B1s(4)-4 ATGTACATATATATTATATATAATACATTATATATTATAAT
5B1s(4)-4R ATGTATATATAATATATATTATGTAATATATAATATTA
5B1recF 5B1rec TGTTATTTTATTTTTTCTATTTTTTTTTTTTTTTTTTCTTTTGATGT
TGTACATATATATT
5B1recR ATATATAATAAATAAAATAAAAAAGATAAAAAAAAAAAAAAAAAAG
AAAACTACAACATGTATATATAATATATATTATGTA
4A3s(1)-1F 4A3s(1)-1 CACATTTTTTTTGGTGCGACTTTATTGTGCATAGTGGTG
4A3s(1)-1R GTGTAAAAAAAACCACGCTGAAATAACACGTATCACCACGCT
4A3s(1)-1.2F 4A3s(1)-1.2 CGACTTTATTGTGCATAGTGGTGCGAATTTATACTTTGGTGCA
4A3s(1)-1.2R AGTTGCACCAAAGTATAAATTCGCACCACTATGCACAATAAAG
TCG
4A3s(1)-2F 4A3s(1)-2 TAGTGATACCACACATGTGGGAAGACCACACATTTTTTT
4A3s(1)-2R ACTATGGTGTGTACACCCTTCTGGTGTGTAAAAAAA
4A3s(1)-3F 4A3s(1)-3 ATCACACATACGTGGTAATACCACATATATAGTGATACCAC
4A3s(1)-3R TAGTGTGTATGCACCATTATGGTGTATATATCACTATGGTGTG
4A3s(1)-c1F 4A3s(1)-c1 CATAGTGGTGCGAATTTATACTTTGGTGCAACTAGGTGCAACAT
TTTACTTTTG
4A3s(1)-c1R GTATCACCACGCTTAAATATGAAACCACGTTGATCCACGTTG
TAAAATGAAAACACGT
4A3s(1)-c2F 4A3s(1)-c2 CTTTTGTGCAACTAGGTGCAACTTGATAAACACTGCGATGGAG
GTGC
Transcriptional regulation of P. falciparum var genes 1599
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whereas a 20-fold molar excess of 4A3s(1)-c2 signifi-
cantly reduced complex formation with 4A3s(1a) (which
harbours only one binding site) no effect was observed
with 4A3s(1b) (Fig. 3E). We therefore conclude that bind-
ing of this factor to SPE2 elements occurs in a co-opera-
tive manner.
To test for cross-reactivity, we used oligonucleotides
5B1rec, 4A3s(8)-1 and repmot, harbouring the re-
cognition motifs CPE, SPE1 and SPE2, respectively,
as competitors. Figure 4 shows that the three DNA-
binding factors represent distinct activities and that
central and subtelomeric var gene promoters interact
with different nuclear proteins. Multiple sequence align-
ments of var gene 5¢ flanking sequences retrieved from
the NCBI Malaria Genetics and Genomics section
(http://www.ncbi.nlm.nih.gov/Malaria/plasmodiumbl.html)
showed that the CPE element was highly conserved
among all seven upsC sequences investigated. Variation
was observed in six nucleotide positions and in the
length of the poly dT stretches only, whereas the 4 bp
inverted repeat was perfectly conserved. Analysis of 12
upsB promoters revealed a perfect conservation of the
SPE1 recognition motif except for two nucleotide posi-
tions. SPE2 elements were present in all upsB
sequences analysed and occurred in arrays of 5–18
repeats. The position of SPE1, SPE2 and CPE with
respect to the ATG start codon of var genes is also con-
served (data not shown).
Stage-specific expression of CPE-, SPE1- and 
SPE2-binding proteins
We investigated the expression of the CPE-, SPE1- and
SPE2-binding activities (CPEBP, SPE1BP and SPE2BP)
across the intraerythrocytic parasite cell cycle (Fig. 5).
To standardize this comparative analysis, we used
stage-specific protein preparations derived from an
equal number of nuclei. SPE1BP first appeared in para-
sites 16–26 h post invasion (h.p.i.) and increased to
maximal levels in parasites older than 24 h.p.i. CPEBP
was not detected until 24–34 h.p.i. and was most pro-
nounced in schizonts. SPE2BP, however, was exclu-
sively expressed in late-stage parasites older than
34 h.p.i. The expression of SPE1BP and CPEBP in tro-
phozoites and schizonts suggested a possible involve-
4A3s(1)-c2R AA GAAAACACGTTGATCCACGTTGAACTATTTGTGACGCTAC
CTCCACGTTGTA
4A3s(1)-c3F 4A3s(1)-c3 GGTGCAACATTTTACTTTTGTGCATATTGGTGCAACATTT
TACTTTGGTGCA
4A3s(1)-c3R CCACGTTGTAAAATGAAAACACGTATAACCACGTTGTAAAAT
GAAACCACGTTGA
repmotF repmot CTTTATTGTGCATAGTGGTGCGAATTTATA
repmotR GAAATAACACGTATCACCACGCTTAAATAT
repmotM1F repmotM1 CTTTATTCTTCATAGTGGTGCGAATTTATA
repmotM1R GAAATAAGAAGTATCACCACGCTTAAATAT
repmotM2F repmotM2 CTTTATTGTGCATAGTGTTTCGAATTTATA
repmotM2R GAAATAACACGTATCACAAAGCTTAAATAT
4A3s(8)-1F 4A3s(8)-1 TGCACGGACACATGCAGTAACCGAGAATTATTATATATAAATAT
4A3s(8)-1R GTGCCTGTGTACGTCATTGGCTCTTAATAATATATATTTATA
4A3s(8)-2F 4A3s(8)-2 ATATAAATATATATATGTATATTTTGGGTTTAGGAAT
4A3s(8)-2R TATATTTATATATATACATATAAAACCCAAATCCTTATGC
EMSA competitors
and probes
Oligonucleotide
name Competitor Oligonucleotide sequence
Table 1. cont.
Fig. 4. Cross-competition EMSAs. EMSA showing the absence of 
cross-competition between CPE, SPE1 and SPE2 and their cognate 
binding factors. n.e., nuclear extract.
Forward (F) oligonucleotides are indicated 5¢ Æ 3¢, reverse (R) oligonucleotides 3¢ Æ 5¢. Restriction enzyme recognition sites are highlighted in 
bold. Point mutations introduced into repmotM1 and remotM2 are italicized and in bold.
1600 T. S. Voss et al.
110
ment in var gene repression as var gene transcription
was shown to occur in parasites up to 18–27 h.p.i. only
(Kyes et al., 2000). We therefore compared stage-spe-
cific transcription of upsB- and upsC-type var genes with
expression of SPE1BP and CPEBP. This was realized
by Northern analysis using total RNA isolated from the
same stages as for isolation of nuclear proteins. Probes
from the conserved 5¢ untranslated regions (UTR) of var
genes 4A3 or 5B1, identifying upsB- and upsC-type var
transcripts, respectively, clearly showed that transcrip-
tion of subtelomeric var genes is turned off earlier than
that of central var genes. Concordantly, the shifted ces-
sation of subtelomeric and central var gene transcription
exactly correlated with the delayed occurrence of
CPEBP over SPE1BP, indicating their involvement in
repression of var gene transcription.
var gene promoter activity analysis by transient 
transfection
We showed recently that both types of var gene promot-
ers were active in transient transfection assays (Voss
et al., 2000). As an alternative approach to identify func-
tional var gene promoter regions, we generated nested 5¢
deletions in the 5B1 and 4A3 promoters. These fragments
were used to replace the full-length promoters in
pCAT5B1 and pCAT4A3 respectively. The data presented
in Fig. 6A reveal two regions in the 5B1 promoter domi-
nantly affecting promoter activity. Deletion of nucleotides
-2522 to -1879 reduced activity to 26%, indicating the
presence of cis-acting elements involved in the activation
of chromosome-central var gene transcription. Further
nucleotide removal to -1508 had no dramatic effect. Dele-
tion of the sequence from -1508 to -1325, harbouring the
entire CPE element, caused an additional drop in pro-
moter activity to barely detectable levels (6% compared
with pCAT5B1). This region may therefore comprise addi-
tional positive regulatory elements and the core promoter.
Deletion to -1228 and -1086 completely abolished pro-
moter activity.
In the 4A3 promoter, deletion of the most 5¢ 419 bp
had no effect on overall promoter activity (Fig. 6B). How-
ever, removal of nucleotides -2202 to -1732 (containing
the SPE2 motifs) resulted in a 2.2-fold increase. Further
deletion to -1210 again caused a stepwise reduction to
the value observed with the full-length constructs. 5¢
removal of the SPE1 motif in pCAT4A3-1114 and
pCAT4A3-1066 caused no effect. The large standard
deviation in the pCAT4A3-804 sample resulted from an
extraordinarily high value obtained in one experiment,
which most probably represented an artifact. The aver-
age relative activity for this construct obtained in the
other three experiments, however, was 28%. Further
deletion to -514 completely abolished promoter activity.
We  therefore  conclude  that  the  region  encompassing
-1066 to -514 contains functional cis-acting elements
involved in activation and basal transcription of subtelom-
eric var genes.
To investigate any possible effect of CPE or SPE1 on
var gene repression, we transiently transfected synchro-
nized parasites with pVLUC5B1-D and pVLUC4A3-D
carrying  internal  deletions  encompassing  CPE  and
SPE1  respectively.  We  used  the  luciferase  gene  for
these experiments as the long half-life of CAT in eukary-
otic cells (50 h) (Thompson et al., 1991) makes this
reporter unsuitable for the analysis of stage-specific pro-
Fig. 5. Stage-specific expression of SPE1BP, CPEBP and SPE2BP 
in relation to var gene transcription. Intraerythrocytic stages are indi-
cated above each lane in hours post invasion (h.p.i.).
A. Top: SPE1-binding activity in nuclear extracts derived from syn-
chronized parasite cultures. Middle: upsB-type var gene transcription 
monitored by Northern analysis of total RNA obtained from the same 
stages. The filter was probed with a radiolabelled PCR fragment 
encompassing nucleotides -460 to -1 of the 4A3 5¢ UTR. Bottom: 
stage-specific 28S Northern as a control for equal RNA loading.
B. Top: CPE-binding activity in nuclear extracts derived from synchro-
nized parasite cultures. Middle: stage-specific Northern analysis of 
upsC-type var gene transcription. The filter was probed with a radio-
labelled PCR fragment encompassing nucleotides -514 to – 237 of 
the 5B1 5¢ UTR.
C. Stage specificity of the SPE2-binding activity.
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moter activity. Deletion of nucleotides -1483 to -1325
(pVLUC5B1-D) resulted in a 1.65-fold average increase
in luciferase activity compared with that obtained with the
parental plasmid pVLUC5B1. Deletion of SPE1 in
pVLUC4A3-D led to a 1.3–fold increase compared with
pVLUC4A3 (Fig. 6C). These results indicate an involve-
ment of the interactions of CPEBP and SPE1BP with
their cognate regulatory binding motifs in stage-specific
repression of chromosome-central and subtelomeric var
gene expression respectively.
Discussion
Plasmodium falciparum var gene expression is controlled
by different yet conserved promoters, and these structural
differences correlate with chromosomal location and ori-
entation of var genes (Voss et al., 2000; Gardner et al.,
2002). Recent findings suggest that cis-acting elements
mediating var gene expression and silencing must be
conserved within every var gene promoter and that regu-
lation of var gene expression is subject to higher level
silencing mechanisms.
We identified three highly conserved var gene pro-
moter elements interacting with distinct DNA-binding
proteins. The SPE1 and SPE2 motifs are specifically
associated with subtelomeric upsB promoters, and CPE
is a characteristic sequence element in chromosome-
internal promoters (upsC). Complex formation with these
elements occurred in a highly sequence-specific manner
and involved three different nuclear activities. Genome-
wide BLAST analysis (http://www.ncbi.nlm.nih.gov/Malaria)
revealed that these elements are exclusively asso-
ciated with var genes. SPE1, SPE2 and CPE have no
significant similarities to eukaryotic transcription factor
binding sites reported in the TRANSFAC database
(http://www.transfac.gbf.de). However, the organization of
Fig. 6. Analysis of 5B1 and 4A3 var gene promoter activities by transient transfection. For transfections using CAT constructs, pCAM5/3 was 
used as a positive control (Crabb and Cowman, 1996; data not shown). pCATw/o, lacking a promoter, was used as a negative control (Voss et al., 
2000). The length of the promoter in each construct is depicted on the left. Activity values are indicated as a percentage of relative CAT or 
luciferase activity compared with the activity obtained with parental constructs. Experiments have been repeated four times.
A. Nested 5¢ deletion analysis of the 5B1 promoter (upsC). The location of CPE is indicated by a filled rectangle. The putative TSS is depicted 
by a flag.
B. 5¢ nested 4A3 promoter (upsB) deletion analysis. The positions of SPE1 and the repeated SPE2 elements are indicated by rectangles. 
Experiments have been repeated four times, and CAT activity has been measured three times in each experiment. Constructs marked by an 
asterisk have been transfected three times only.
C. Effect of internal promoter deletions on promoter activity. In pVLUC5B1-D, nucleotides -1483 to -1325 were deleted from the 5B1 promoter 
including CPE (–1427 to -1357). Nucleotides -1180 to -1073 [including SPE1 (–1171 to -1127)] were deleted from the 4A3 promoter in 
pVLUC4A3-D. Control transfections without plasmid DNA yielded activity values between -14 and 0.
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the SPE2 motif as two direct 6 bp repeats spaced by four
nucleotides is reminiscent of nuclear hormone receptor
(NHR) response elements (reviewed by Aranda and Pas-
cual, 2001). Whether this is of any significance for the
nature of the SPE2-binding protein remains to be eluci-
dated, most of all because NHRs have as yet only been
described in metazoans.
var genes are transcribed in parasites up to 18–27 h.p.i.
(Kyes et al., 2000). Here, we show for the first time that
subtelomeric var messages were observed in parasites
up to 18 h.p.i. only, whereas chromosome-internal var
transcripts were still detected in parasites 16–26 h.p.i.
This was in perfect correlation with the occurrence of
SPE1BP 18 h.p.i. and the 4–8 h delayed expression of
CPEBP. These results showed that the structural differ-
ences in var gene promoters reflect functional and regu-
latory differences in transcriptional repression of var
genes located in different chromosomal domains. They
further suggested that SPE1 and its cognate binding fac-
tor SPE1BP are directly involved in repression of subte-
lomeric var genes, whereas chromosome-internal var
gene transcription is repressed 4–8 h later by the interac-
tion of CPEBP with CPE.
In transient transfection experiments, internal deletion
of stretches harbouring SPE1 or CPE from the subtelom-
eric or chromosome-internal promoter led to an increase
in luciferase activity compared with the wild-type promot-
ers (1.65-fold for CPE and 1.3-fold for SPE1). These
results clearly hint at an involvement of these regulatory
elements in var gene repression. However, the absence
of a pronounced difference in activity between wild-type
and mutant promoters indicates that more complex pro-
cesses are involved. On one hand, and as suggested by
others (Scherf et al., 1998; Deitsch et al., 1999), epige-
netic mechanisms may be involved in the regulation of var
gene expression. When working with episomes, such
effects may impede the investigation of promoter regula-
tory processes, as the chromatin configuration of episo-
mal and chromosomal DNA may differ substantially. For
example, it has been shown that episomal var gene pro-
moters are desilenced irrespective of the transcriptional
state of the endogenous promoter (Deitsch et al., 1999).
Similar findings have been obtained for the P. falciparum
gbp130 promoter, in which the loss of developmental
restriction of the episomal promoter was attributed to
observed differences in chromatin structure between epi-
somal and chromosomal copies (Horrocks and Lanzer,
1999). Furthermore, even if replicated plasmids were
properly assembled into chromatin during S-phase, rapid
loss of episomes as a result of inefficient segregation (van
Dijk et al., 1997; O’Donnell et al., 2001) and continuous
uptake of naked plasmid DNA into parasite nuclei during
intracellular growth (Deitsch et al., 2001b) would mask the
repressive effects of SPE1 or CPE. On the other hand,
additional trans-acting factors may participate in var
repression and, thus, total inhibition of repression would
only be observed after preventing these interactions as
well. Studies using transgenic parasites carrying muta-
tions in SPE1 and CPE in chromosomal var promoters are
definitely needed to explore further their effect on var gene
repression.
We identified several regions involved in activation of
var gene transcription in both promoters. 5¢ nested
removal of a fragment containing the CPE motif from the
5B1 promoter resulted in a decrease in activity to barely
detectable levels, suggesting the presence of positive
cis-acting element(s) and the core promoter within the
deleted region. It is therefore not surprising that no
repressive effect was observed upon nested deletion of
CPE. A second region displaying strong activating prop-
erties is positioned further upstream (-2522 to -1879) as
deletion of this stretch retained only 26% activity. 5¢
deletion to -1228 and -1086 (including the putative TSS
at -1167) led to a complete abolishment of promoter
activity and suggests that the TSS site mapped for var7b
(Deitsch et al., 1999) is conserved among chromosome-
central var genes. Deletion analysis of the subtelomeric
4A3 promoter revealed a functional region with activation
potential between nucleotides -1066 and -504. Our
results also indicate that the TSS of subtelomeric var
genes is located between nucleotides -804 and -514.
We were not able to detect any DNA–protein interactions
in the fragments participating in transcriptional activation
of var genes. This does not imply, however, that such
interactions do not exist. Factors involved in transcrip-
tional activation of a single var gene are likely to be of
low abundance, aggravating their detection in standard
gel retardation experiments. Furthermore, we cannot
exclude the possibility that the binding conditions used in
our experiments were inappropriate for stable complex
formation involving other sequences and nuclear
proteins.
The interaction of SPE2BP with SPE2 occurred in a
highly sequence-specific manner. By sequence compari-
son, we found that SPE2 elements occur in arrays of 5–
18 repeats in upsB promoters, and these arrays are
located close to the rep20 repeat region. We showed that
the presence of multiple reiterated SPE2 motifs facilitated
co-operative protein binding. Degenerate rep20 tandem
repeats did not interfere with SPE2 binding, confirming
that SPE2 arrays represent a defined subtelomeric var
gene promoter element providing multiple binding sites for
a distinct nuclear protein.
We hypothesize that the function of SPE2BP may be to
participate in transcriptional silencing of subtelomeric var
genes. (i) We observed a 2.2-fold increase in promoter
activity upon deletion of the SPE2 repeat array. (ii) It is
known that assembly of silent chromatin requires transi-
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tion through S-phase in other organisms (Miller and
Nasmyth, 1984; Firestein et al., 2000). It was also con-
vincingly shown that silencing of episomal transcription
mediated by a var gene promoter in P. falciparum required
plasmid passage through S-phase (Deitsch et al., 2001a).
SPE2BP was specifically expressed during S-phase and
mitosis in parasites 34–44 h.p.i. and, thus, this activity
may be involved in establishing the silenced state of sub-
telomeric var genes in newly developing merozoites. (iii)
Perinuclear localization of telomeric clusters facilitates
telomeric silencing in Saccharomyces cerevisiae (Maillet
et al., 1996; Andrulis et al., 1998), and high concentra-
tions of proteins essential for silencing are found in this
nuclear compartment (Gotta et al., 1996; Maillet et al.,
1996). As in yeast, clusters of P. falciparum telomeres
locate to the nuclear periphery (Freitas-Junior et al.,
2000). Orthologues of most of the yeast proteins involved
in telomeric gene silencing (e.g. RAP1, SIR2-4, MLP, Ku-
complex) have been identified in the P. falciparum
genome (Scherf et al., 2001), raising the possibility that
this parasite uses similar mechanisms to silence genes
close to chromosomal ends. In such a model, the SPE2
elements could act as silencers interacting with regula-
tory proteins to initiate nucleation and assembly of
silenced chromatin spreading throughout the nearby var
gene. Co-operative binding of the regulatory factors to
reiterated SPE2 motifs could prove essential in efficient
co-repressor recruitment and may be important to estab-
lish readily and inherit reliably the silent state of subtelo-
meric var genes. A recent study reported that var gene
silencing involves co-operative interactions between the
var intron and 5¢ flanking region (Deitsch et al., 2001a).
These experiments have only been done with a chromo-
some-central var promoter, and it remains to be tested
whether this is also true for subtelomeric var promoters.
Considering the structural and functional differences in
the conserved var promoters and a probable different
nuclear location of subtelomeric and central var genes, it
is conceivable that silencing of subtelomeric var genes is
mediated by different mechanisms.
Our results shed new light on transcriptional regulation
of the var gene family and inevitably raise the question
about the biological significance of the structural and func-
tional differences in var gene promoters. The observed
differences might only represent an evolutionary result of
the spreading of var genes throughout the parasite
genome where different chromosomal and nuclear
domains may impose different overall regulatory mecha-
nisms. But these findings might also reflect distinct func-
tional var gene subsets. Variant-specific antibodies play
an important role in protection from clinical disease (Bull
et al., 1998) and, therefore, antigenic variation is a pre-
requisite for survival in the human host. We hypothesize
that, in naive hosts, expression of chromosome-central
var genes may prove beneficial for the parasite. Chromo-
some-central var genes reside in stable genomic domains
(Pologe and Ravetch, 1988; Lanzer et al., 1993) where
only little sequence variation over time is expected to
occur. Similarly, upsC-type var genes may be quite stable
over time because of their inverse orientation and cen-
tromere-proximal location compared with upsB-type var
genes. These genes may code for PfEMP1 variants that
confer stable and high-affinity binding of iRBCs to
selected host receptors, thus efficiently preventing spleen-
dependent killing. In contrast, subtelomeric var genes
located in highly recombinogenic regions and subject to
frequent ectopic recombination events (Freitas-Junior
et al., 2000) may have increased antigenic variability, pos-
sibly coupled with decreasing binding affinity. In hyperim-
mune individuals, expression of subtelomeric var genes
would allow successive exposure of highly variable
PfEMP1 molecules to escape existing anti-PfEMP1
responses. Based on agglutination frequencies of field
isolates, Bull et al. (2000) similarly proposed the existence
of a PfEMP1 subset functionally selected for optimal
cytoadherence properties in young children that might
play an important role in causing severe disease. In older
children, immune selection would be more important, dis-
placing optimally cytoadherent variants by those with
novel epitopes. Monitoring of var gene expression in the
field as well as advances in our understanding of
PfEMP1–host receptor interactions will be important in
testing this hypothesis.
In conclusion, we show for the first time that tran-
scriptional repression of var genes located in different
chromosomal domains uses different mechanisms.
Interactions of different nuclear proteins with distinct
promoter elements unique to either subtelomeric or
chromosome-internal var gene promoters are involved
in these processes. Our findings would support pro-
grammed var gene regulation and open the way for the
identification and functional characterization of molecu-
lar components engaged in this process. This will be of
great value in our understanding of antigenic variation
and PfEMP1-mediated virulence.
Experimental procedures
Parasite cultures
Plasmodium falciparum 3D7 parasites were cultured in
100 mm and 150 mm Petri dishes at 5% haematocrit as
described previously (Trager and Jensen, 1978) in RPMI
medium supplemented with 0.5% albumax (Gibco BRL).
Growth synchronization was achieved by sorbitol lysis (Lam-
bros and Vanderberg, 1979).
Parasite nuclear extracts
Parasites were released from RBCs by saponin lysis. Nuclear
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proteins were extracted into high-salt buffer from isolated
parasite nuclei as described previously (Voss et al., 2002).
Subcloning of var gene 4A3 and 5B1 5¢ flanking regions
The 4A3 5¢ flanking region encompassing nucleotides -2312
to -569 was excised from pCAT4A3 (Voss et al., 2000) with
EcoRV and PacI. After digestion of the purified promoter
fragment with ApaLI, AvaII, DdeI, DraI and NdeI, subfrag-
ments were treated with Klenow enzyme to polish 5¢ over-
hangs. Blunt-ended restriction fragments were cloned into
pGEM3-Zf(+) (Promega) in a cycle-restriction ligation as
described previously (Push et al., 1997). The SfcI–HindIII
fragment of the 5B1 promoter encompassing nucleotides
-2142 to -248 was excised from pCAT5B1 (Voss et al., 2000)
and digested further with SspI. Restriction fragments were
cloned as above. After transformation into Escherichia coli,
individual clones were identified by sequencing. Using this
approach, we obtained plasmid clones carrying subfrag-
ments 4A3s(1+3a), (2), (3a), (3b), (4)–(10) and 5B1s(1), (4)–
(7) (Fig. 1).
Probes and competitor DNA used in EMSAs
Promoter fragments subcloned into pGEM3-Zf(+) were
excised with BamHI and SacI and agarose gel purified.
Insert 4A3s(1+3a) was digested further with Tsp509I and
Sau3AI to obtain fragments 4A3s(1a) and 4A3s(1b). Frag-
ment 4A3s(5) was obtained by BglII digestion of the 4A3-B
polymerase chain reaction (PCR) product amplified with
primers 4A3-1732F and 4A3-1347R (Table 1). PCR frag-
ments 5B1-B and 5B1-C were amplified with primer pairs
5B1-1879F/5B1-1655R and 5B1-1681F/5B1-1200R respec-
tively. 5B1-B was digested with XbaI and NdeI to yield frag-
ments 5B1s(2a) and 5B1s(2b); 5B1C was digested with
AseI to generate 5B1s(3) (Fig. 1). Fragments were radiola-
belled with Klenow enzyme by incubating 1 pmol of DNA at
30∞C for 20 min in 1 ¥ React2 buffer (Gibco BRL) in the
presence of 10 mCi of [a32-P]-dCTP and 50 mM each dATP/
dGTP/dTTP. Labelled fragments were excised from 5% non-
denaturing polyacrylamide gels and eluted overnight into
buffer E (0.1% SDS, 500 mM NH4 acetate, 1 mM EDTA),
followed by precipitation and resuspension in 1 ¥ React3
buffer (Gibco BRL).
Double-stranded (ds) oligonucleotides used as competitors
or probes (Table 1) were obtained by annealing equimolar
amounts of complementary oligonucleotides in 1¢React3 at
95∞C for 5 min followed by slow cooling to room temperature.
Annealing was confirmed by 20% PAGE analysis. ds oligo-
nucleotide probes 4A3s(8)-1 and 5B1rec were labelled as
above and purified using Sephadex G-25 spin columns
(Amersham).
EMSA
Crude nuclear proteins (1.5–3 mg) were incubated with 5 fmol
of radiolabelled probe in 20 ml of 1 ¥ EMSA buffer [20 mM
Hepes, pH 7.8, 60 mM KCl, 0.5 mM EDTA, 2 mM dithiothre-
itol (DTT), 2 mM MgCl2, 25 mM ZnCl2, 0.1% Triton X-100, 10%
glycerol] containing 2 mg pg poly-(dI–dC) as non-specific
competitor DNA for 20 min at room temperature. An aliquot
of 200 fmol of single-stranded (ss) oligonucleotide 5B1motF
(5¢-AGAAATGTGGTAGATAATATAGATAGAAAG-3¢) was in-
cluded in every reaction to prevent the formation of non-
specific ssDNA–protein complexes (Voss et al., 2002). Bind-
ing reactions were analysed on 5% or 6% polyacrylamide
gels in 0.5% TBE. For competition experiments, labelled
probes were added 10 min after incubation of protein and
competitor DNA.
Transfection constructs
Transfection constructs used in this study were derivatives of
pCAT4A3 and pCAT5B1. In these plasmids, var gene 5¢
flanking regions and the P. falciparum calmodulin gene 3¢
region control the expression of the chloramphenicol acetyl-
transferase (cat) gene (Voss et al., 2000). pCAT4A3 was
digested with HindIII and BamHI, and pCAT5B1 was
digested with HindIII to eliminate the var gene promoter. 5¢
nested deletions of the 4A3 promoter were established by
PCR using the primer 4A3-28R in conjunction with the
respective 4A3 forward primers (Table 1). 4A3-28R is posi-
tioned at -1 with respect to the initiation ATG and harbours
a BamHI site; all forward primers carry a HindIII recognition
sequence. PCR products were cloned into the BamHI–
HindIII backbone of pCAT4A3. 5¢ nested deletions of the
5B1 promoter were obtained by PCR using 5B1EABR
together with the forward 5B1 primers (Table 1). 5B1EABR
is located at position -209 with respect to the initiation ATG
of var gene 5B1 and includes a wild-type HindIII site. A
HindIII site is also present in all 5B1 forward primers. PCR
products were cloned into the HindIII backbone of pCAT5B1
in sense orientation.
pVLH/int (kindly provided by K. Deitsch), carrying the
var7b promoter (Deitsch et al., 2001a), was used to gener-
ate luciferase constructs. The var intron present in pVLH/int
was excised with BamHI and SpeI, and the plasmid was
religated (pVLUC) after polishing with Klenow enzyme. The
5B1 promoter, amplified from pCAT5B1 with primers T7-
KpnI_F and 5B1-HpaI_R (-108), was ligated into KpnI–
HpaI-digested pVLUC, thus replacing the var7b promoter
(pVLUC5B1). Likewise, the 4A3 promoter [primers T7-
KpnI_F and 4A3-HpaI_R (-1)] was introduced to generate
pVLUC4A3. To obtain an internal 114 bp deletion in the 4A3
promoter (encompassing SPE1), we cloned the HindIII-
digested PCR fragment generated with primers 4A3-2621F
and 4A3-1180R (nucleotides -2621 to -1180) into the Hin-
dIII site of pCAT4A3-1066 (pCAT4A3-D). The PCR fragment
amplified with primers 5B1-2522F and 5B1-1483R was
digested with HindIII and cloned into the upstream HindIII
site of pCAT5B1-1325 to generate pCAT5B1-D, carrying an
internal deletion of 158 bp (including CPE). The 5B1-D and
4A3-D promoters were amplified as above and cloned into
KpnI–HpaI-digested pVLUC to obtain pVLUC5B1-D and
pVLUC4A3-D respectively.
Isolation of parasite total RNA and Northern analysis
Parasite total RNA was isolated and stored as described
previously (Kyes et al., 2000). For Northern analysis, equal
amounts of RNA extracted from synchronized parasite cul-
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tures were electrophoretically separated on a 0.8% agarose
gel (5 mM GTC) and vacuum transferred to Hybond-XL
membranes (Amersham). Subtelomeric var transcripts were
detected with a 460 bp probe (-460 to -1 of the 4A3 5¢
flanking region) amplified with oligonucleotides 17F (5¢-GTT
TATATATTTTGTAAAATTATAA/TATGAG-3¢) and 4A3-28R.
Chromosome-central var gene transcription was monitored
with a 277 bp PCR fragment (-514 to -237) generated with
primers 5B1-514F (5¢-GCATAAGCTTCCATCACATATAGTAC
GACTAAGAAACA-3¢) and 5B1EABR. PCR fragments were
gel purified and radiolabelled with [a32-P]-dATP and Klenow
polymerase using primers 4A3-28R or 5B1EABR respec-
tively. Hybridization was performed at 42∞C in UltraHyb buffer
(Ambion). The 28S RNA probe was amplified from 3D7
genomic DNA with primers Pf28SF (5¢-GTGATGAGAT
TGAAGTCAGACG-3¢) and Pf28SR (5¢-AGTTCAACGAAC
CTCTTCTCC-3¢).
Parasite transfection and reporter assays
Transient transfection of cultured 3D7 P. falciparum ring-stage
parasites and CAT assays were performed as described pre-
viously (Voss et al., 2000). For luciferase assays, saponin-
released parasites were lysed in reporter lysis buffer
(Promega) at time points according to the occurrence of the
respective DNA-binding activities, i.e. 20 h.p.i. for parasites
transfected with 4A3 promoter constructs, and 30 h.p.i. for
parasites transfected with 5B1 promoter constructs (Fig. 5).
The lysate was freeze–thawed once. Luciferase activity in
parasite lysates was determined using the luciferase assay
system (Promega) and the Autoluminat LB 953 luminometer.
Sequence analysis
Sequence data for P. falciparum chromosomes were obtained
from The Sanger Centre (http://www.sanger.-ac.uk/Projects/
P_falciparum), from The Institute for Genomic Research
(http://www.tigr.org), from the Naval Medical Research
Centre and from The Stanford DNA Sequence and Tech-
nology Centre (http://www-sequence.stanford.edu/group/
malaria). Sequencing of P. falciparum chromosomes was
accomplished as part of the Malaria Genome Project with
support from The Wellcome Trust, the Burroughs Wellcome
Fund and the US Department of Defense.
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Pictures of study site and of study participants 
 
 
 
Madang Province at the North Coast of Papua New Guinea (Photo Mirjam Kaestli, 2003) 
 
 
 
 
 
 
Maiwara school, study site of longitudinal study  
(Photo Mirjam Kaestli, 2001) 
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Children of Maiwara school, participating in the longitudinal study  
(Photo Mirjam Kaestli, 2001) 
 
 
 
 
 
 
 
Children of Maiwara school area (Photo Mirjam Kaestli, 2001) 
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Typical house in the Maiwara school area 
(Photo Mirjam Kästli, 2001) 
 
 
 
 
 
 
 
 
Blood collection of asymptomatic controls (Photo Mirjam Kaestli, 2001) 
 
 
 
 
122 
 
 
 
 
 
 
 
 
 
 
 
 
 
Children of Deguir and Yagaum in the catchment area of the case-control study  
(Photo Mirjam Kästli, 2003) 
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